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Abstract 
 
Deletion of PTEN selectively in T cell progenitors in the thymus results in the rapid 
development of aggressive T cell lymphomas in a mouse model for T-ALL. We 
showed that PTEN-/- T cell lymphoma/leukaemia cells were metabolically active as 
they readily took up key nutrients. Thus, they had high rates of glucose, glutamine, 
leucine and transferrin uptake, and expressed constitutively high levels of CD71, the 
transferrin receptor, and CD98, the System L amino acid transporters. Moreover, 
PTEN-/- T cell lymphoma/leukaemia cells had high levels of mTORc1 activity. PTEN 
deletion results in accumulation of PI(3,4,5)P3 and activation of AKT. The present 
report has addressed whether AKT is the driver of the metabolic changes seen in 
PTEN-/- T cell lymphoma/leukaemia cells. We showed that PTEN deletion in 
thymocytes prior to malignant transformation, resulted in a robust activation of AKT 
but did not cause T cells to increase glucose, glutamine or leucine uptake or activate 
mTORc1. In this context, we noted that PTEN-/- T cell lymphoma/leukaemia cells but 
not PTEN-/- non-transformed thymocytes expressed high levels of the transcription 
factor Hif1α that is required for optimal glucose uptake and glycolysis in normal 
effector T lymphocytes. We therefore evaluated the importance of Hif1α in T cell 
lymphomagenesis caused by PTEN deletion. These experiments identified the 
regulation of Hif1α expression as a critical step in the malignant transformation of 
PTEN-/- T cell progenitors. They also revealed that the metabolic changes that occur 
in PTEN-/- T lymphoma/leukaemia cells are not a direct consequence of 
PI(3,4,5)P3 signalling, but must be mediated by the secondary genetic alterations 
required for malignant transformation in PTEN-/- T cell progenitors. 
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1 Chapter: Introduction 
1.1 PI3K signalling 
1.1.1 Lipids as second messengers 
The lipids that are present in the plasma membrane and their derivatives have second 
messenger roles and are crucial for the signal transduction from membrane bound 
receptors to molecules in cytoplasm and nucleus. One example is the 
phosphatidylinositol (PI) and its phosphorylated forms that consist around 10% of the 
total cellular phospholipids. The inositol ring of PI is linked to the lipid via the 1-
hydroxyl group. Three out of the five remaining hydroxyl groups on PI can be 
phosphorylated by kinases to generate at least eight isoforms that differ in the 
numbers and position of phosphate groups around the inositol ring (Cantley 2002; 
Vanhaesebroeck & Waterfield 1999).  
 
1.1.2 Introduction to PI3K  
Class I phosphoinositide 3-kinases (PI3Ks) are lipid kinases that are activated by 
different stimuli, i.e. growth factors, hormones, inflammatory stimuli, 
neurotransmitters or antigens (Hawkins et al. 2006) and their function is to 
phosphorylate the phosphatidylinositol-(4,5)-bisphosphate (PI(4,5)P2) on its inositol 
head group to generate phosphatidylinositol-(3,4,5)-trisphosphate (PI(3,4,5)P3). The 
high levels of PI(3,4,5)P3 can be metabolised to phosphatidylinositol-(4,5)-
bisphosphate (PI(4,5)P2) by the Phosphatase and tensin homologue (PTEN) protein or 
to the phosphatidylinositol-(3,4)-bisphosphate by the pair of phosphatases, SHIP1 
and SHIP2 (SH2-domain containing inositol phosphatase) (Vanhaesebroeck et al. 
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2010). PI(3,4,5)P3 is an important molecule in cells as it controls cellular growth, 
cell-cycle entry, cell migration and cell survival (Cantley 2002) 
 
The Class I PI3Ks are heterodimers that are composed of a catalytic subunit, 
responsible for the lipid kinase activity and an adaptor subunit that links the catalytic 
subunit to the upstream activating signals (Okkenhaug 2013). They are then 
subdivided into two groups: class IA and class IB. Class IA is composed of 3 
isoforms of the p110 catalytic subunit: α, β, δ that associate with a p85 regulatory 
subunit. Class IB is composed of p110γ catalytic subunit and the p101 or p87 
regulatory subunits. p110δ is expressed selectively in haematopoietic cells 
(Okkenhaug & Fruman 2010). While class IA enzymes act downstream of kinase 
receptors, class IB enzymes are regulated by the G-protein-coupled receptors 
(Vanhaesebroeck et al. 2010). 
 
1.1.3 The importance of PI3K in T cells 
In quiescent naïve cells, PI(3,4,5)P3 intracellular levels are low however they increase 
rapidly following triggering of the T cell antigen receptor (TCR) with antigenic 
peptides presented on major histocompatibility complex (MHC) molecules on the 
surface of antigen presenting cells (APC) (Costello et al. 2002; Harriague & Bismuth 
2002). Costello at al., showed that T cells can maintain long contacts with antigen 
loaded APC and during this time they maintain high levels of PI(3,4,5)P3 (Costello et 
al. 2002). 
 
The sustained accumulation of PI(3,4,5)P3 in T cells undergoing immune activation 
requires constant engagement of the TCR and PI3K activation (Costello et al. 2002; 
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Huppa et al. 2003). Signals from co-stimulatory molecules, such as CD28, are 
important during this response, but on their own, do not induce production of 
PI(3,4,5)P3 in T cells (Garcon et al. 2008). Hence, T cells that encounter activated 
APC do not generate PI(3,4,5)P3 unless the APC expresses the specific peptide/MHC 
complex (Costello et al. 2002; Garcon et al. 2008). There are however other 
physiological stimuli such as cytokines that can directly induce PI(3,4,5)P3 generation 
in T cells. Interleukin-2 (IL-2) is one such example. Immune activated T cells that are 
maintained in IL-2 can sustain high cellular levels of PI(3,4,5)P3 over several days 
(Cornish 2006; Sinclair et al. 2008). Other cytokines such as IL-15 and IL-7 can also 
induce PI(3,4,5)P3 accumulation, however the relative potency of these different 
cytokines can vary, e.g. immune activated T cells maintained in IL-15 only have 
relatively low levels of PI(3,4,5)P3 compared to IL-2 cultured cells (Sinclair et al. 
2008).  In mature T cells the majority of PI(3,4,5)P3 is produced by the actions of the 
p110 δ catalytic subunit (Garcon et al. 2008).  
 
What do we know about the role of PI3K in T cell? Deletion of p110δ (Okkenhaug et 
al. 2002) or p110γ (Sasaki et al. 2000) isoforms in the thymus does not result in major 
disruption of thymocytes development. However, double deletion of both isoforms 
has pronounced effects on T cells in the thymus as it leads to the block in early T cell 
proliferation that is associated with β selection (thymus development is discussed in 
section 1.3.1) (Swat et al. 2006; Webb et al. 2005). These data, thus, suggest that 
PI3K activity in thymus is essential for the survival and proliferation of these cells. 
Studies using conditional deletion of p110δ catalytic subunit of PI3K, loss-of-
function mutation in p110δ catalytic subunit (D910A) or selective inhibitor of p110δ, 
IC87114, contributed to our understanding of the role of PI3K in peripheral T cells.  
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T cells can be divided by the expression of CD4/CD8 co-stimulatory molecules, into 
CD4+ and CD8+ cells. Generally, CD4+ cells provide helper function to either 
immune activated CD8+ T cells or B cells. PI3K regulates CD4+ T helper cells 
proliferation after stimulation with TCR and also controls CD4+ T cell differentiation 
into Th subtypes, i.e. Th1 and Th2 cells. Thus, CD4+ expressing PI3K inactive 
(D910A) mutant or IC87114 treated mice have impaired production of cytokines 
(Soond et al. 2010; Okkenhaug et al. 2006). Moreover, PI3K is also required for the 
production of T follicular helper cells in germinal centres, a place where high-affinity 
antibodies are generated by cooperative work of T and B cells (Rolf et al. 2010). 
Additionally, PI3K is involved in development and homeostasis of CD4+ T 
regulatory cells (Treg) and is crucial for full Treg-mediated suppression (Tregs are 
responsible for limiting the responses of mainly T effector cells to antigen and/or 
inflammatory stimuli) (Patton et al. 2011). PI3K p110δ is also important in 
controlling the differentiation of immune activated effector CD8+ T cells, PI3K 
p110δ signalling thus regulates the production of effector cytokines and controls the 
expression of adhesion molecules and chemokine receptors that control T cell 
migration (Macintyre et al. 2011). 
 
1.1.4 PI3K- PI(3,4,5)P3 signalling in T cells 
PI(3,4,5)P3 in the plasma membrane acts as a tether for proteins that contain plekstrin 
homology (PH) domains permitting their recruitment to the plasma membrane, and, 
therefore, their subcellular localisation. PI(3,4,5)P3 regulated proteins include the 
serine/threonine protein kinase B (PKB/AKT, here called AKT), phosphoinositide-
dependent kinase-1 (PDK1), Tec tyrosine family kinases and guanine-nucleotide-
exchange proteins for Rho family GTPases (Okkenhaug & Vanhaesebroeck 2003).  
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The Tec kinases in T cells comprise Tec and Itk, and these kinases control the release 
of calcium into the cytoplasm by phosphorylating phospholipase C γ (Scharenberg & 
Kinet 1998), thus contributing to the sustained calcium signals that are required in the 
initial phase of T cell activation. One of the mediators of calcium signals in T cells is 
phosphatase calcineurin. This phosphatase regulates the nuclear localisation of the 
transcription factor NFAT that mediates expression of cytokines (Winslow et al. 
2003; Im & Rao 2004).  The Rho family GTPases, in particular RhoA, are important 
for survival and proliferation of early T cell progenitors in the thymus (Mullin et al. 
2007; Cleverley et al. 1999). Moreover, Finlay at al., proposed that proliferation of 
PTEN null T cell lymphoma/leukaemia cells is dependent on RhoA as inactivation of 
RhoA in PTEN null T cell progenitors blocks the development of T cell tumours 
(Finlay et al. 2009). 
 
1.1.5 Downstream effectors of PI3K/ PI(3,4,5)P3 in T cells: AKT 
AKT is the best-studied PI(3,4,5)P3-regulated kinase. It is a serine/threonine kinase 
that belongs to the AGC kinase family (L. R. Pearce et al. 2010). The interaction of 
the PH domain of AKT with PI(3,4,5)P3 allows AKT to co-localise with the 
constitutively active PDK1, another PH domain-containing kinase of the AGC kinase 
family (Calleja et al. 2007). Once in close proximity, PDK1 can phosphorylate AKT 
on a critical residue, Thr308, localised within the T loop site. In addition, the binding 
of AKT to PI(3,4,5)P3 also induces a conformational change in the protein that 
facilitates this phosphorylation of Thr308 by PDK1 (Mora et al. 2004). While 
PI(3,4,5)P3 is an important mechanism for activation of AKT, the co-localisation of 
AKT and PDK1 can be mediated via a second mechanism. The phosphorylation of 
AKT on Ser473, mediated by mTORc2, creates a docking site for PDK1. PDK1 
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contains a PIF-pocket that can bind to the phosphorylated Ser473 on AKT, thus 
bringing PDK1 in proximity of AKT, permitting the phosphorylation of Thr308 in 
AKT, and stimulating the activation of AKT (Sarbassov et al. 2005). AKT is the only 
kinase in AGC family that can be activated via these two independent mechanism, in 
contrast to other kinases such as protein kinase C or serum-and glucorticoid-induced 
kinase that can be only activated via the PIF-pocket mechanism (L. R. Pearce et al. 
2010). It is not well understood how mTORc2 is regulated and activated in this 
process, however there is evidence suggesting that PI3K activity is involved, as PI3K 
inhibitors prevent mTORc2 activation (Sparks & Guertin 2010). Either of these 
mechanisms is sufficient to stimulate AKT phosphorylation. Thus, T cells that 
express a knock-in mutant of PDK1 (K465E) that has a PH domain mutation that 
prevents the binding of PI(3,4,5)P3 shows residual phosphorylation of AKT on 
Thr308 (Waugh et al. 2009). Similarly, deletion of Rictor, a regulatory component of 
mTORc2, in immune activated CD8+ T cells (Pollizzi et al. 2015) or in immune 
activated CD4+ T cells leads to decrease but not ablation of AKT phosphorylation on 
Thr308 (K. Lee et al. 2010).   
 
1.1.6 Substrates of AKT: Foxo 
Important downstream substrates of AKT are the Foxo1 and Foxo3a transcription 
factors. Phosphorylation of Foxos by AKT leads to their exclusion from nucleus and 
their sequestration in the cytoplasm by 14-3-3 proteins, thus inhibiting their function 
as transcription factors (Biggs et al. 1999; Calnan & Brunet 2008). The Foxo 
transcription factors control a diverse set of genes in T cells (Hedrick et al. 2012). For 
example, in naïve T cells, one of the target genes of Foxo proteins is the α chain of 
the IL-7 receptor (Kerdiles et al. 2009; Hedrick et al. 2012). IL-7R signalling is 
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important in controlling T cell development in the thymus (K. Kim et al. 1998; 
Rodewald et al. 2001) and maintaining the homeostasis of naïve T cells (Kerdiles et 
al. 2009), therefore PI3K-AKT-Foxo signalling is important in controlling the 
development of T cells. 
 
Foxo1/3 transcription factors control also the expression of Kruppel-like factor 2 
(KLF2) (Preston et al. 2013) that regulates expression of CD62L, the chemokine 
receptor CCR7 (Kerdiles et al. 2009) and sphingosine-1-phosphate receptor 1 (Cyster 
& Schwab 2012). All of these molecules are involved in T cells trafficking.  Thus, 
PI3K activity in effector CD8+ T cells, by causing the exclusion of Foxo proteins 
from the nucleus, leads to downregulation of expression of these genes and to 
changes of T cell trafficking (Sinclair et al. 2008; Finlay et al. 2009). The AKT-Foxo 
pathway is also important for immune activated CD8+ T cells. Hence the inhibition 
of AKT leads to the re-expression of Foxo target genes, such as IL-7 receptor, Klf2 
and to the loss of Foxo repressed genes such as Interferon γ, a cytokine critical for 
effector function of immune activated CD8+ cells (Macintyre et al. 2011).   
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Figure 1-1 PI3K- PI(3,4,5)P3-AKT activation in T cells.  
PI(3,4,5)P3 is produced from PI(4,5)P2 by PI3K. PI(3,4,5)P3 is dephosphorylated by PTEN to 
PI(4,5)P2 or by SHIP to PI(3,4)P2. Following T cell antigen receptor stimulation of cytokine 
signalling, PI(3,4,5)P3 accumulates in the plasma membrane and this leads to recruitment of 
proteins containing PH domains. One of them is AKT. Binding of the PH domain of AKT to 
PI(3,4,5)P3 in the membrane leads to conformational change that allows for the 
phosphorylation of AKT on Thr308 by PDK1 and Ser473 by mTORc2. Active AKT 
phosphorylates Foxo transcription factors and this leads to Foxos exclusion from the nucleus 
to the cytoplasm where they are captured by 14-3-3 proteins. Phosphorylated Foxos are no 
longer able to initiate transcription of their target genes, such as IL-7 or Klf2. 
 
1.2 The negative regulator of PI3K: PTEN 
1.2.1 PTEN as a tumour suppressor 
PTEN, also known as mutated in multiple advanced cancers (MMAC1) or TGFβ-
regulated and epithelial cell-enriched phosphatase (TEP1), was identified in 1997 by 
three independent research groups (J. Li et al. 1997; Steck et al. 1997; D. M. Li & 
Sun 1997) as a result of experiments to map a region of chromosome 10q23 that was 
frequently mutated in cancers. The PTEN protein was found to share similarity to the 
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catalytic domain of members of the protein tyrosine phosphatase family and to the 
cytoskeletal proteins tensin and auxillin.  
The proper activity of protein phosphatases is critical for the controlled 
phosphorylation of substrates and any deregulation in their activity can contribute to 
diseases such as cancer (Tonks 2006). As the Pten gene was identified through its 
association with mutations in cancers and because of its homology to a phosphatase, 
it was suggested that PTEN was a tumour suppressor. Screening of multiple cell lines, 
xenografts, and primary tissues revealed that PTEN function can be lost due to both 
genetic mutations and posttranslational modifications (Ali et al. 1999; Bonneau & 
Longy 2000; Teng et al. 1997). Importantly, mutation or loss in only one of the PTEN 
alleles is sufficient to cause tumour formation (Suzuki et al. 1998; Di Cristofano et al. 
1998; Podsypanina et al. 1999). Somatic deletions or mutations of PTEN are most 
often found in glioblastoma and endometrial cancers and to lesser extend in prostate, 
breast, colon and lung (Bonneau & Longy 2000).   
The importance of PTEN function is also highlighted by the findings that germline 
mutations in PTEN cause hereditary disorders called PTEN hamartoma tumour 
syndromes (Bonneau & Longy 2000), such as Cowden syndrome and Bannayan-
Riley-Ruvalcaba syndrome. These are autosomal dominant diseases characterised by 
cellular overgrowth and the formation of benign hamartomas. 80% of Cowden 
syndrome and 60% of Bannayan-Riley-Ruvalcaba syndrome are caused by PTEN 
mutations (Eng 2003).  
PTEN function is not just important for preventing aberrant growth of cells, it is also 
essential for development. While homozygous loss of PTEN in mice leads to early 
embryonic lethality (Suzuki et al. 1998; Di Cristofano et al. 1998; Podsypanina et al. 
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1999),  loss of one PTEN allele results in high susceptibility to tumours, such as 
teratocarcinoma and prostatic cancer but also to high frequency of T cell lymphomas 
(Suzuki et al. 2008; Xue et al. 2008). The conditional deletion of PTEN in the 
haematopoietic cells (HSC) compartment in mice results in development of 
myeloproliferative disorders which give rise to acute myeloid/T cell lymphoid 
leukaemia (Jiwang Zhang et al. 2006; Guo et al. 2008). Moreover, tissue-specific 
deletion of PTEN in haematopoietic stem cells or thymocytes using Cre-loxP 
strategies results in T leukaemogenesis or lymphomagenesis (Guo et al. 2008; 
Hagenbeek & Spits 2007; X. Liu et al. 2010).  
  
1.2.2 Other functions of PTEN 
The role of PTEN is to dephosphorylate PI(3,4,5)P3 to PI(4,5)P2. It is well established 
that PTEN null cells have increased levels of AKT activity due to increased levels of 
PI(3,4,5)P3 in the plasma membrane (Maehama & Dixon 1998; Myers et al. 1998), 
and this process can be reversed by re-expression of PTEN (Dahia et al. 1999; 
Stambolic et al. 1998). This ability of PTEN to antagonise the AKT activity is 
conserved in Drosophila (Jingxiang Huang & Manning 2009) and C. elegans (Ogg & 
Ruvkun 1998). The loss of PTEN, and hence activation of PI3K/PI(3,4,5)P3 
signalling, was reported to stimulate cell migration in MEFs or leukocytes for 
example (Lacalle et al. 2004; Leslie et al. 2007; Liliental et al. 2000) and re-
expression of PTEN can rescue this phenotype (Liliental et al. 2000). Additionally, 
deletion of PTEN specifically in muscle tissues has been shown to protect mice from 
long-term insulin resistance and diabetes caused by a high-fat diet (Wijesekara et al. 
2005). However, loss of PTEN in the liver had the opposite effect and leads to 
increased insulin sensitivity and glucose tolerance (Stiles et al. 2004). Therefore, 
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these data argue that PTEN, depending on the environment, can assume different 
roles.  
 
1.2.3 The structure of PTEN protein 
The PTEN gene encodes a 403 amino acid protein (Leslie & Downes 2004). The N-
terminal domain contains the protein tyrosine phosphatase catalytic domain and the 
C-terminal region contains the C2 domain that is involved in membrane interaction. 
The phosphatase domain of PTEN contains the highly conserved active site motif 
(CX5R) that is a signature motif found in all protein tyrosine phosphatases and dual 
specific phosphatases. This motif contains the residues essential for catalysis 
(Vazquez & Sellers 2000). The active site pocket of PTEN is positively charged and 
larger than other protein tyrosine phosphatases. The phosphatase activity of PTEN is 
involved in its tumour suppression function as point mutations in the catalytically 
active region of PTEN disrupts this function (Myers et al. 1997; Papa et al. 2014).  
Furthermore, PTEN contains a short regulatory N-terminal region that mediates 
PTEN recruitment to the membrane (Das et al. 2003; Walker et al. 2004). On the C-
terminal tail, PTEN contains a cluster of Ser/Thr phosphorylation residues, a PEST 
sequence and a PDZ protein binding site that mediates protein-protein interactions 
(Leslie & Downes 2004).  
 
1.2.4 PTEN as protein and lipid phosphatase 
The catalytic activity of PTEN is dependent on the cysteine 124 within the CX5R 
signature motif. The sulfhydryl group of the cysteine functions as a nucleophile that 
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attacks the phosphorous atom of its substrate, with the formation of a thiophosphate-
enzyme intermediate (Myers et al. 1997; Zhou et al. 1994). Point mutation of cysteine 
124 to serine leads to complete loss of phosphatase activity with loss of PTEN ability 
to control cellular growth (Furnari et al. 1998). Identification of potential 
physiological substrates for PTEN performed by Myers and co-workers, revealed that 
PTEN was preferentially active against acidic substrates, such as the highly acidic 
and artificial random copolymer of glutamate and tyrosine (polyGly4,Tyr1) (Myers et 
al. 1997). Additionally, they showed that PTEN was able to dephosphorylate proteins 
phosphorylated on serine and threonine residues, albeit to much lower degree. While 
it was clear that PTEN exhibited phosphatase activity towards proteins, the activity 
towards these substrates was low, suggesting that there were other non-protein 
substrates.  
 
Indeed, further studies showed that PTEN had a strong phosphoinositide 3-
phosphatase activity both in vitro and in vivo. Expression of the catalytically inactive 
mutant, C124S, resulted in the accumulation of PI(3,4,5)P3 in the plasma membrane 
despite the lack of insulin stimulation (Maehama & Dixon 1998). Moreover, 
characterisation of the lipid phosphatase activity of PTEN demonstrated that it can 
hydrolyse PI(3)P, PI(3,4)P2 and PI(3,4,5)P3, showing high specificity for the latter 
even when compared with its water-soluble head group IP4 (McConnachie et al. 2003; 
Myers et al. 1998). The large and positively charged active site of PTEN is, therefore, 
adapted to the high negative charge and large size of the phosphorylated inositol head 
group of PI(3,4,5)P3 (J. O. Lee et al. 1999). These data thus confirms that PI(3,4,5)P3 
is a physiological lipid substrate for PTEN. 
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While the role of PTEN as lipid phosphatase is well described, its role as a protein 
phosphatase is less clear. However, it is known that via its protein phosphatase 
activity PTEN can regulate migration and invasion of glioma cells (Leslie et al. 
2009). Thus cells expressing mutated PTEN G129E, that retains only the protein 
phosphatase activity, have impaired migration compared to cells expressing PTEN 
WT. Additionally, a recent report showed that protein phosphatase activity of PTEN 
can autodephosphorylate itself and thus regulates lipid phosphatase activity 
(Tibarewal et al. 2012).  
 
1.3 Introduction to T cell development 
In the previous section we mentioned that heterozygous loss of PTEN leads to 
development of tumours in different tissues with high frequency of T cell lymphoma. 
Therefore, in this section T cell development will be discussed.  
 
1.3.1 Development of αβ T cells 
T cell development allows for the generation of T cells that express functional and 
mature T cell antigen receptor complexes (TCR) and either CD4 or CD8, the co-
receptors of major histocompatibility complex (MHC) (Boehmer et al. 1999). There 
are two classes of TCR receptors expressed on T cells: αβ (here we will discuss their 
development) and γδ. The TCR is composed of two highly variable chains: αβ or γδ 
linked to invariant chains: CD3γ, δ, ε and ζ. There is a great variability in the 
specificity of the TCR for the processed antigens and it is dependent on the structure 
of the antigen-binding site. The variability of the structure of TCRα and β chains is 
achieved via the gene rearrangement processes of the genes that encode these proteins 
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(described below). The αβ TCRs can recognise antigens presented to them by MHC 
class I (if the CD8 co-receptor is expressed) or MHC class II (if the CD4 co-receptor 
is expressed). 
 
T cells are generated from bone marrow progenitors (Shah & Zuniga-Pflucker 2014). 
T cell progenitors in the thymus do not express CD4 or CD8 co-receptors and hence 
are called double negative (DN). As CD4/CD8 DNs progress through their 
development they are characterised by different expression of CD25, the α chain of 
the cytokine receptor for IL-2, and CD44. T cell progenitors are thus CD25-CD44+ 
(DN1). In the next, DN2 phase, cells become CD25+CD44+ and start to rearrange the 
TCRβ loci, a process that is mediated by RAG1 and RAG2 genes, and DNA-
modifying proteins that are involved in the repair of DNA double-strand breaks. 
TCRβ rearrangements are required for the assembly of the functional TCR and 
production of mature T cells, progressing through the DN3 stage where thymocytes 
are CD25+CD44-. Once the β chain of TCR has been rearranged successfully, 
thymocytes start to express the pre-TCR complex that is composed of β chain, pre-Tα 
and CD3 molecule (Michie & Zúñiga-Pflücker 2002). The pre-TCR then promotes 
the survival and induces proliferation of thymocytes and their progression into DN4 
stage (CD25-CD44-). It is a crucial step during thymus development and it is called β 
selection, because only thymocytes with properly rearranged β chain can proliferate 
and become CD4/CD8 double positive (DP) cells. Thus, T cells in mice deficient for 
RAG genes expression are not able to properly assemble pre-TCR and hence their 
development is stopped at the DN3 stage (Shinkai et al. 1992).  
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The differentiation through the DN1 to DN3 stage is promoted by the signals that are 
derived from thymic epithelial cells. In particular, Notch-mediated signals delivered 
by binding to Delta ligand (Radtke et al. 1999) and signals delivered by Interleukin-7 
(IL-7) (Peschon et al. 1994; Maki et al. 1996) are crucial for thymocytes 
development. In this context, Notch1 is essential for specification and commitment of 
the developing thymocytes to the T cell lineage (Ciofani & Zúñiga-Pflücker 2007) by 
inducing the expression of transcription factors, including Gata3, Tcf1 and Hes1. An 
absence of Notch signals in haematopoietic cells, abrogates the development of T 
cells, and instead allows for the accumulation of immature B cells and DC in the 
thymus (Feyerabend et al. 2009). Additionally, Notch1 has been shown to be essential 
for the β selection in αβ T cells, as it promotes the survival of DN pre-T cells by 
maintaining their size, glucose uptake and metabolism (Ciofani & Zúñiga-Pflücker 
2005).  
 
During the next step of T cell differentiation, DN thymocytes up-regulate the 
expression of the CD4 and CD8 co-receptors, becoming so called double positive 
cells (Germain 2002; Mariathasan et al. 1999). CD4/CD8 DP cells initiate TCRα 
rearrangements, a process that is again controlled by the RAG1 and RAG2 genes. The 
rearrangement of the α chain locus occurs in repeated cycles to allow higher number 
of cells to produce functional T cell receptor. The newly formed TCR expressed on 
surface of CD4/CD8 DP cells then interacts with MHC molecules (expressed on the 
surface of thymic epithelial cells) to become either CD4+ or CD8+ single positive 
(SP) mature T cells. Moreover, depending on the strength and duration of the 
interaction between TCR and self-peptide MHC complex thymocytes are either 
positively or negatively selected. Thus if TCR has an intermediate affinity/avidity for 
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self-peptide-MHC complexes, thymocytes will be positively selected and survive. 
When TCR has high affinity for self-antigens, thymocytes will undergo death by 
apoptosis (negative selection). If TCR fails to engage in the interaction with self-
peptide-MHC complexes this will lead to their death by neglect (Germain 2002). 
Positive selection allows for survival of these thymocytes that have some potential to 
recognize self-antigens and that will be able to activate when encounter self-MHC 
loaded with ‘foreign’ antigen. 
 
 
Figure 1-2 αβ T cell development in the thymus.  
The main function of the thymus is to generate a repertoire of T cells capable of recognizing 
a variety of antigens without significant self-reactivity. Rearrangements of the TCRα and 
TCRβ genes allow for the production of diverse range of TCR receptors. Thymocytes that 
successfully rearranged TCRβ chain survive and proliferate (β selection) and start to 
rearrange TCRα chain. Expression of mature TCR on thymocytes surfaces trigger positive or 
negative selection. Positive selection leads to production of CD4+ or CD8+ T cells. Notch 
signals support the commitment of DN1 cells to become T cells and later supports survival of 
cells during β selection. Il-7 signalling is an important factor in supporting survival and 
proliferation of early T cell progenitors.  
 
1.4 T cell acute lymphoblastic leukeamia 
1.4.1 What is T cell acute lymphoblastic leukaemia (T-ALL)? 
T cell development in the thymus is a crucial step for the production and maintenance 
of mature T cells that function in peripheral organs as part of the adaptive immune 
CD4+8+ 
DP 
CD4+ 
CD8+ 
CD44-  
CD25- 
CD44+ 
CD25+ 
CD44+ 
CD25- 
DN1   DN2 DN3 DN4 DN1 DN  DN3 DN4 
CD4/CD8  
DP 
CD44+ 
CD25- 
CD44  
CD25+ 
CD44- 
CD25+ 
CD4 - 
CD25
 chain 
rearrangements 
 selection 
 chain 
rearrangements 
positive 
selection 
CD8+ 
CD4+ 
IL-7 Notch 
bone marrow 
progenitors 
Notch 
 
 
37 
 
system. However, any abnormalities that arise during this stage may have serious 
consequences and can lead to development of diseases, such as T-ALL. T-ALL is a 
severe, hematological disorder that originates in T cell progenitors in the thymus 
(Armstrong et al. 2009; Bressanin et al. 2012). It affects both adults and children but 
has peak prevalence in children between the ages of 2 and 5 years old (Pui et al. 
2008). This disease is still not fully curable with the mortality rate higher in adults 
(40-50%) than it is in children (20%). The genetic mutations that underpin the 
development of T-ALL are still not fully determined, but it is thought that multiple 
genetic events contribute to its formation rather than a single mutation (Jinghui Zhang 
et al. 2012).  
 
1.4.2 Notch mutations in T-ALL 
Aberrant activation of Notch1 signalling is found in 60% of T-ALL cases (González-
García et al. 2012). As already mentioned, during T cell fate determination, the 
interaction between Notch1 and Delta-like ligands mediates T cell specification. 
Activating mutations in Notch can arise from a number of different types of 
mutations. A relatively infrequent chromosomal translocation (7;9) between Notch1 
and Tcrb gene were identified in T-ALL (Weng et al. 2004). The most common 
mutations that contribute to around 50% of all T-ALL are activating mutations that 
are located within the PEST and HD domains, both involved in stability of Notch1 
(Andersson et al. 2011). These mutations regulate the stability of Notch1 and are 
associated with increased expression of the intracellular domain of Notch1 (NICD), 
which can then translocate to the nucleus and can induce expression of target genes 
(Sulis et al. 2008). Additionally, constitutively active Notch1 was found to be 
necessary to sustain the growth and activity of self-renewing T-ALL initiating cells 
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(or leukaemia initiating cells, LIC) that are capable of transforming into leukaemic 
cells. These cells are maintained by signals from the Notch1 pathway and blocking 
Notch1 activity can efficiently inhibit LIC activity (Armstrong et al. 2009).  
 
1.4.3 IL-7R mutations in T-ALL 
IL-7 is an important cytokine during the early thymus development and also in 
maintaining homeostasis, differentiation and activity of peripheral T cells (Ribeiro et 
al. 2013). In vivo studies have shown that IL-7 is important for the progression of T-
ALL (Silva et al. 2011). Human T-ALL cells transplanted into immunodeficient mice 
that lacked the ability to express IL-7, initiated leukaemia more slowly that human T-
ALL transplanted into immunodeficient mice expressing IL-7. Mice that overexpress 
IL-7Rα spontaneously develop T cell lymphomas. Indeed, the analysis of human T-
ALL samples shows that mutations in the IL-7R are associated with tumourigenesis 
(Zenatti et al. 2011) and  deregulated signalling of IL-7/IL-7R was shown to 
contribute to 10% of all T-ALL (Shochat et al. 2011; Zenatti et al. 2011; Ribeiro et al. 
2013). Heterozygous somatic mutations in the Il-7R gene resulting in gain-of-
function, lead to the promotion of T cell growth regardless of the availability of IL-7. 
The canonical IL-7 signalling assumes that upon IL-7 binding to IL-7Rα, the receptor 
dimerises with the common γ chain and initiate activation of the tyrosine kinases 
JAK1 and JAK3 (Walsh 2012). In contrast, the most common mutation of the IL-7R 
in T-ALL creates an unpaired cysteine residue in the extracellular juxtamembrane-
transmembrane interface region that enables the homodimerization of IL-7Rα chains 
and the subsequent activation of the tyrosine kinase JAK1 phosphorylation 
irrespective of IL-7 availability, common γ chain or JAK3 (Ribeiro et al. 2013).  
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1.4.4 PTEN mutations in T-ALL 
Changes in the expression or activity of PTEN have been linked to the formation of 
human T-ALL. Different mechanisms of PTEN inactivation have been described in 
the literature. Genetic mutations contribute to about 20% of T-ALL cases (Zenatti et 
al. 2011). There is a subset of T-ALL that develops due to Pten mutations that lead to 
its inactivation. Approximately 30% of these mutations can be found in exon 7 and 
result in C-terminal protein truncation (Jotta et al. 2010; Gutierrez et al. 2009) and 
truncated PTEN is targeted for the degradation (Georgescu et al. 1999). Moreover, 
sequence alterations in PI3K and AKT genes were identified in approximately 20% 
of human T-ALL samples (Gutierrez et al. 2009). In addition to genetic loss or 
mutations of PTEN, data indicates that inactivation of the PTEN protein can 
contribute to T-ALL progression. In this respect, analysis of human T-ALL samples 
revealed that in some cases, while mRNA of Pten was intact and the PTEN protein 
was expressed, the activity of PTEN was diminished and this inversely correlated 
with hyperactivation of PI3K and AKT. The authors proposed that the 
posttranslational modification of PTEN, by either phosphorylation mediated by the 
serine/threonine protein kinase caseine kinase 2 or by the catalytic inactivation of the 
protein by reactive oxygen species can directly downregulate the activity of PTEN 
(Silva et al. 2008).   
 
1.4.5 PTEN null mouse model of T-ALL  
Cre-loxP mediated deletion of PTEN specifically in early T cell progenitors in the 
thymus of mice has allowed a direct study of the role of PTEN in T cells (Hagenbeek 
& Spits 2007; Hagenbeek et al. 2004). It was shown that initially loss of PTEN in T 
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cells is associated with the normal development of thymocytes and that other tumour-
initiating events must occur to promote tumour development (Xue et al. 2008). This 
lag period is characterised by several features. First, PTEN loss in T cells leads to an 
increased survival of PTEN null thymocytes. While development of normal early 
thymocytes requires IL-7 signalling and pre-TCR signals, PTEN null T cell 
progenitors are able to survive and proliferate at normal rates without pre-TCR and/or 
IL-7 signalling (Hagenbeek et al. 2004). Secondly, mature PTEN null T cells that 
develop in the thymus have decreased ability to home to secondary lymphoid organs, 
which leads to decreased number of T cells in the periphery, known as lymphopenia 
(Finlay et al. 2009). In normal thymocytes Klf2 induces expression of chemokine 
CCR7 and adhesion molecule CD62L, molecules that are involved in migration from 
blood vessels to secondary lymphoid organs (Carlson et al. 2006). In PTEN null 
thymocytes, as a result of AKT phosphorylation and exclusion of Foxo transcription 
factors from the nucleus, there is a reduction of Klf2 mRNA, that leads to 
downregulation of expression of CCR7 and CD62L at both message and protein level 
(Finlay et al. 2009). Thus, PTEN null thymocytes fail to normally express CCR7 and 
CD62L and fail to properly home to lymph nodes and spleen. Thirdly, PTEN null 
thymocytes, in particular CD4+ T cells are hyperproliferative, autoreactive and have 
increased production of cytokines compared to normal thymocytes (Suzuki et al. 
2001).  
After a lag period of around 10-12 weeks after birth, mice with PTEN null T cell 
progenitors will develop tumours (Hagenbeek & Spits 2007). Why do mice with 
thymocytes specific PTEN deletion develop tumours?  It was proposed that PTEN is 
critical in maintenance of genomic integrity and the disruption of PTEN leads to 
chromosomal translocations and centromere breakage (Shen et al. 2007). Thus, 
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secondary mutations are necessary to induce tumour development in mice with 
thymocyte specific PTEN deletion (Hagenbeek & Spits 2007; Xue et al. 2008). It was 
proposed that premalignant changes that occur in thymocytes make them susceptible 
to c-Myc translocations that are the main secondary mutation in PTEN null T cell 
lymphoma/leukaemias (Guo et al. 2011; Xue et al. 2008). Some of the studies 
proposed that one group that is particularly susceptible to translocations are 
CD4/CD8 double positive thymocytes (Guo et al. 2008; Guo et al. 2011). However, 
as mice with T cell specific deletion not only develop tumours that are of CD4/CD8 
DPs origin, other thymic populations, like CD4 and CD8 or CD4/CD8 double 
negative thymocytes must also be able to acquire secondary mutations. The tumours 
that develop in mice with PTEN specific deletion are mainly monoclonal and 
disseminate into peripheral organs such as spleen or lymph nodes. A common method 
to examine if the T cell lymphomas are monoclonal or polyclonal is to analyse the 
TCRβ variable region. This analysis revealed that PTEN null T cell tumours are 
composed of relatively mature, clonally expanded post β-selected thymocytes 
(Hagenbeek & Spits 2007). Importantly, only deletion of PTEN in early T cell 
progenitors allows for the tumour development. If PTEN is deleted in naïve T cells in 
the periphery, these mice remain tumour free (Soond et al. 2012).  
 
1.5 Metabolic regulation in T-ALL and normal T cells  
Analysis of primary T cell lymphoma/leukaemia cells from mice where PTEN had 
been deleted showed that these cells are big, blast-like cells, implying that they might 
be metabolically active (Finlay et al. 2009). In this context, activation of naïve T cells 
(small, metabolically quiescent cells) by TCR stimulation is associated with a striking 
change in T cell growth, size and proliferation that needs to be matched by a 
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metabolic reprogramming (Finlay 2012). In particular, activated T cells up-regulate 
expression of glucose transporters (Glut1 and Glut3), glucose uptake and switch from 
metabolising glucose primarily through oxidative phosphorylation to using the 
glycolytic pathway despite no limitation in the availability of oxygen (aerobic 
glycolysis) (Maciver et al. 2008; Fox et al. 2005). Glycolysis is regulated by rate 
limiting glycolytic enzymes, such as hexokinase, phosphofructokinase, pyruvate 
kinase and lactate dehydrogenase (Lunt & Vander Heiden 2011). This switch, known 
as the Warburg effect (Vander Heiden et al. 2009), mirrors the situation seen in many 
solid tumours and allows for the production of biosynthetic precursors, such as 
pyruvate, than then are used for the production of lipids, nucleic acids and proteins. It 
is recognised that acute leukaemia cells also undergo a glycolytic switch and have 
high rates of glucose uptake and lactate output (Boag et al. 2006; Akers et al. 2011; 
W.-L. Chen et al. 2014; Hulleman et al. 2009).  
 
Not much is known about the uptake of amino acids by PTEN null T-ALL cells, 
however, in normal T cells it is known that immune activation is associated with 
massive increase in amino acid uptake due to upregulation of expression of amino 
acid transporters (Sinclair et al. 2013; R. Wang et al. 2011a; Cornish 2006; Preston et 
al. 2015). Thus regulated uptake of amino acids is also important for proliferating 
cells for the production of biosynthetic precursors and fuelling translation. In 
particular, large neutral amino acids (LNAA), such as leucine, are important for these 
processes (Sinclair et al. 2013). Intracellular leucine is also sensed by the lumen of 
the lysosome (Zoncu et al. 2011), and is a potent activator of mammalian target of 
rapamycin complex 1 (mTORc1), a kinase that plays a central role in regulation of 
metabolism via phosphorylation of components of translational machinery (discussed 
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in section 1.5.2) (BEUGNET et al. 2003; Proud 2007; Sinclair et al. 2013). Another 
important essential amino acid for many cells is glutamine (Carr et al. 2010). 
Glutamine cooperates with leucine to induce mTORc1 activation. On one hand, 
transport of glutamine into the cell is followed by its efflux and simultaneous import 
of leucine. Thus, glutamine availability is rate limiting for uptake of leucine by the 
cell (Nicklin et al. 2009). On the other hand, it was proposed that production of α-
ketoglutarate from glutamine via glutaminolysis is facilitated by leucine (Duran et al. 
2012). α-Ketoglutarate then can stimulate the recruitment of mTORc1 to the 
lysosome where RHEB can activate it.  
 
One other important protein for rapidly proliferating cells is transferrin, as transferrin 
transports iron inside the cell (Ponka & Lok 1999). Iron acts as a cofactor for a 
number of cellular enzymes, including ribonucleotide reductase, a rate-limiting 
enzyme for DNA synthesis (Richardson & Ponka 1997). The importance of iron in 
cellular proliferation has been demonstrated by the findings that the treatment of cells 
with iron chelators halts DNA synthesis (Robbins & Pederson 1970; White et al. 
1990; Kemp et al. 1995). Recent studies have shown that c-Myc, a critical oncogene, 
controls transferrin receptor expression in normal T cells (Preston et al. 2015). Also 
expression of transferrin receptor is used as marker for tumour cells (Daniels et al. 
2012). 
 
1.5.1 Regulation of metabolism in T cells and T-ALL cells 
In certain cell systems, such as skeletal muscles or adipocytes, the serine/threonine 
kinase AKT plays a key role in maintaining cellular metabolism by regulating 
glucose homeostasis (Hajduch et al. 2001; C. J. Green et al. 2008; Mahfouz et al. 
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2014). In the thymus, PI3K-induced activation of AKT was proposed to support the 
metabolism of developing early T cell progenitors (Juntilla & Koretzky 2008). 
During the CD4/CD8 double negative stage, thymocytes enter β selection, a process 
that requires an increase in metabolism to sustain rapid cell proliferation. T cell 
progenitors that lack the expression of the two AKT isoforms expressed in thymus 
have reduced glucose uptake and fail to develop beyond the CD4/CD8 DN stage 
(Juntilla et al. 2007). This phenotype can be rescued by the expression of a 
constitutively active mutant of AKT that restores the viability and glycolytic rates of 
early T cell progenitors (Ciofani & Zúñiga-Pflücker 2005). Additionally, PI(3,4,5)P3-
PDK1-mediated activation of AKT in T cell progenitors is required for the expression 
of nutrient receptors, such as CD71 and CD98 (Kelly et al. 2007), that are important 
to support the growth and proliferation of these cells.  
 
PI3K-AKT activation has been also proposed to play a role in controlling glucose 
metabolism in immune activated peripheral T cells. Early studies showed that the 
inhibition of PI3K signalling caused reduction in the expression of the glucose 
transporter, Glut1, and a reduction in the uptake of glucose in antigen receptor 
activated T cells (Frauwirth et al. 2002). However, these experiments used 
LY294002, a PI3K inhibitor that has many off target effects (Bain et al. 2007; Gharbi 
et al. 2007). Further studies that have used selective inhibitors of AKT (AKTi), or 
PI3K – p110δ (IC87114) in TCR activated effector CD8+ T cells, found that PI3K-
AKT signalling is dispensable for the glucose uptake and proliferation of immune 
activated T cells (Macintyre et al. 2011). There is therefore contradictory data 
regarding the role of AKT in controlling metabolism of mature T cells.  
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In this thesis we wanted to ask whether AKT activation plays a role in controlling the 
metabolism of T leukaemic cells. There are two studies that have suggested that 
activation of PI3K-AKT signalling regulates glucose uptake and proliferation in T-
ALL populations (Barata 2004; Hagenbeek et al. 2014). However, these studies used 
LY294002 as a pharmacological tool to inhibit PI3K-AKT activation and therefore 
should be interpreted with caution. In contrast to the above reports, a study performed 
by Finlay at al., suggested that that the upstream activator of AKT, PDK1 is not 
necessary to sustain metabolism and proliferation in PTEN-induced T-ALL (Finlay et 
al. 2009). In normal T cell progenitors, PDK1 is essential for the proliferation and 
survival of these cells (Hinton et al. 2004). However, PTEN can bypass the PI3K-
PDK1-AKT-mediated control of metabolic checkpoint and PTENxPDK1 null T cell 
progenitors can survive and proliferate normally (Finlay et al. 2009). Therefore, we 
wished to further dissect the role of AKT in controlling the metabolism and nutrient 
transport in T-ALL cells. We also wanted to understand if there are other pathways 
through which the metabolism of T cell progenitors/T-ALL cells can be regulated.  
 
One kinase that is important in immune activated T cell metabolism is the mTORc1 
kinase. This kinase could potentially also plays a role in controlling the metabolism 
of T-ALL tumours. In this respect the loss or the genetic deletion mTORc1 function 
can delay the development of T cell tumours in a mouse model of PTEN deletion in 
haematopoietic cells (Tandon et al. 2011; Kalaitzidis et al. 2012). In addition, it is 
known that mTOR catalytic inhibitors can be cytotoxic for T-ALL (Evangelisti et al. 
2011). Furthermore, administration of a mTORc1 specific inhibitor, rapamycin, leads 
to a depletion of the leukaemia initiating T cells that are able to produce tumours 
(Yilmaz et al. 2006). 
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1.5.2 mTORc1  
1.5.2.1 Overview 
mTOR is a serine/threonine kinase that belongs to the PI3K-related kinase family 
(Lempiainen & Halazonetis 2009; Schmelzle & Hall 2000) and is the catalytic 
component of two complexes, mTORc1 and mTORc2. mTORc1 consists of the 
scaffolding protein Raptor (regulatory-associated protein of mTOR), PRAS40 (the 
proline-rich AKT substrate 40kDa), Deptor (DEP-domain containing mTOR-
interacting protein) and mLST8 (mammalian lethal with Sec13 protein 8) (Laplante & 
Sabatini 2013). mTORc2 consists of the scaffolding protein Rictor (raptor-
independent companion of TOR), mLST8, mSIN1 and Proctor (Protein observed with 
rictor) (Guertin & Sabatini 2007). mTORc1, in contrast to mTORc2, is sensitive to 
the drug rapamycin that is used as an immunosuppressant, mainly in transplantation 
procedures (Saunders et al. 2001). Rapamycin, by binding to the FKBP12 domain on 
mTOR, can block the association of Raptor with mTOR and hence prevent mTORc1 
activity (Brown et al. 1994).  
 
1.5.2.2 Signalling up-stream of mTORc1 
As an environmental sensor, mTORc1 integrates signals from amino acids, growth 
factors, oxygen, stress and energy status to regulate intracellular processes involved 
in protein translation, lipid biosynthesis and autophagy (Laplante & Sabatini 2012). 
The activation of mTORc1 is promoted by the availability of amino acids and is 
decreased when there is shortage of nutrients, leading to a decrease in cellular 
biosynthesis and an increase in autophagy (Yu et al. 2010; Korolchuk et al. 2011; 
Boya et al. 2013). How is mTORc1 activity regulated? Recent studies showed that 
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activation of mTORc1 takes place on lysosomes (Sancak et al. 2010; E. Kim et al. 
2008). mTORc1 is directly activated by the Ras homologue enriched in brain (RHEB) 
GTPase (Yee & Worley 1997; Saucedo et al. 2003). RHEB activity is regulated by 
the tuberous sclerosis complex (TSC) that consists of TSC1, TSC2 and TBC1D7 
(Saucedo et al. 2003; Manning & Cantley 2003). TSC2 is localised on the lysosome 
and inhibits mTORc1 activity by suppressing the activity of RHEB. However, insulin 
receptor driven activation of AKT (Yecies & Manning 2011) leads to the 
phosphorylation of TSC2 on several sites, out of which Ser939 and Thr1262 are 
highly conserved (Menon et al. 2014; Demetriades et al. 2014). This phosphorylation 
leads to the inhibition of the GAP activity of the TSC1-TSC2-TBC7 complex towards 
RHEB (Menon et al. 2014; Dibble et al. 2012). Additionally, phosphorylation of 
TSC2 facilitates its binding to 14-3-3 proteins and this further sequesters TSC away 
from the lysosomally bound RHEB (Cai et al. 2006). Therefore, phosphorylation of 
TSC2 by AKT allows for RHEB-GTP loading and, potentially, mTORc1 activation 
(Menon et al. 2014). MAPK signalling, via ERK1/2 mediates the phosphorylation of 
TSC2 on Ser660 and Ser540 and this leads to the disintegration of the TSC2 complex 
and hence mTORc1 activation (L. Ma et al. 2005). In contrast to AKT and ERK, 
phosphorylation of TSC2 by AMPK on Ser1388 leads to an increased activity of 
TSC2 and further inhibition of mTORc1 (Inoki et al. 2002). Additionally, AKT can 
directly contribute to mTORc1 activation by phosphorylating and inactivating 
PRAS40, a negative regulator of mTORc1 signalling (Sancak et al. 2007). 
 
Full activation of mTORc1 requires signals from growth factors and from amino 
acids, in particular leucine (Menon et al. 2014). The amino acid sensing of mTORc1 
functions through a mechanism that is independent of TSC2. Amino acids are sensed 
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on the lysosome by an unknown mechanism that is dependent on Rag GTPases and 
involves the vATPase (Zoncu et al. 2011) that can activate the GEF activity of the 
Ragulator complex (Bar-Peled et al. 2012) towards the heterodimer of RagA/B and 
RagC/D (RagA/BGTP-RagC/DGDP). Then, the active RagA recruits mTORc1 to the 
lysosome (Sancak et al. 2010), which can be activated by RHEB that is constitutively 
present on the lysosome. Also glutamine availability is important for mTORc1 
activity (described in section 1.5). 
 
 
Figure 1-3 Model of mTORc1 activation.  
Amino acids, e.g. leucine are crucial for mTORc1 activation. Leucine levels are sensed on the 
lysosome to initiate the cascade of events involving vATPase, Ragulator complex and RagA 
that recruits mTORc1 from the cytosol to the lysosome. Activation of PI3K e.g. by growth 
factors, initiate AKT activation that phosphorylates and inhibits TSC2 function, allowing 
GTP-loading of RHEB and RHEB activates mTORc1. Figure based on (Bar-Peled & Sabatini 
2012; Menon et al. 2014).  
 
What is known about mTORc1 activation in T cells? While naïve T cells present only 
low mTORc1 activation, consistent with the fact that they are quiescent cells, 
activated T cells show high levels of mTORc1 activity (Waickman & Powell 2012). 
Amino acid-driven mTORc1-regulating pathways are crucial for the maintenance of 
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mTORc1 activity in T cells (Sinclair et al. 2013). Additionally, TCR induced 
calcium-calcineurin signalling leads to the upregulation of the expression of System L 
amino transporters that transport large neutral amino acids, such as leucine, into the 
cell (Sinclair et al. 2013). Leucine is an mTORc1 activator (BEUGNET et al. 2003; 
Proud 2007). In T cells, Slc7a5 plays a crucial role (Sinclair et al. 2013). While 
Slc7a5 expression is not important for the development of T cells and maintenance of 
naïve T cells, it is crucial for the differentiation of effector CD8+ cells. Slc7a5 null T 
cells, thus, are not able to perform the metabolic switch that is required for their 
activation.  
 
The contribution of the AKT-TSC2 signalling to the activation of mTORc1 is still not 
fully understood in T cells. A study by Shrestha at al., proposed that the deletion of 
TSC1 in T cells leads to increased mTORc1 activity only seen in TCR stimulated, but 
not in quiescent T cells (Shrestha et al. 2014). Similarly, deletion of TSC2 in T cells 
leads to only a slight upregulation of mTORc1 activity in quiescent T cells (Pollizzi 
et al. 2015). However, there are no studies addressing if active AKT promotes the re-
localisation, or decrease in GAP activity, of TSC2 in T cells. Our laboratory has 
shown that inhibition of the PI3K-AKT pathway with specific inhibitors does not 
inhibit mTORc1 activity (Macintyre et al. 2011), but instead has found that PDK1 is 
the major regulator of mTORc1 activity in T cells (Finlay et al. 2012). Moreover, 
mTORc1, rather than AKT, controls metabolism in normal T cells by regulating the 
expression of Hypoxia-inducible factor 1α (Hif1α) (Finlay et al. 2009). 
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1.5.2.3 Downstream targets of mTORc1 
mTORc1 has two main substrates: initiation factor 4E binding protein 1 (4E-BP1) 
and the p70 S6 ribosomal kinase1 (S6K1) (Laplante & Sabatini 2012). 
Phosphorylated 4E-BP1 enables the eIF4E-promoted cap methylation of mRNAs 
characterised by a 5’ terminal oligopyrimidine (TOP) motif (Thoreen et al. 2012). 
Similarly, phosphorylation of S6K by mTORc1 leads to an increase in mRNA 
biogenesis, cap-dependent translation, elongation and translation of ribosomal 
proteins (X. M. Ma & Blenis 2009). Additionally, mTORc1 is a positive regulator of 
transcription factors, such as sterol regulatory element binding protein (Porstmann et 
al. 2008) and peroxisome proliferator-activated receptor γ (J. E. Kim & J. Chen 2004) 
that control expression of genes involved in lipid and cholesterol homeostasis. 
Moreover, mTORc1 is involved in repressing autophagy, by phosphorylating and 
inhibiting ULK1 and autophagy-related gene (ATG13), proteins that are required for 
the generation and activation of autophagy specific activity (Ganley et al. 2009; 
Hosokawa et al. 2009).  
 
1.5.3 Hypoxia inducible factor α (Hif1α) 
1.5.3.1 Overview  
mTORc1 controls the expression of glucose transporters and glycolytic enzymes in T 
cells. It has been proposed that mTORc1 exerts these functions by regulating Hif1α 
expression (Finlay et al. 2012). Hif1α was identified at the enhancer of the 
erythropoietin gene under hypoxic conditions (Semenza & G. L. Wang 1992; R. 
Wang & D. R. Green 2012). There are three isoforms of Hifα: Hif1α, Hif2α and 
Hif3α. Whereas Hif1α is ubiquitously expressed, expression of Hif2α is 
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predominantly confined to tissues such as brain, heart, lung or kidney (Wiesener et al. 
2003). In this section we will focus on Hif1α, as lymphocytes exclusively express 
Hif1α isoform.  
 
Hif1α and its binding partner Hif1β are members of the basic-helix-loop-helix 
Per/ARNT/Sim (bHLH-PAS) family of transcription factors (G. L. Wang et al. 1995). 
In order to induce expression of target genes Hif1α must dimerise with Hif1β 
(Salceda et al. 1996) via the bHLH and part of the PAS domain and then with DNA 
via the bHLH domain (Jiang et al. 1996; Sang et al. 2002). Hif1α function is critical 
during embryogenesis as mice with Hif1α deletion die prematurely mainly due to a 
lack of blood vessel formation (Ryan et al. 1998; Iyer et al. 1998; Kotch et al. 1999). 
In contrast, deletion of one allele of Hif1α rescues mice from death but impairs their 
physiological responses when challenged by hypoxia (Kline et al. 2002). Initially, the 
primary function of Hif1α was considered to be in the processes involved in 
erythropoiesis and angiogenesis (Josko et al. 2000). Subsequently, it was discovered 
that Hif1α also stimulates expression of glycolytic enzymes. Hypoxic cells, due to 
expression of Hif1α and its transcriptional activity, are able to upregulate the 
expression of glucose transporters and rate-limiting glycolytic enzymes (C. Chen et 
al. 2001; Wenger 2002).  
 
1.5.3.2 Hif1α regulation 
The expression of Hif1α under 21% O2 is prevented because Hif1α protein is 
ubiquitinated and subjected to proteasomal degradation by the von Hippel Lindau 
protein (pHVL) (Maxwell et al. 1999). This is in contrast to hypoxic conditions that 
allow for the stabilization and accumulation of Hif1α protein expression due to 
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reduced degradation by the pVHL. The degradation of Hif1α under normoxic 
conditions is mediated by prolyl hydroxylase domain-containing proteins 1, 2 and 3 
(PHD1, PHD2, PHD3) that catalyse hydroxylation of conserved proline residues 
(Pro402 and Pro564). PHD2 has the highest affinity for Hif1α. The hydroxylated 
Hif1α is then targeted for degradation by the E3 ubiquitin ligase containing pVHL 
(Ivan et al. 2001; Kenneth & Rocha 2008).  
 
The mechanism by which Hif1α translation is regulated is still not fully understood. It 
has been proposed that mTORc1 (Hudson et al. 2002) and MAPK (Fukuda et al. 
2002) signalling pathways are involved in Hif1α translation. The translational 
repressor 4E-BP1 can be phosphorylated by mTORc1 and MAPK and, thus, allows 
eIF4E to promote cap-dependent translation of mRNA (Thoreen et al. 2012). 
However, the discovery that Hif1α mRNA does not contain the 5’ TOP motif rejected 
this hypothesis and left the question open. Nonetheless, mTORc1 does play a role in 
Hif1α T cells regulation because treatment with rapamycin abolishes Hif1α 
translation and not mRNA expression (Finlay et al. 2012).  
 
1.5.3.3 The role of Hif1α in T cells and T-ALL cells 
What is known about Hif1α signalling in T cells? The Hif1α protein is absent in naïve 
T cells and mRNA is only expressed after TCR mediated activation under hypoxic 
conditions and this expression of Hif1α is needed for the repression of activation-
induced death in T cells that promotes their survival (Lukashev et al. 2001; Makino et 
al. 2003). However, it was shown that Hif1α ablation in TCR activated T cells does 
not have a detrimental effect on the T cells, but instead leads to the overproduction of 
pro-inflammatory cytokines, i.e. IFNγ, TNFα, IL-2, IL4 and IL13 under normoxic 
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and hypoxic conditions (Lukashev et al. 2006). The data, thus, argue that Hif1α is 
important for the negative regulation of T cells and may have an anti-inflammatory 
function; however, it is not fully understood how this function is regulated. The most 
recent work performed in different types of lymphocytes, i.e. effector CD8+ cells or 
effector CD4+ (Th17 cells) cells showed that Hif1α directly contributes to the 
glycolytic behaviour of these cells by promoting expression of glucose transporters 
and rate-limiting glycolytic enzymes (Shi et al. 2011; E. V. Dang et al. 2011; Finlay 
et al. 2012). There is not much known about the Hif1α role in T-ALL. However, the 
current data imply that pharmacological inhibition or deletion of Hif1α in leukaemia 
inducing cells, that are capable of promoting tumours, leads to their elimination (Y. 
Wang et al. 2011b; Giambra et al. 2015).   
 
1.5.4 c-Myc in T cells and T-ALL 
mTORc1 is an important metabolic regulator in normal T cells and could be  
important in controlling metabolism in T-ALL cells. However T-ALLs also express 
c-Myc and this molecule is also a key regulator of metabolism in many cell systems 
including T cells (Schubbert et al. 2014; Roderick et al. 2014; Weng et al. 2006; 
Bonnet et al. 2011; Wise et al. 2008). Expression of c-Myc is crucial for T cell 
activation as it induces glucose and glutamine metabolism (R. Wang et al. 2011a). 
Additionally, levels of c-Myc protein are tightly controlled in immune activated T 
cells by the T cell antigen receptor and the key pro-inflammatory cytokine, IL-2 
(Preston et al. 2015). Importantly, c-Myc is constantly phosphorylated by GSK3 on 
Thr58 and targeted for degradation, therefore it can only accumulate in cells that are 
metabolically active and have high rates of protein synthesis.  
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The importance of c-Myc as a proto-oncogene in lymphomas was first noticed in 
Burkitt’s lymphomas, where c-Myc was mutated due to translocations of the gene 
(Taub et al. 1982; Dalla-Favera et al. 1982). c-Myc translocations t(8;14)(q24;q11) 
between c-Myc and Tcra chain are relatively infrequent in human T-ALL (less than 
1%) (Shima et al. 1986; Erikson et al. 1986), however the overexpression of c-Myc 
protein is commonly observed in T-ALL. One mechanism by which c-Myc mRNA is 
overexpressed is via Notch1 activation (Palomero et al. 2006; Weng et al. 2006). 
Another mechanism by which malignant cells increase the expression of c-Myc 
protein is by preventing its proteasomal degradation. c-Myc can be phosphorylated on 
Thr58 and this phosphorylation targets c-Myc for degradation (Welcker, Orian, Jin, et 
al. 2004b) Thus, inactivating mutations or deletions in E3 ubiquitin ligase, Fbw7, 
contributes to the formation of T-ALL (O'Neil et al. 2007). Also, in Burkitt’s 
lymphoma, the Thr58 site on c-Myc is frequently found to be mutated leading to 
stabilization of c-Myc protein (Bhatia et al. 1993). Due to the frequent c-Myc 
mutations in T cell leukaemia, its role in tumourigenesis was already studied. It was 
shown that the inhibition of bromodomain (a potent regulator of c-Myc expression) 
that downregulate c-Myc transcription or deletion of c-Myc by shRNA in leukaemia 
initiating cells led to impaired proliferation of malignant cells (Schubbert et al. 2014; 
Roderick et al. 2014). Moreover, genetic ablation of c-Myc in PTEN null 
haematopoietic cells prevents tumourigenesis, arguing for the critical role of c-Myc (J 
Zhang et al. 2011).  
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1.6 Aims of thesis 
Deletion of PTEN selectively in T cell progenitors in the thymus results in the rapid 
development of aggressive T cell lymphomas in a mouse model for T-ALL. In the 
present thesis we will use this mouse model of T-ALL to explore the signaling 
pathways that control metabolism in T-ALL. Normal T cells precisely regulate 
expression of key nutrient receptors, in particular they tightly regulate expression of 
LNAA (e.g. leucine), glutamine and glucose transporters as well as transferrin 
receptor. The aim of the present study was to examine the regulation of the nutrient 
uptake in PTEN null T-ALL and to address the relative contributions of PI3K/AKT, 
mTORc1 and Hif1α in the metabolism of these cells.  
In the first part we will explore what is the capacity of PTEN null T-ALL to take up 
leucine, glutamine, glucose and transferrin. Once we have established the metabolic 
status of the PTEN T-ALL, we will examine whether PTEN deletion is sufficient to 
initiate uptake of key nutrients. For this question, we will utilise leukaemic T cells 
isolated from tumour bearing PTENfl/fl x LckCre+ mice and non-transformed 
thymocytes isolated from tumour free PTENfl/fl x LckCre+ mice.  
A key question is the role of mTORc1 and Hif1α in controlling T-ALL metabolism. 
Therefore in the second part of this thesis we want to understand if mTORc1 is active 
in PTEN null leukaemic T cells. Furthermore, we will evaluate if mTORc1 can drive 
the metabolism in PTEN null T-ALL cells and also, if and when Hif1α is expressed 
and whether its expression is mTORc1-dependent.  
Finally, given the importance of Hif1α in regulating glucose metabolism and 
glycolysis and the fact that the increased glucose uptake is the hallmark of increased 
metabolism, we will examine how deletion of Hif1α in PTENfl/fl x LckCre+ mice 
contributes to the development of T cell leukaemia/lymphoma cells.  
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2 Chapter: Materials and Methods 
2.1 Transgenic mice 
2.1.1 PTENfl/fl x LckCre+/- mice 
PTENfl/fl mice, in which LoxP sites flank exon 5 of the Pten gene, were generated and 
described by Hagenbeek at al. (Hagenbeek et al. 2004). To delete PTEN, PTENfl/fl 
mice were backcrossed with mice expressing Cre recombinase under the control of 
the proximal Lck promoter. This allows for deletion of flanked PTEN in early T cell 
progenitors in the thymus (the deletion is completed by the DN3 stage of thymus 
development). Mice used in experiments: PTEN-/- non-transformed thymocytes were 
obtained from PTENfl/fl x LckCre+ mice culled before 6th week of age and hence before 
development or symptoms of tumours. PTEN-/- T cell lymphoma/leukaemia cells 
were isolated from PTENfl/fl x LckCre+ mice culled when the signs of tumour occurred 
and typically included hunched posture, rough coat, lack of mobility and/or swollen 
abdomen/neck. As controls, mice with the genotypes PTENfl/fl x LckCre- or PTENwt/wt 
x LckCre+ (WT) were used.  
 
2.1.2 Hif1αfl/fl x LckCre+/- mice 
Hif1αfl/fl mice, in which LoxP sites flank exon 2 of the Hif1α gene, were purchased 
from the Jackson Laboratory™. Hif1αfl/fl mice were backcrossed with mice 
expressing Cre recombinase under the control of the proximal Lck promoter, which 
allows for deletion of flanked Hif1α in early T cell progenitors. To examine the role 
of Hif1α in T cells, Hif1αfl/fl x LckCre+ mice were compared to Hif1αwt/wt x LckCre+ or 
Hif1αfl/fl x LckCre- (WT).  
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2.1.3 PTENfl/fl x Hif1αfl/fl x LckCre+/- mice 
PTENfl/fl x Hif1αfl/fl x LckCre+/- mice were generated by crossing mice with floxed 
PTEN alleles, floxed Hif1α alleles, and mice expressing Cre recombinase under the 
control of the proximal Lck promoter. To establish the role of Hif1α in PTEN null 
mice, PTEN-/- x Hif1α-/- T cell lymphoma/leukaemia cells from PTENfl/fl x Hif1αfl/fl x 
LckCre+ mice were compared to WT thymocytes from PTENfl/fl x Hif1αfl/fl x LckCre- 
mice (WT). PTENfl/fl x Hif1αfl/fl x LckCre+ mice were culled when the signs of tumour 
occurred and typically included hunched posture, rough coat, lack of mobility and/or 
swollen abdomen/neck.  
 
2.1.4 Mice maintenance 
All mice in this study were bred and maintained in the Wellcome Trust Biocentre 
Transgenic Resource Unit, University of Dundee in compliance with UK Home 
Office Animals (Scientific Procedures) Act 1986 guidelines. 
 
2.2 Cell culture 
2.2.1 Reagents 
§ Hamster-anti-mouse CD3 (2C11), R&D Systems/CRUK hybridoma unit 
§ anti-CD28 antibody, Life technologies 
§ β-mercaptoethanol, Sigma 
§ Fetal bovine serum, Life Technologies 
§ Penicilin/Streptomycin, Life Technologies 
§ Recombinant human IL-2 (Proleukine®), Novartis 
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§ RPMI (Rosewell Park Memorial Institute) 1640 (+L-glutamine, +glucose), 
Life Technologies 
§ RPMI (Rosewell Park Memorial Institute) 1640 (-glutamine, +glucose), Life 
technologies 
§ DMEM (Dullbecco’s Modified Eagle’s Medium), Life Technologies 
§ α-MEM (Minimum Essential Medium eagle-α), Life Technologies 
§ IMEM (Iscove's Modified Dulbecco's Medium), Life Technologies 
§ HBSS (Hank’s Balanced Salt Solution), Life Technologies 
 
2.2.2 Cell culture media and solutions 
T-ALL medium: IMEM with 10% (v/v) FBS, 100 U/ml penicillin-G and 100 µg/ml 
streptomycin. 
 
Thymocyte medium: DMEM, 10% (v/v) FBS, 100 µM β-mercaptoethanol, 100 U/ml 
penicillin-G, 100 µg/ml streptomycin. 
 
OP9 medium: α-MEM, 20% (v/v) FBS, 100 µM β-mercaptoethanol. 
 
Glutamine free medium: RPMI 1640 pre-supplemented with 25 mM glucose, 10% 
(v/v) FBS, 100 U/ml penicillin-G, 100 µg/ml streptomycin. 
 
Amino acid free medium: HBSS, 10% (v/v) FBS, 100 U/ml penicillin-G, 100 µg/ml 
streptomycin. 
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CTLs medium: RPMI 1640 pre-supplemented with 25 mM glucose and 300 mg/mL 
L-glutamine, 10% (v/v) FBS, 100 µM β-mercaptoethanol, 100 U/ml penicillin-G, 100 
µg/ml streptomycin. 
 
ACK (Ammonium-Chloride-Potassium) buffer, to lyse red blood cells: 155 mM 
ammonium chloride, 10mM potassium bicarbonate, 0.1 mM 
ethelenedieaminetetraacetic acid (EDTA). The buffer was adjusted to pH 7.8 and 
autoclaved. 
 
2.2.3 In vitro T-ALL cell culture 
The PTEN-/- T leukemic cell lines, F04, F07 and F15, were maintained at 0.3x106 
cells/ml in T-ALL medium incubated at 37°C with 5% CO2. To investigate nutrient 
deprivation, cells were switched to Glutamine-free medium or Amino acid-free 
medium and incubated at 37°C with 5% CO2. To subject cells to hypoxic conditions, 
cells were cultured at 37°C with 5% CO2 and 1% O2. 
 
2.2.4 In vitro thymocytes cell culture 
Thymi were obtained from age- and sex- matched WT and PTENfl/fl x LckCre+, 
Hif1αfl/fl x LckCre+ or PTENfl/fl x Hif1αfl/fl LckCre+ mice. To obtain a single cell 
suspension, the thymi were passed through a 70µm cell strainer. Thymocytes were 
maintained at 10x106 in Thymocyte medium at 37°C with 5% CO2. To subject the 
thymocytes to hypoxic conditions, cells were cultured at 37°C with 5% CO2 and 1% 
O2. 
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2.2.5 In vitro OP9 cultures generation 
OP9-DL1 system allows the assessment of Notch responsiveness in pre-T cells in 
vitro. OP9 bone marrow stromal cells expressing the Notch ligand OP9-DL1 (Schmitt 
et al, 2004b) and control OP9 cells were a gift from Juan Carlos Zuniga- Pflucker 
(Toronto, Canada). OP9 cells were maintained in the OP9 medium. DN thymocytes 
were purified using CD4+ and CD8+ T cell isolation kits (Miltynei Biotec) and were 
co-cultured on OP9 and OP9-DL1 monolayers for the required duration of culture. 
On the day of harvest, thymocytes were filtered through 50 µm filters to remove OP9 
cells.  
 
2.2.6 In vitro cytotoxic T cell generation 
Spleens and lymph nodes were obtained from age and sex matched WT and PTENfl/fl 
x LckCre+, Hif1αfl/fl x LckCre+ or PTENfl/fl x Hif1αfl/fl LckCre+ mice and passed through 
a 70µm cell strainer to disaggregate the cells. Red blood cells were lysed by treating 
the cell suspension with 5 ml of ACK buffer for less than a minute. Cells were then 
washed and resuspended in CTLs medium. T cells were activated by addition of 500 
ng/mL 2C11 and 4 ng/mL αCD28 in the presence of 20 ng/mL IL-2. After 48 hours, 
cells were washed and resuspended in CTLs medium with 20 ng/mL IL-2. The 
following day, CD8+ cells were purified using a CD8+ T cell isolation kit (Miltynei 
Biotec). Following purification the cells were washed and resuspended in CTLs 
medium and maintained in exponential growth with 20 ng/mL IL-2 for a further 4 
days. 
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2.2.7 Auto MACS purification of CD8+ T cells 
CD8+ T cells or DN thymocytes were isolated from a spleen or thymus cell 
suspension using an auto MACS CD8+ T cell isolation kit or CD8+ and CD4+ 
isolation kit, respectively. The cells of interest were isolated by depletion of non-
labelled cells (negative selection). The cell suspension was indirectly labelled with a 
cocktail of biotin-conjugated monoclonal antibodies binding to the unwanted cells. 
Following incubation with the antibodies, the cells to be deleted were magnetically 
labelled with streptavidin-beads. Then, using MACS columns and a MACS separator, 
magnetic separation was performed. During the separation the magnetically labelled 
non-CD4+/CD8+ T cells were depleted by their retention on a MACS column in the 
magnetic field of a MACS separator, while the unlabelled T cells pass through the 
column. The non-labelled cells were collected and the purity was tested by flow 
cytometry analysis.  
 
2.2.8 Inhibitor treatments and stimulations 
Where indicated cells were treated with inhibitors at the following concentrations: 
• Rapamycin at 20 nM 
• AKT inhibitor VIII (AKTi) at 1µM 
• Phorbol ester at 25 ng/ml 
• Pervanadate at 100 µM 
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2.3 Assessment of Hif1αfl and PTENfl deletion  
2.3.1 DNA extraction 
DNA was extracted from 1-5x106 WT thymocytes or tumours isolated from PTENfl/fl 
x Hif1αfl/fl x LckCre+ mice using the Ultra Clean® Tissue & Cells DNA isolation kit, 
as per the manufacturer’s instructions. The concentration of the extracted DNA was 
determined using a Nanodrop spectrophotometer (Thermo Scientific).  
 
2.3.2  Assessment of deletion by PCR 
Deletion of exon 2 in Hif1α and exon 5 in PTEN was assessed by PCR of 50 ng DNA 
using the following primers: 
• Hif1α loxP F: GCCTTACCTAGTAAAGCAAG 
• Hif1α loxP R: GCAAAGAATCTTGGTGTTAC 
• Hif1α R: GCGCTGCTGGAAACAATCACAAGAA 
• PTEN loxP F: GGTGCTGGTGTCCAAAATGT 
• PTEN loxP R: GGGCAGTACTGGAAAGATGG 
• PTEN R: ATAGCTATTAGTGTCTTAACCTGCCC 
 
2.4 Flow cytometric analysis 
Flow cytometric data were obtained using a FACS Verse or a FACS LSRII Fortessa. 
The collected events were stored without gates and the data were analysed using 
FlowJo version 9.6.4 data analysis software (Tree star inc.). 
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2.4.1 Reagents for flow cytometry 
§ HBSS, Life Technologies  
§ Phosphate buffered saline (PBS) tablets, Sigma 
§ Fetal bovine serum, Life Technologies 
§ Methanol, VWR International 
§ Paraformaldehyde, Sigma 
§ DMEM, Life technologies 
§ Bovine serum albumine (BSA), Sigma 
§ Transferrin, Alexa Fluor conjugate, Invitrogen 
§ Holo-transferrin, Sigma 
§ DAPI, Invitrogen 
 
2.4.2 Solutions for flow cytometry 
FACS buffer: 0.5% (v/v) FBS in HBSS 
Fixing buffer: 1% (w/v) paraformaldehyde in water 
Permeabilization buffer: 90% (v/v) methanol in water 
Transferrin free medium: DMEM with 5% (w/v) BSA, 100 µM β-mercaptoethanol, 
100 U/ml penicillin-G, 100 µg/ml streptomycin 
Acid wash: 150mM NaCl, 20 mM citric acid, adjusted to pH 5.0 
 
2.4.3 Cell counting by flow cytometry 
Cells were resuspended in PBS and counted using the Verse Flow cytometer. The 
number of cells per 1 ml was calculated as follows: cells/volume x dilution x 106.  
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2.4.4 Antibodies for flow cytometry 
Antibodies recognising specific targets (see Table 1.1) were directly conjugated to the 
flurophores: Fluorescein Isothiocyanate (FITC), R-Phycoerythrin (PE), 
Allophycocyan (APC), Peridinin-chlorophyll proteins (PerCP), Briliant Violet (BV), 
Horizon V450 (HV450). 
 
 
Table 1 Flow cytometry antibodies and their conjugates 
 
Antibodies and working dilution
Clone/
catalogue 
number
Company
Thy1.1 (FITC) 1:200, (APC) 1:400,
(BV510) 1:200
53-2.1, HIS51
Pharmingen, 
eBioscience, 
Biolegend
Thy1.2 (APC) 1:400 HIS51 eBioscience
CD8 (FITC, PE, PerCP-Cy5.5,
APC, HV450, BV510) 1:200
53-6.7
Pharmingen,
Biologened
CD4 (PECy7, BV605) 1:200 RM 4-5
Pharmingen, 
Biolegend
B220 (HV500) 1:200 RA3-682 BD Horizon
TCR (PerCP Cy5.5, APC ef 780)
1:200
H57-597 eBioscience
CD25 (FITC, PECy7) 1:200 7D4, PC61 Pharmingen
CD44 (APC ef780) 1:200 IM7 Pharmingen
CD71 (PE, APC) 1:200 C2, R17217
eBioscience 
Pharmingen
CD98 (PE) 1:200 RL388 eBioscience
CD24 (PerCP Cy5.5) 1:200 M1/69 eBioscience
Alexa-647 conjugated transferrin
 1:100
T23366 Invitrogen
pS6 (Ser235/236) 1:100 #4558
Cell Signaling 
Technology
Alexa-647 conjugated anti-rabbit
1:5000
711605152
Jackson 
ImmunoReaserach
FITC conjugated anti-rabbit
1:100
111095003
Jackson 
ImmunoReaserach
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2.4.5 Live cell staining 
Cells (1-3x106) were stained at previously determined saturating concentrations of 
antibody at 4ºC for a minimum of 5 minutes in FACS buffer. Cells were washed and 
resuspended in FACS buffer prior to acquisition. A minimum of 20000 relevant 
events was collected. Live cells were gated according to their forward scatter (FCS) 
and side scatter (SSC) profiles or, when analysing transferrin uptake or cell cycle, the 
live cells were identified as DAPI negative populations (1µg/ml of DAPI).  
 
2.4.6 Analysis of intracellular phospho-S6 staining/levels in fixed cells 
Ex vivo isolated thymocytes were either left untreated or stimulated with 20 nM 
rapamycin or 25 ng/ml Phorbol ester at 37ºC for 30 minutes prior to staining. Cells 
were stained for the cell surface markers Thy1, CD4 and CD8 for 5 minutes, before 
being fixed in fixing buffer at 37ºC for 15 minutes and permeabilised with 
permeabilization buffer at -20º C for at least 60 minutes. Cells were washed twice 
after permeabilization and incubated with primary antibody against pS6 (Ser235/236) 
at RT for 30 minutes. Cells were again washed twice and incubated with secondary 
antibody: either FITC conjugated anti-rabbit 
or Alexa -647 conjugated anti-rabbit secondary antibodies at RT for another 30 
minutes. Cells were washed twice, resuspended in FACS buffer prior to acquisition. 
A minimum of 20000 relevant events was collected.  
 
2.4.7 Transferrin uptake assays 
Ex vivo isolated thymocytes (1x106 cells) were incubated in filtered, pre-warmed 
Transferrin free medium at 37º C for 2 hours. Next, cells were resuspended in 100 µl 
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of 0.5% (w/v) BSA/DMEM and treated as follows: left untreated at 37° C, treated 
with 5 µg/ml transferrin with or without 500 µg/ml holo-transferrin, or treated with 5 
µg/ml transferrin on ice. Transferrin uptake was measured over a 10 minutes period. 
Uptake of transferrin was stopped by placing cells on ice, after which they were 
washed twice with acid wash to strip surface-bound transferrin. The cells were then 
resuspended in FACS buffer. Cell surface staining for the Thy1, CD4, CD8, and 
CD71 was then performed and transferrin uptake was quantified from the 
fluorescence emission at 647 nm.  
 
2.4.8 Cell cycle analysis 
Ex vivo isolated thymocytes (5x106 cells) were incubated with 10 µg/ml Hoechst-
33342 (Molecular probes) in DMEM with 1% (v/v) FBS at 37º C for 30 minutes. 
Next, cells were stained for the surface markers Thy1, CD4 and CD8 as described 
before. Immediately before analysis, cells were resuspended in FACS buffer 
containing 1µg/ml DAPI. Data were analysed using doublet discrimination module 
and fitted to the Watson-pragmatic model (Watson et al. 1987). 
 
2.4.9 Fluorescence Activated Cell Sorting (FACS) 
FACS was performed on a BD Influx™ Cell Sorter by Dr Rosemary Clarke or Arlene 
Wigham, University of Dundee. Ex vivo isolated thymocytes were stained for the 
surface markers Thy1, CD4, CD8 as described and prior to sorting cells were 
resuspended in FACS buffer containing 1µg/ml DAPI. Double positive thymocytes 
were sorted. 
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2.5 Metabolic assays 
2.5.1 Measurements of glucose, glutamine or leucine uptake. 
2.5.1.1 Reagents 
§ RPMI 1640 (+glutamine, -glucose), Life technologies 
§ RPMI 1640 (-glutamine, +glucose), Life technologies 
§ HBSS, Life technologies  
§ Deoxy-D-glucose, 2-[1,2-3H(N)]-, Perkin Elmer 
§ L-[3,4-3H(N)]-Glutamine, Perkin Elmer 
§ L-[3,4,5-3H(N)]-Leucine, Perkin Elmer 
 
1.5.1.2 Glucose analogue/glutamine/leucine uptake assay 
Glucose, glutamine and leucine uptakes were performed in the same manner, with the 
uptake of nutrients being measured over 4 minute periods. A total of 4x106 of ex vivo 
isolated thymocytes were washed and re-suspended in 800 µl of glucose-free, FCS-
free medium (glucose uptake) or FCS-free HBSS (glutamine/leucine uptake) as 
appropriate. Then, 1x106 thymocytes, in 200 µl of the appropriate medium, were 
loaded on top of 500 µl phthalatediisononylester oil (Sigma-Aldrich) mixed in 1:1 
ratio with poly(dimethyloiloxane-co-methyl-phenylsiloxane) oil (Sigma-Aldrich) 
containing 200 µl of 0.5 µCi/ml deoxy-D-glucose, 2-[1,2-3H(N)]- in glucose-free 
medium or 0.5 µCi/ml L-[3,4-3H(N)]-Glutamine in HBSS or 0.5 µCi/ml L-[3,4,5-
3H(N)]-Leucine in HBSS. After 4 minutes of exposure to the radiolabelled nutrients, 
cells were spun at 8000 rpm for 3 minutes and washed twice with deionised water to 
remove the excess of oil. Cell pellets were lysed with 200 µl of 1M NaOH, and the 
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incorporated 3H radioactivity was quantified via liquid scintillation counting using a 
Beckman LS 6500 Scintillation Counter. Each condition was performed in triplicate.  
 
2.5.2 Measurement of lactate production 
2.5.2.1 Reagents 
§ Glycine, Sigma-Aldrich 
§ Hydrazine monohydrate, Sigma-Aldrich 
§ β- Nicotinamide adenine dinucleotide hydrate (NAD+), Sigma-Aldrich 
§ Rabbit muscle lactate dehydrogenase VII (LDH), Sigma-Aldrich 
§ L- Lactate, Sigma-Aldrich 
 
1.5.2.2 Lactate production assay 
The lactate assay is based on a colorimetric reaction in which L(+)-lactate is oxidised 
by lactate dehydrogenase (LDH) that exhibits a maximum absorbance at 450 nm. For 
measuring lactate output, 1x106 ex vivo isolated thymocytes were washed, 
resuspended in DMEM medium containing 10% (v/v) dialysed FCS and cultured for 
4 hours. After this time, cells were pelleted down and supernatant collected and 
stored at -80ºC. For the lactate standard curve, sodium lactate at concentration of 40 
mM was used to make 2-fold serial dilutions. 100 µl of cell supernatants and 
standards were added in triplicates into a 96-well plate and mixed with 100 µl of a 
master-mix reaction containing: 320 mM glycine, 320 mM hydrazine, 2.4 mM NAD+ 
and 3U/ml LDH. The plate was then incubated at 25ºC for 10 minutes and the 
absorbance was read in a cytofluor II Fluorescence Multi-Well Plate Reader 
(Perceptive BioSystems), excitation 360 nm, emission 460 nm, gain 45x. Lactate 
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content was determined by subtracting the background signal from all readings and 
then constructing a standard curve of log[lactate] versus absorbance, fitted using a 
sigmoidal model. 
 
2.6 SDS-PAGE and Western blotting 
2.6.1 Reagents  
§ 4x LDS sample buffer, Life Technologies 
§ cOmplete protease inhibitor cocktail, Roche 
§ Powdered non-fat milk, Marvel 
§ TCEP (tris(2-carboxyethyl)phosphine), Thermo 
 
2.6.2 Solutions  
RIPA lysis buffer: 50 mM HEPES pH 7.4, 150 mM NaCl, 1% (w/v) NP-40, 0.5% 
(w/v) sodium deoxycholate, 0.1% (w/v) SDS, 10% (w/v) glycerol, 1 mM EDTA, 1 
mM EGTA, 50 mM NaF, 5 mM sodium pyrophosphate, 10 mM sodium β-
Phosphoglycerate, 0.5 mM sodium orthovanadate, 1 mM neutralised TCEP, with 1 
tablet cOmplete Protease inhibitor Cocktail tablet per 10 ml 
 
Tris lysis buffer: 50 mM NaCl, 10 mM Tris-HCl pH 7.05, 30 mM sodium 
pyrophosphate, 50 mM NaF, 5 µM ZnCl2, 10% (w/v) glycerol, 0.5% (w/v) Triton, 1 
mM neutralised TCEP, with 1 tablet cOmplete Protease inhibitor Cocktail tablet per 
10 ml 
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SDS-PAGE gel (resolving): 8 or 10% acrylamide, 0.1% (w/v) SDS, 0.375 M Tris-
HCL pH 8.8 
 
SDS PAGE gel (stacking): 4% acrylamide, 0.1% (w/v) SDS, 0.125 M Tris-HCl pH 
6.8 
 
Transfer buffer: 48 mM Tris, 39 mM glycine in 20% (v/v) methanol 
PBS-T: phosphate buffered saline (PBS), 0.05% (w/v) Tween-20 
Ponceau S: 0.1% Ponceau S, 0.5% (v/v) acetic acid 
 
2.6.3 Antibodies 
Antibodies (see Table 2) were diluted in 5% (w/v) non-fat milk in PBS-T or in 5% 
(w/v) BSA. 
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Table 2 Western blot antibodies  
 
2.6.4 Sample preparation, SDS-PAGE and Western blotting 
Cells were washed with ice cold PBS and lysed in Tris buffer or RIPA buffer at 
40x106 cells/ml (for thymocytes) or 20x106/ml (for CTLs) on ice for 15 minutes and 
then sonicated with a Branson Digital Sonicator to shear DNA. The lysates were then 
spun down in a refrigerated bench mini centrifuge at 14000 rpm for 15 minutes to 
remove non-soluble proteins. Samples were then mixed with 4x LDS buffer and 
TCEP, and incubated in 95ºC for 5 minutes to denature and reduce the proteins. 
Samples were loaded on a SDS-PAGE gel with a fixed acrylamide concentration of 8 
to 12% depending on the molecular weight of the proteins to be analysed. A Mini-
Antigen catalogue number Company
PTEN sc-7974 Santa Cruz Biotechnology, Inc.
pAkt (T308) #4056 Cell Signalling Technology
pAkt (S473) #4058 Cell Signalling Technology
pan Akt #9272 Cell Signalling Technology
S6K (T389) #9239 Cell Signalling Technology
pan S6K #9202 Cell Signalling Technology
Hif1 alpha 241809 R&D Systems
Hif1 beta sc-8076 Santa Cruz Biotechnology, Inc.
c-myc #9402 Cell Signalling Technology
pan S6 #2317 Cell Signalling Technology
Smc1 A300-055A Bethyl Laboratries, Inc.
pPRAS40 (T246) #13175 Cell Signalling Technology
pan PRAS40 #2691 Cell Signalling Technology
pTSC2 (T1462) #3611 Cell Signalling Technology
pan TSC2 #4308 Cell Signalling Technology
cleaved Notch1 
(Val1744)
#4147 Cell Signalling Technology
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Protean system (Bio-Rad) was used for electrophoresis and blotting of proteins. 
Samples were run at a fixed voltage of 100 V for 120 minutes or until the running dye 
from the sample buffer had left the gel. The proteins were then transferred onto 
Hybond-N membranes (GE Healthcare) on ice for 90 minutes. Transfer and equal 
loading was confirmed with Ponceau S staining. The membrane was washed with 
water and was then blocked with 5% (w/v) milk in PBS-T or 5% (w/v) BSA in PBS-
T at RT for 60 minutes. Blots were probed with primary antibodies, at optimised 
concentrations (1 µg/ml in most cases), diluted in 5% (w/v) milk in PBS-T or 5% 
(w/v) BSA in PBS-T at 4ºC overnight. Membranes were then washed three times 
with PBS-T at RT for 10 minutes then incubated with HRP tagged secondary 
antibody diluted in 5% (w/v) milk in PBS-T or 5% (w/v) BSA in PBS-T (1:5000) for 
60 minutes. Membranes were washed three times with PBS-T at RT for 20 minutes 
before detected proteins were visualised using ECL.  
 
2.7 Quantitative Mass Spectrometry 
2.7.1 Reagents 
§ Deepwell Plate 96/500, Lo Bind, Eppendorf 
§ Deepwell Plate 96/1000, Lo Bind, Eppendorf 
§ Pierce Detergent Removal Spin Plates, Thermo 
§ Sep-Pak C18 SPE cartridges, Waters 
§ Sep-Pak tC18 96-well µElution plate, Waters 
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2.7.2 Solutions 
Urea buffer lysis: 8 M urea, 100 mM Tris-HCl, pH 8.0 with 2x cOmplete protease 
inhibitor tablet and 1x PhosStop phosphatase inhibitor tablet per 10 ml. 
Digest buffer: 100 mM Tris-HCl pH 8.0, 0.1 mM CaCl2 
Desalting wash buffer: 0.1% (v/v) TFA 
Desalting elution buffer: 0.1% (v/v) TFA, 50% (v/v) acetonitrile 
SAX buffer: 10 mM sodium borate, pH 9.3, 20% (v/v) acetonitrile 
 
2.7.3 Sample lysis and in solution digest 
Ex vivo isolated thymocytes from PTENfl/fl x LckCre- (WT) mice and tumour cells 
from PTENfl/fl x LckCre+ mice were purified using Dead cell removal kit (Miltynei, 
Biotec) according to manufacturer’s protocol. 20x106 isolated cells were washed 
three times with cold HBSS and transferred into a 2.0 ml Lo Bind Eppendorf tube. 
Cells were lysed in 0.2 ml of urea lysis buffer and vigorously mixed at RT for 15 
minutes. The samples were then sonicated with a Branson Digital Sonicator and 
mixed for another 15 minutes. The protein concentration was determined by BCA 
assay as per manufacturer’s instructions. DTT, at a working concentration of 10 mM, 
was added to reduce cysteines and the samples were incubated at 30ºC for 30 min. 
Then, IAA was added, at a working concentration of 50 mM, and lysates were 
incubated in the dark at RT for 45 minutes to alkylate the sulfhydryl groups of the 
cysteines. Lysates were diluted with digest buffer to 4 M urea. LysC was added to the 
samples in a 50:1 (protein:LysC) ratio, and the samples were incubated at 30ºC 
overnight. The samples were then diluted to 0.8 M urea with digest buffer and trypsin 
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was added in a 50:1 (protein:trypsin) ratio to the samples. The samples were then 
incubated for further 8 hours at 30ºC before the resulting peptides were desalted.  
 
2.7.4 Sample desalting using Sep-Pak cartridges 
Samples were adjusted to 1% (v/v) TFA using 10% (v/v) TFA. The Sep-Pak 
cartridges were washed twice with 1 ml elution buffer and equilibrated twice with 1 
ml wash buffer before the acidified peptide samples were loaded. The flow through 
was loaded again to ensure maximal peptide binding. The peptide-loaded cartridges 
were washed three times with 1 ml washing buffer. Peptides were eluted into 2.0 ml 
Eppendorf tubes by two elutions of 600 µl elution buffer. The eluted peptides were 
reduced to dryness in a vacuum concentrator.  
 
2.7.5 Strong anion exchange chromatography 
The dried peptides were resuspended in 210 µl SAX buffer and the pH was readjusted 
to 9.3 with 1 M NaOH if necessary. Samples were injected and peptides separated by 
a Dionex Ultimate 3000 HPLC system equipped with an AS24 strong anion exchange 
column, using a similar protocol to the hSAX method described previously (Ly et al. 
2014). Peptides were chromatographed using a borate buffer system, namely 10 mM 
sodium borate, pH 9.3 (Buffer A) and 10 mM sodium borate, pH 9.3 + 0.5 M sodium 
chloride (Buffer B) and eluted using an exponential elution gradient into 12 fractions 
of 750 µl.  
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2.7.6 Desalting with tC18 Sep-Pak 96-well plate 
Fractions from the strong anion exchange chromatography were adjusted to 1% (v/v) 
TFA with 10% (v/v) TFA. Each well of the desalting plate was washed with 0.2 ml 
acetonitrile and equilibrated with 0.2 ml desalting buffer. The samples were then 
slowly applied onto the columns and washed first with 0.8 ml and then with 0.2 ml of 
the desalting wash buffer. The samples were then eluted into an Eppendorf 1000µl 
96-well plate with 0.2 ml desalting elution buffer. Samples were reduced to dryness 
in a vacuum concentrator.  
 
2.7.7 Liquid chromatography mass spectrometry (LC-MS/MS) 
Samples from desalting were resuspended at a concentration 0.066 µg/µl in 5% 
formic acid and 15 µl was used for analysis. Peptide chromatography was performed 
using Dionex RSLCnano HPLC. Peptides were loaded onto a 0.3 mm id x 5 mm Pep-
Map-C18 column using the following mobile phases: 2% acetonitrile + 0.1% formic 
acid (Solvent A) and 80% acetonitrile + 0.1% formic acid (Solvent B). The linear 
gradient began with 5% B to 35% B over 156 minutes with a constant flow of 300 
nl/min. The peptide eluent flowed into nanoelectrospray emitter at the front end of a 
Velos Orbitrap mass spectrometer (Thermo Fisher, San Jose, CA). A typical ‘Top15’ 
acquisition method was preformed. Briefly, the primary mass spectrometry scan 
(MS1) was performed in the Orbitrap at 60000 resolution. Then, the top 10 most 
abundant m/z signals were chosen from the primary scan for collision-induced 
dissociation and MS2 analysis in the Orbitrap mass analyser at 17500 resolution. 
Precursor ion charge state screening was enabled and all unassigned charge states, as 
well as singly charged species, were rejected. 
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2.7.8 Mass spectrometric data analysis by MaxQuant 
The data were processed, searched and quantified using the MaxQuant software 
package version 1.4.1.2 as described previously (Cox & Mann 2008), using the 
default settings and employing the mouse Uniprot database from October 2013 and 
the contaminants database supplied by MaxQuant. The following settings were used 
to assign peptides to masses: two miscleavages were allowed; carbamidomethylation 
on cysteine was treated as a fixed modification; enzymes were specified as Trypsin 
and LysC; variable modifications included in the analysis were methionine oxidation, 
deamination of glutamine and aspargine, N-terminal pyroglutamic acid formation, 
and protein N-terminal acetylation. Default MaxQuant settings included a mass 
tolerance of 7 ppm was for precursor ions, and a tolerance of 0.5 Da for fragment 
ions. A reverse database was used to apply a maximum false positive rate of 1% for 
both peptide and protein identification. This cut-off was applied to individual spectra 
and whole proteins in the MaxQuant output. The match between runs feature was 
activated with an allowed time window of 2 minutes. All proteins were quantified on 
the basis of unique proteins with the requantification enabled.  
 
Further downstream analysis was performed using the proteomic ruler in Persues 
software (Wisniewski et al. 2014) to calculate the copy numbers of each protein and 
Microsoft Excel. Student’s t-test was performed to determine statistical significance 
of recurring ratios.  
 
2.8 Data analysis and statistical evaluation 
All quantified data were processed in Microsoft Excel. Statistical evaluation was 
performed using Prism version 6 for Macintosh. Prism was used to generate bar and 
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line graphs, dot plots, column and survival graphs. Statistical tests used to determine 
significant differences were two-tailed t-tests for the experiments where the mean of 
at least 3 biological replicates were included and for the survival kinetics: Log-rank 
(Mentel-Cox) and Gehan-Breslow-Wilcoxon. Differences were considered significant 
when p<0.05. In figure legends, biological replicate assumes the use of single mouse 
and independent experiment assumes a replicate of an experiment performed on a 
different day.  
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3 Chapter: Nutrient uptake in primary PTEN-/- T cell 
lymphoma/leukaemia cells 
 
3.1 Introduction 
The objective of this study was to study the regulation of nutrient uptake in a mouse 
model of T-ALL. The model of choice was to use the mice with specific PTEN 
deletion in T cell progenitors in thymus generated and described by Hagenbeek at al., 
(Suzuki et al. 2001; Hagenbeek et al. 2004; Hagenbeek & Spits 2007). Mice with 
PTEN alleles floxed with LoxP Cre excision sites were backcrossed with mice that 
express Lck-cre transgene. The completion of deletion of floxed alleles is finished 
early during thymocytes development, at the CD4/CD8 double negative (DN3/DN4) 
stage (Gu et al. 1994). Initially, PTEN null mice show normal thymus development 
but around 8-10 weeks of age they develop aggressive T cell lymphoma/leukaemias 
that model T-ALL (Hagenbeek & Spits 2007; Hagenbeek et al. 2004). The PTEN null 
T cell lymphoma/leukaemia cells disseminate into peripheral lymph nodes and 
spleen. PTENfl/fl x LckCre+ mice die around 17 weeks of age (Finlay et al. 2009; 
Hagenbeek & Spits 2007). Importantly, T-ALLs have additional, secondary 
mutations, such as c-Myc translocations, IL-7R mutations or Notch activation, which 
occur around the transformation time making them a good model of human T-ALL 
(Bonnet et al. 2011; J Zhang et al. 2011; Shochat et al. 2011; Weng et al. 2004; 
Zenatti et al. 2011). 
 
In this chapter we will explore the nutrient uptake of PTEN-/- T cell 
lymphoma/leukaemia cells from the PTENfl/fl x LckCre+ mice.  It is well established 
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that tumour cells switch to aerobic glycolysis to metabolise glucose and increase 
glucose uptake to meet their metabolic demands (Hanahan & Weinberg 2011; Vander 
Heiden et al. 2009). However, change in the uptake of other nutrients is equally 
important for rapidly proliferating cells. For example elevated glutamine uptake and 
subsequent glutaminolysis is frequently observed in tumour cells which are 
considered to be glutamine addicted (Duran et al. 2012; Wise & Thompson 2010). It 
is known that T cell lymphoma/leukaemia cells have high levels of glucose uptake 
(Boag et al. 2006; Akers et al. 2011) but very little is known about whether they also 
increase uptake of other key nutrients such as amino acids and transferrin. 
Accordingly, we have explored patterns of nutrient uptake in primary PTEN-/- T cell 
lymphoma/leukaemia cells that develop in PTENfl/fl x LckCre+ mice. The control 
population used was WT thymocytes as these are the best-matched normal, non-
transformed T cells for the PTEN-/- T cell lymphoma/leukaemia cells. 
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3.2 Results 
3.2.1 PTEN-/- T cell lymphoma/leukaemia cells 
PTENfl/fl x LckCre+ mice developed aggressive T cell lymphoma/leukaemias and mice 
typically became sick and culled once the symptoms occurred, such as hunched 
posture, rough coat, lack of mobility and/or swollen abdomen/neck. WT mice 
remained healthy during the course of experiment. The median survival for PTENfl/fl 
x LckCre+ mice was 68 days (Fig. 3-1).  
 
 
Figure 3-1 PTENfl/fl x LckCre+ mice develop tumours and die prematurely.  
Graph showing the Kaplan-Meier curve for PTENfl/fl x LckCre+ and WT mice (PTENfl/fl x 
LckCre-). In the experiment 40 mice of each genotype were used. Once tumour development 
was observed in PTENfl/fl x LckCre+ mice, they were sacrificed along with age-matched 
controls (PTENfl/fl x LckCre- mice). If PTENfl/fl x LckCre- mice were tumour free at the time of 
sacrifice, they were marked as live. **** p< 0.0001 was calculated by Log-rank (Mantel-
Cox) test and by Gehan-Breslow-Wilcoxon test.  
 
 
Flow cytometric analysis of forward and side scatter of ex vivo isolated PTEN-/- T cell 
lymphoma/leukaemia cells showed that these cells are large, blast-like cells in 
comparison to WT thymocytes (Fig. 3-2a). WT thymus typically contained around 
120 to 130 million cells whereas the T cell tumours isolated from the PTENfl/fl x 
LckCre+ mice had 3-fold higher cell numbers (Fig. 3-2b). 
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Figure 3-2 A comparison of the size and cellularity of PTEN-/- T cell 
lymphoma/leukaemia cells and WT thymocytes.  
a. Flow cytometric analysis of WT thymocytes and PTEN-/- T cell lymphoma/leukaemia cells 
presented as dot plot graph (left) and histogram of Thy1 positive cells (right) showing their 
size. b. Total numbers of Thy1 positive cells for WT thymocytes and PTEN-/- T cell 
lymphoma/leukaemia cells. Data are shown as mean from 3 biological replicates from 3 
independent experiments; * p<0.05 was calculated by t-test. c. Graph bar showing the 
percentage of viable cells in each stage of cell cycle of WT thymocytes and PTEN-/- T cell 
lymphoma/leukaemia cells. DNA was stained with Hoechst 33342 and non-viable cells 
excluded with DAPI. Cell cycle populations were determined by fitting the data to the 
Watson-pragmatic model. Data are shown as mean +/- SD from 3 biological replicates from 3 
independent experiments; *p<0.0001 was calculated by multiple t-test. d. Western blot 
analysis of WT thymocytes and PTEN-/- T cell lymphoma/leukaemia cells was performed 
with antibodies against PTEN and SMC1. SMC1 was used as a loading control. Equal 
numbers of cells were lysed. Numbers represent molecular weights markers and are given in 
kDa. Data are representative of at least 3 biological replicates.  
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We also examined the cell cycle status of the ex vivo PTEN-/- T cell 
lymphoma/leukaemia cells. To analyse this, the percentage of cells in each cell cycle 
phase was assayed by staining with the intracellular DNA of viable WT thymocytes 
and PTEN-/- T cell lymphoma/leukaemia cells with Hoechst 33342 and then fitted to 
the Watson-pragmatic model (Watson et al. 1987). This cell cycle analysis showed 
that the majority of WT thymocytes (approximately 90%) were in G1 phase, around 
5% was in S phase and less than 1% were in G2 phase of cell cycle (Fig. 3-2c). In 
contrast, PTEN-/- T cell lymphoma/leukaemia cells had significantly lower percentage 
of cells in G1 phase – on average 62% whereas approximately 30% of cells were in S 
phase and 4% were in G2 phase of cell cycle. Therefore, there was a nearly 6-fold 
increase in cells in S phase in PTEN-/- T cell lymphoma/leukaemia cells compared to 
WT thymocytes. These data were consistent with a high proliferative capacity for the 
PTEN-/- T cell lymphoma/leukaemia cells. 
 
The Western blot analysis in Fig. 3-2d shows that the T cell lymphoma/leukaemia 
cells from the PTENfl/fl x LckCre+ mice failed to express PTEN consistent with the fact 
that were generated from PTEN null T cell progenitors (Hagenbeek & Spits 2007). 
 
3.2.2 Primary PTEN-/- T cell lymphoma/leukaemia cells show increased glucose 
uptake compared to WT thymocytes 
The increase in cell size of PTEN-/- T cell lymphoma/leukaemia cells could indicate 
that these cells are more metabolically active than quiescent thymocytes and naïve 
peripheral T cells. We therefore monitored the cellular uptake of 3[H]-2-
Deoxyglucose ([3H] 2-DG) to assess glucose transport in primary ex vivo T cell 
lymphoma/leukaemia cells isolated from the PTENfl/fl x LckCre+ mice. As negative 
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control, we monitored the glucose transport capacity in WT thymocytes that comprise 
predominantly quiescent CD4/CD8 DPs and SP populations. For a positive control, 
we monitored glucose uptake in IL-2 maintained cytotoxic T cells (CTLs). Previous 
studies have shown that these cells have high rates of glucose uptake and high rates of 
glycolysis (Macintyre et al. 2011; Finlay et al. 2012).  
 
The data showed that ex vivo WT thymocytes had very low rates of glucose uptake 
compared to CTLs. The T cell lymphoma/leukaemia cells from the PTENfl/fl x LckCre+ 
mice had higher rates of glucose uptake compared to WT thymocytes (Fig. 3-3a). The 
rates of glucose uptake by the PTEN-/- T cell lymphoma/leukaemia cells were almost 
2-fold lower than in the CTLs. Similar results were obtained when the ability of 
PTEN-/- T cell lymphoma/leukaemia cells to take up glucose was expressed per mass 
of cellular protein rather than per cell number. The analysis showed that T cell 
lymphoma/leukaemia cells isolated from PTENfl/fl x LckCre+ mice increased this 
process 4 to 8-fold when compared to WT thymocytes.  
 
The high rates of glucose transport by CTLs reflect that these cells upregulate 
expression of the glucose transporters, Glut1 and Glut3, and are expressed in the 
range of 6.2x104 molecules of Glut1 and 7.3x104 molecules of Glut3 (Hukelmann et 
al. 2015). To explore whether increased expression of glucose transporters could 
explain the increased glucose uptake seen in the T cell lymphoma/leukaemia cells 
from PTENfl/fl x LckCre+ mice we performed an unbiased label-free quantitative (LFQ) 
mass spectrometry based proteomics analysis of the PTEN-/- T cell 
lymphoma/leukaemia cells and WT thymocytes. In this experiment we analysed 3 
PTEN-/- T cell lymphoma/leukaemia cells and 3 WT biological controls and the 
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experiment was performed in collaboration with Dr Jens Hukelmann. Full details of 
the protocols are in the materials and methods. 
An average of 6509 proteins were identified in the WT controls and an average of 
6552 proteins were identified in PTEN-/- T cell lymphoma/leukaemia cells (Fig. 3-3c). 
Intensity based absolute quantification (IBAQ) values were used to estimate the 
abundance of proteins in the cell and the protein copy numbers (Wisniewski et al. 
2014). The IBAQ values are derived from the sum of intensities for all MS peaks of 
all peptides matching one protein and then divided by the number of theoretically 
observable peptides (Ly et al. 2014). The proteomic analysis did not detect expression 
of Glut1 in either WT thymocytes or the PTEN-/- T cell lymphoma/leukaemia cells. 
However expression of Glut3 was detected in both samples. This was a relatively low 
abundant protein in both the WT and the PTEN-/- T cell lymphoma/leukaemia cell 
samples but on average the abundance of Glut3 in PTEN-/- T cell 
lymphoma/leukaemia cells was increased 2-fold compared to WT thymocytes (Fig. 3-
3d). In terms of the abundance of Glut3 in the PTEN-/- T cell lymphoma/leukaemia 
cells compared to the CTL controls, this is difficult to estimate, as the experiments 
were not carried out at the same time. However, it could be beneficial to perform the 
Western blot analysis and test the levels of Glut1 and Glut3 expression in WT 
thymocytes, PTEN-/- T cell lymphoma/leukaemia cells and CTLs.   
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Figure 3-3 A comparison of glucose uptake and expression of glucose transporters by 
PTEN-/- T cell lymphoma/leukaemia cells and WT thymocytes.  
a. Ex vivo isolated WT thymocytes and PTEN-/- T cell lymphoma/leukaemia cells and IL-2-
maintained CTLs were assayed for 3[H]-2-Deoxyglucose uptake. Units show counts per 
minute per 1x106 cells. Error bars show SD of 1 biological replicate. Data are representative 
of 3 biological replicates from 3 independent experiments. b. Fold change of glucose uptake 
by WT thymocytes and PTEN-/- T cell lymphoma/leukaemia cells in units per mass of cellular 
protein (1mg/ml) normalised to WT thymocytes. The analysis was performed on 3 biological 
replicates from 3 independent experiments.  c. The numbers of protein identified in LFQ-MS 
experiment for WT thymocytes and PTEN-/- T cell lymphoma/leukaemia cells. d. Glut3 
abundance (IBAQ) identified by LFQ-MS experiment for WT thymocytes and PTEN-/- T cell 
lymphoma/leukaemia cells (3 biological replicates from 1 experiment).  
 
 
One way of comparing the tumour data with the historical CTLs data is to say that in 
CTLs we detected 6792 proteins in total and Glut1 and Glut3 were ranked at 1621 
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lymphoma/leukaemia cells samples we detected 6552 proteins and Glut3 was ranked 
as the 5410th most abundant protein.   
 
Together, these data argue that the increased glucose transport in the PTEN-/- T cell 
lymphoma/leukaemia cells was explained by increased expression of Glut3. The fact 
that rates of glucose transport in the T cell lymphoma were lower than in CTLs could 
be because the CTLs had high levels of expression of both Glut1 and Glut3 
(Hukelmann et al. 2015) whereas the PTEN-/- T cell lymphoma/leukaemia cells had 
only expressed Glut3. 
 
In CTLs, high rates of glucose uptake fuel glycolysis. In this respect the proteomic 
data showed that the T leukaemic cells had increased expression of multiple 
glycolytic enzymes including hexokinase 2, pyruvate kinases, and lactate 
dehydrogenase compared to the WT thymocytes (Table 3) and their expression was 
increased by 2 to 7 fold.  
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Table 3 The expression of glycolytic enzymes by PTEN-/- T cell lymphoma/leukaemia 
cells compared to WT thymocytes.  
Fold change of the abundance (IBAQ) of enzymes involved in glycolysis identified in LFQ-
MS experiment for PTEN-/- T cell lymphoma/leukaemia cells. Data based on 3 biological 
replicates from 1 experiment. Enzymes are ordered according to their appearance in 
glycolytic pathway.  
 
 
The first rate-limiting enzyme in glycolysis is hexokinase 2. We assessed its 
expression and noted that it was the most upregulated enzyme among the glycolytic 
enzymes in T cell lymphoma/leukaemia cells isolated from PTENfl/fl x LckCre+ mice 
(Table 3). The other interesting rate-limiting enzyme is pyruvate kinase M2 (PKM2). 
Overexpression of PKM2 isoform is a hallmark of cancer and other rapidly 
proliferating cells (Mazurek et al. 2005). We detected expression of PKM2 and 
PKM1 isoforms. Interestingly, expression of both isoforms was increased in PTEN-/- 
T cell lymphoma/leukaemia cells compared to WT thymocytes (2 and 3 fold increase, 
Table 3). However, the PKM2 isoform was much more abundant and ranked as 33rd 
most expressed protein compared to PKM1 ranked as 3727th most expressed protein 
in PTEN-/- T cell lymphoma/leukaemia cells. PKM2 was also the most abundant 
isoform in CTLs and its expression was increased by approximately 60 times over the 
PKM1 expression (Hukelmann et al. 2015). To validate these data we will test the 
 KO = PTEN-/- T cell lymphoma/leukaemia
KO1 KO2 KO3
Protein name
Gene 
name fold change fold change fold change
Hexokinase-2 Hk2 3.60 6.67 4.56
Glucose-6-phosphate isomerase Gpi 2.54 1.28 2.56
6-phosphofructokinase type C Pfkp 3.37 1.22 1.99
Fructose-bisphosphate aldolase A Aldoa 4.94 1.94 3.50
Triosephosphate isomerase Tpi1 2.32 1.68 2.02
Glyceraldehyde-3-phosphate dehydrogenase Gapdh 1.53 1.89 2.57
Alpha-enolase Eno1 2.88 1.58 2.54
Pyruvate kinase PKM2 PKM2 2.72 2.15 3.65
Pyruvate kinase PKM1 PKM1 2.54 4.61 2.55
L-lactate dehydrogenase A chain Ldha 2.58 1.50 2.05
 
 
88 
 
expression of rate-limiting enzymes such as PKM1 and PKM2 and HK2 in WT 
thymocytes, PTEN-/- T cell lymphoma/leukaemia cells and CTLs. 
 
The increased expression of glycolytic enzymes in the PTEN-/- T cell 
lymphoma/leukaemia cells prompted us to assess their glycolytic capacity and 
compared it to WT thymocytes and IL-2 maintained CTLs. To do this, we measured 
how much lactate was produced by the different cells. Figure 3-4a shows that WT 
thymocytes produced only approximately 60 nmoles of lactate per hour per 106 cells 
in contrast to CTLs, which upregulated this process by 10-fold. PTEN-/- T cell 
lymphoma/leukaemia cells increased the lactate production by 2-fold compared to 
WT thymocytes, however, they were not as glycolytic as CTLs that produced 
approximately 4 times more lactate. The analysis of lactate production expressed per 
mass of cellular protein of PTEN-/- T cell lymphoma/leukaemia cells in Fig. 3-4b 
shows an increase of 1.3 fold compared to WT thymocytes. Since both the size and 
protein fold change of PTEN-/- T cell lymphoma/leukaemia cells compared to WT 
thymocytes were similar, these data, then, suggested that primary T cell 
lymphoma/leukaemia cells isolated from PTENfl/fl x LckCre+ had increased glycolysis 
although not as high as CTLs.  
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Figure 3-4 A comparison of lactate production by PTEN-/- T cell lymphoma/leukaemia 
cells and WT thymocytes. 
a. Lactate production by ex vivo isolated WT thymocytes, PTEN-/- T cell 
lymphoma/leukaemia cells and IL-2 maintained CTLs was measured over a period of 4 
hours. One million of cells was used. The data are shown as mean from 2 biological 
replicates from 2 independent experiments. b. Fold change of lactate production by WT 
thymocytes and PTEN-/- T cell lymphoma/leukaemia cells in units per mass of cellular 
protein (1mg/ml) normalised to WT thymocytes. The analysis was performed on 3 biological 
replicates from 3 independent experiments. 
 
 
3.2.3 PTEN-/- T cell lymphoma/leukaemia cells increased glutamine uptake 
compared to WT thymocytes 
The amino acid glutamine is required for protein synthesis and can also be diverted 
into metabolic intermediates such as pyruvate and lactate or for catabolic processes 
known as glutaminolysis (R. Wang et al. 2011a; Nakaya et al. 2014; Carr et al. 2010). 
We then analysed the proteomic data for the PTEN-/- T cell lymphoma/leukaemia 
cells for expression of glutamine transporters i.e. Slc38a1, Slc38a2 and Slc1a5. The 
data show that Slc38a1 was increased in abundance in PTEN-/- T cell 
lymphoma/leukaemia cells (5 to 14-fold) compared to WT thymocytes. There was 
also an increase in the abundance of Slc1a5 in PTEN-/- T cell lymphoma/leukaemia 
cells compared to WT thymocytes (2 to 4-fold). In contrast, the expression of Slc38a2 
was only increased in one of the PTEN-/- T cell lymphoma/leukaemia cells samples 
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compared to WT thymocytes. Therefore, it is probable that PTEN-/- T cell 
lymphoma/leukaemia cells preferentially upregulated expression of Slc38a1 over 
Slc1a5 or Slc38a2.  
 
We then examined the glutamine transport capacity of PTEN-/- T cell 
lymphoma/leukaemia cells and compared to WT thymocytes. We used CTLs as 
positive controls in these experiments. Figure 3-5b shows that ex vivo isolated WT 
thymocytes had low level of 3[H]-Glutamine uptake in contrast to CTLs that showed 
high rates of glutamine uptake. Primary PTEN-/- T cell lymphoma/leukaemia cells 
also strikingly increased rates of glutamine uptake compared to WT thymocytes (Fig. 
3-5b). Similarly when the ability of PTEN-/- T cell lymphoma/leukaemia cells to take 
up glutamine was expressed per mass of cellular protein, T cell lymphoma/leukaemia 
cells isolated from PTENfl/fl x LckCre+ mice increased this process 4 to 20-fold when 
compared to WT thymocytes (Fig. 3-5c). 
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Figure 3-5 A comparison of expression of glutamine transporters and glutamine uptake 
by PTEN-/- T cell lymphoma/leukaemia cells and WT thymocytes.  
a. Protein copy numbers estimated from IBAQ values identified in LFQ-MS experiment for 
WT thymocytes and PTEN-/- T cell lymphoma/leukaemia cells and their fold change. Data 
calculated for 3 biological replicates from 1 experiment. b. Ex vivo isolated WT thymocytes, 
PTEN-/- T cell lymphoma/leukaemia cells and IL-2 maintained CTLs were assayed for 3[H]- 
glucose uptake. Units show counts per minute per 1x106 cells. Error bars show SD of 1 
biological replicate. Data are representative of 3 biological replicates from 3 independent 
experiments. c. Fold change of glutamine uptake by WT thymocytes and PTEN-/- T cell 
lymphoma/leukaemia cells in units per mass of cellular protein (1mg/ml) normalised to WT 
thymocytes. The analysis was performed on 3 biological replicates from 3 independent 
experiments. 
 
 
How important is high glutamine uptake for PTEN-/- T cell lymphoma/leukaemia 
cells? The primary T cell lymphoma/leukaemia cells from PTENfl/fl x LckCre+ mice 
could not be maintained in culture. However, Hagenbeek at al., have previously 
derived a PTEN null murine T leukaemic cell line (F15) from T cell 
lymphoma/leukaemia cells that develop in PTENfl/fl x LckCre+ mice (Hagenbeek et al. 
2014). We, therefore, assessed the impact of glutamine deprivation on this F15 
PTEN-/- T leukaemic cell line. The data (Fig. 3-5a) show that F15 cells cultured in 
full media showed a 6-fold increase in cell number after 2 days in the culture. In 
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contrast F15 cells deprived of glutamine did not proliferate during the course of 
experiment; rather their numbers decreased. In addition, while the majority of F15 
cells kept in full media were alive, more than 90% of F15 cells deprived of glutamine 
were dead, as judged by DAPI stain, after 2 days of culture (Fig. 3-6b). Therefore, we 
showed that survival of PTEN-/- T leukaemic cell line was dependent on external 
glutamine availability. 
 
 
Figure 3-6 The impact of glutamine withdrawal on PTEN-/- T cell lymphoma/leukaemia 
cells survival.  
PTEN-/- leukaemic cells were cultured either in full media or media deprived of glutamine for 
48 hours. a. Proliferation curve and b. percentage of alive-DAPI negative cells. Data shown 
as representative of 2 biological replicates from 2 independent experiments. 
 
 
3.2.4 PTEN-/- T cell lymphoma/leukaemia cells increase uptake of leucine 
compared to WT thymocytes 
We next investigated if PTEN-/- T cell lymphoma/leukaemia cells show any changes 
in leucine uptake. This amino acid is crucial for the de novo protein synthesis but also 
for mTORc1 activity (BEUGNET et al. 2003; Schriever et al. 2013). System L amino 
acid transporters transport leucine (Verrey et al. 2004; Sinclair et al. 2013) and the 
proteomic data showed that the PTEN-/- T cell lymphoma/leukaemia cells had 
0
20
40
60
80
100
days in culture            0                1                2   
%
 o
f l
iv
e 
ce
lls
   
 
D
AP
I n
eg
at
iv
e 
 
full media glutamine washout
no
 o
f c
el
ls
 p
er
 1
 m
l
 x
 1
06
   
  
days in culture  0                        1                         2   
0
1
2
3
b.a.
 
 
93 
 
increased expression of CD98, a subunit of the System L amino acid transporters 
(Fig. 3-7a). On average PTEN-/- T cell lymphoma/leukaemia cells upregulated 
expression of CD98 by 2-fold compared to WT thymocytes. Interestingly, one of the 
tumour sample showed that CD98 was upregulated more than 5-fold. System L amino 
acid transporters comprise a heterodimer of CD98 (Slc3a2) and either Slc7a5 (also 
known as LAT1), Slc7a8 (LAT2), Slc7a7 (y+LAT1) or Slc7a6 (y+LAT2) (Sinclair et 
al. 2013).  We detected both Slc7a5 and Slc7a6 in the PTEN-/- T cell 
lymphoma/leukaemia cells, however there was huge variability between expression 
of these molecules in the different T cell Tumour samples and the WT thymocytes 
(data not shown). 
 
 CD98 expression can also be monitored by flow cytometry and the data (Fig. 3-7b) 
show increased surface expression of CD98 in ex vivo isolated PTEN-/- T cell 
lymphoma/leukaemia cells compared to WT thymocytes. Accordingly, we examined 
the System L amino acid transport capacity (3[H]-Leucine uptake) of the primary ex 
vivo isolated PTEN-/- T cell lymphoma/leukaemia cells and compared to WT 
thymocytes and to IL-2 maintained CTLs. Figure 3-7c shows that ex vivo isolated WT 
thymocytes had low level of 3[H]-Leucine uptake in contrast to CTLs that 
upregulated leucine uptake by more than 30-fold. Primary PTEN-/- T cell 
lymphoma/leukaemia cells increased the rates of leucine uptake compared to WT 
thymocytes and interestingly, they were as capable or even better than CTLs (Fig. 3-
7c). The analysis of the ability of PTEN-/- T cell lymphoma/leukaemia cells to take up 
leucine expressed per mass of cellular protein showed that T cell 
lymphoma/leukaemia cells isolated from PTENfl/fl x LckCre+ mice increased this 
process 11 to 18-fold compared to WT thymocytes (Fig. 3-7d). These data indicated 
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that PTEN-/- T cell lymphoma/leukaemia cells did increase their leucine uptake 
through System L amino acid transporters. 
 
 
Figure 3-7 A comparison of CD98 expression and leucine uptake by PTEN-/- T cell 
lymphoma/leukaemia cells and WT thymocytes.  
a. Protein copy numbers estimated from IBAQ values identified in LFQ-MS experiment for 
WT thymocytes and PTEN-/- T cell lymphoma/leukaemia cells and their fold change. Data 
calculated for 3 biological replicates from 1 experiment. b. Flow cytometric analysis 
presented as histogram showing expression of CD98 surface marker for ex vivo WT 
thymocytes and PTEN-/- T cell lymphoma/leukaemia cells. Data are representative of at least 
3 biological replicates. c. Ex vivo isolated WT thymocytes, PTEN-/- T cell 
lymphoma/leukaemia cells and IL-2 maintained CTLs were assayed for 3[H]- leucine uptake. 
Units show counts per minute per 1x106 cells. Error bars show SD of 1 biological replicate. 
Data are representative of 3 biological replicates from 3 independent experiments. d. Fold 
change of leucine uptake by WT thymocytes and PTEN-/- T cell lymphoma/leukaemia cells in 
units per mass of cellular protein (1mg/ml) normalised to WT thymocytes. The analysis was 
performed on 3 biological replicates from 3 independent experiments. 
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3.2.5 PTEN-/- T cell lymphoma/leukaemia cells upregulate transferrin uptake 
compared to WT thymocytes 
Expression of transferrin and high levels of transferrin are a hallmark of rapidly 
proliferating cells (O'Donnell et al. 2006). The proteomic data showed that PTEN-/- T 
cell lymphoma/leukaemia cells had increased expression of CD71 (Fig. 3-8a). Two of 
the T cell lymphoma/leukaemia samples had the fold change of approximately 7 
while the third T cell lymphoma/leukaemia sample showed upregulation of CD71 by 
22-fold compared to WT thymocytes. We also measured CD71 expression by flow 
cytometry on surface of PTEN-/- T cell lymphoma/leukaemia cells and WT 
thymocytes. Figure 3-8b shows that while WT thymocytes maintained low level of 
CD71 expression, PTEN-/- T cell lymphoma/leukaemia cells had much higher 
expression of CD71. In the next experiment, we tested whether the CD71 receptor 
was functional by measuring the cellular uptake of transferrin by PTEN-/- T cell 
lymphoma/leukaemia cells, WT thymocytes and IL-2 maintained CTLs. We used a 
FACS based assay to monitor cellular uptake of APC conjugated transferrin. Cells 
were starved of transferrin for 2 hours after which the uptake of transferrin was 
performed at 37ºC for 10 minutes. The data in Fig. 3-8c show that WT thymocytes 
did not have the ability to take up transferrin compared to CTLs, which showed the 
highest uptake of transferrin (red line). However, primary PTEN-/- T cell 
lymphoma/leukaemia cells showed a marked increase in transferrin uptake that was 
comparable with the uptake observed in CTLs, implying that tumour cells have great 
capacity in transferrin uptake. The uptake of labeled transferrin by the PTEN-/- T cell 
lymphoma/leukaemia cells was specific as it was blocked by unlabeled holo-
transferrin and by incubating the cells treated with labeled transferrin on ice (Fig. 3-
8d). These data indicated that CD71 expressed on PTEN-/- T cell 
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lymphoma/leukaemia cells was thus functional and permitted the uptake of transferrin 
into the cells.  
 
 
Figure 3-8 A comparison of expression of CD71 and transferrin uptake by PTEN-/- T cell 
lymphoma/leukaemia cells and WT thymocytes.  
a. Protein copy numbers estimated from IBAQ values identified in LFQ-MS experiment for 
WT thymocytes and PTEN-/- T cell lymphoma/leukaemia cells and their fold change. Data 
calculated for 3 biological replicates from 1 experiment. b. c. d. Flow cytometric analysis 
presented as histograms showing b. expression CD71 and c. transferrin uptake by WT 
thymocytes, PTEN-/- T cell lymphoma/leukaemia cells and IL-2 maintained CTLs. Untreated 
cells were tested to take up transferrin at 37ºC. d. Histograms depicting transferrin uptake for 
untreted cells kept at 37ºC (solid grey) or cells kept at 37ºC incubated together with holo-
transferrin to block transferrin uptake (green), or kept at 37ºC where no labeled transferrin 
was added (orange) or kept on ice to block the transport (blue). Expression of CD71 and 
transferrin uptake was measured on Thy1 positive cells. Data are representative of at least 3 
biological replicates from 3 independent experiments.  
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3.3 Discussion 
In this chapter we explored nutrient uptake in primary T cell lymphoma/leukaemia 
cells that develop in PTENfl/fl x LckCre+ mice, a mouse model for T-ALL. The data 
showed that these primary T cell lymphoma/leukaemia cells had high rates of glucose 
uptake and they expressed high levels of glycolytic enzymes.  
 
Cells that exhibit an increased need for energy and macromolecule synthesis switch 
from metabolising glucose by oxidative phosphorylation to utilizing aerobic 
glycolysis (Finlay 2012). Aerobic glycolysis has an important advantage over 
oxidative phosphorylation – the intermediates produced during glycolysis act as a 
source of carbon to generate biosynthetic precursors that are then used for production 
of DNA, proteins and phospholipids (Finlay 2012; Lunt & Vander Heiden 2011). One 
crucial requirement in aerobic glycolysis is to sustain high levels of glucose uptake by 
maintaining expression of the glucose transporters. Our MS-based analysis of the 
protein content of PTEN-/- T cell lymphoma/leukaemia cells revealed that Glut3 could 
be the putative glucose transporter in PTEN-/- T cell lymphoma/leukaemia cells. It is 
interesting that in activated CTLs the transporters Glut1 and Glut3 are expressed at 
comparable levels (personal communication with Dr Jens Heukelmann). However, 
Glut3 has a higher affinity for glucose and greater transport capacity for glucose 
(Simpson et al. 2008). It is thus possible that PTEN-/- T cell lymphoma/leukaemia 
cells selectively upregulated the more efficient glucose transporter to increase uptake 
of glucose. In this respect, microarray analysis of samples from pediatric precursor B-
ALL cells revealed that the elevated expression of Glut3 corresponds with increased 
rates of glucose uptake (Hulleman et al. 2009) suggesting that Glut3 alone is 
sufficient for the increased glucose metabolism in ALL. However, the failure of the 
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PTEN-/- T cell lymphoma/leukaemia cells to expressed both Glut1 and Glut3 could 
explain why their glucose transport capacity was less than that of CTLs.  
 
Another interesting observation from the MS data of the primary PTEN-/- T cell 
lymphoma/leukaemia cells isolated from PTENfl/fl x LckCre+ mice was the high 
abundance of PKM2 versus PKM1 (33rd vs. 3727th rank according to protein 
abundance). In this context, it was shown that overexpression of PKM2, but not 
PKM1 is frequently observed in cancer and other rapidly proliferating cells (Mazurek 
et al. 2005). PKM2 thus, can exist in a dimeric form with low catalytic activity and 
this leads to accumulation of phosphoenolpyruvate and other glycolytic intermediates 
that serve as biosynthetic precursors for synthesis of amino acids and phospholipids. 
The PKM1/2 isoforms both use phosphoenolpyruvate as a substrate during glycolysis 
but PKM2 can also function as a protein kinase for STAT3 and MEK5 (Gao et al. 
2012) and is co-activator for Hif-1α mediated transcription (Luo et al. 2011). The 
quantity of PKM2 in the PTEN-/- T cell lymphoma/leukaemia cells could permit this 
enzyme to have multiple roles as a transcriptional and metabolic regulator.  
 
The present data did show evidence for an increase in lactate production in the PTEN-
/- T cell lymphoma/leukaemia cells. Lactate is the end product of glycolysis produced 
from pyruvate by lactate dehydrogenase (Vander Heiden et al. 2009). Several groups 
have shown that leukaemic cell lines are highly glycolytic and that inhibiting 
glycolysis but not oxidative phosphorylation (Boag et al. 2006; Akers et al. 2011) 
leads to reduction in proliferation and cells viability. Proteomics data showed that 
PTEN-/- T cell lymphoma/leukaemia cells increased expression of rate-limiting 
glycolytic enzymes. The most changed was hexokinase 2, a crucial enzyme, as it 
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catalyses the first reaction of glycolytic pathway (Lunt & Vander Heiden 2011; 
Wilson 2003). However, we observed that although PTEN-/- T cell 
lymphoma/leukaemia cells produced lactate they did not have the high glycolytic 
rates seen in CTLs, a control population of normal proliferating T cells.   
 
The cell cycle status of PTEN-/- T cell lymphoma/leukaemia cells indicated that they 
were a proliferating population of cells. An important nutrient for proliferating cells is 
transferrin (Ponka & Lok 1999; White et al. 1990; Kemp et al. 1995) as it transports 
iron inside the cell. Iron is a crucial cofactor for a number of cellular enzymes, 
including ribonucleotide reductase that enables for progression of cell cycle (Robbins 
& Pederson 1970). The present data showed that the PTEN-/- T cell 
lymphoma/leukaemia cells expressed high levels of CD71, the transferrin receptor, 
and had high rates of transferrin uptake. This is consistent with the fact that high 
levels of CD71 have been reported on some although not all primary human 
leukaemic samples (Q. Liu et al. 2014). 
 
Glutamine, next to glucose, is an important nutrient for rapidly proliferating cells. 
Our MS experiment identified that glutamine transporters such as Slc38a1 and 
Slc1a5, were more abundant in PTEN-/- T cell lymphoma/leukaemia cells compared 
to WT thymocytes. Furthermore, we also showed that PTEN-/- T cell 
lymphoma/leukaemia cells could efficiently take up glutamine. Elevated levels of 
glutamine uptake and subsequent glutaminolysis are frequently observed in tumour 
cells that are described as being ‘glutamine addicted’ (Duran et al. 2012; Wise & 
Thompson 2010). One important function for glutamine in cells is to regulate the 
activity of mTORc1 (Duran et al. 2012). Simultaneous efflux of glutamine from the 
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cell with the uptake of large neutral amino acids such as leucine is rate-limiting step 
in activation of mTORc1 (Nicklin et al. 2009). Glutamine uptake and glutaminolysis 
can also control mTORc1 activity by facilitating the lysosomal localisation of this 
kinase. In this respect, it is important to mention that lysosome is thought to be a 
platform for optimal mTORc1 activation. Even though the process is not fully 
understood, the presence of leucine on the lysosomal lumen initiates a series of 
events, involving the vATPase that activates GEF activity of the Ragulator complex 
towards RagA. Active RagA then recruits mTORc1 to the lysosome that can be 
activated by RHEB (Bar-Peled et al. 2012; Sancak et al. 2010; Zoncu et al. 2011; 
Sancak et al. 2008).  
 
In this chapter we showed that primary PTEN-/- T cell lymphoma/leukaemia cells 
increased expression of CD98, the heavy chain of the transporter that pairs up with 
Slc7a5, Slc7a6 or Scl7a7, compared to WT thymocytes. We also detected expression 
of Slc7a5 and Slc7a6 but their expression was very variable precluding from forming 
firm conclusions. It is possible, that with the approach that we took, we might have 
underrepresented membrane proteins due to technical problems. Because we used 
urea based lysis buffer that did not contain any detergents, we might have not fully 
solubilised hydrophobic membranes. Nonetheless, we showed that T cell 
lymphoma/leukaemia cells from PTENfl/fl x LckCre+ mice had very high rates leucine 
uptake consistent with high expression of System L amino acid transporters. In this 
context, LNAA such as leucine are major positive regulator of mTORc1 activity 
(Sinclair et al. 2013; BEUGNET et al. 2003). We, therefore, speculate that glutamine 
together with leucine might contribute to elevated mTORc1 activity in PTEN-/- T cell 
lymphoma/leukaemia cells and we will discuss it further in Chapter 5.  
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Taken together, we have established that primary PTEN-/- T cell lymphoma/leukaemia 
cells express elevated levels of glucose, glutamine and leucine and transferrin 
receptors and as a result show an increase in the uptake of key nutrients. In the next 
chapter we will discuss whether PTEN deletion alone is sufficient to initiate these 
metabolic changes or whether they are a consequence of secondary mutations 
acquired during the malignant transformation.  
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4  Chapter: PTEN deletion is not sufficient to initiate 
glucose, glutamine or leucine uptake in T cell progenitors 
 
4.1  Introduction  
In the previous chapter we showed that PTEN-/- T cell lymphoma/leukaemia cells had 
high rates of transport of several key nutrients: glucose, glutamine, leucine and 
transferrin. In this chapter, we will examine if these high levels of nutrient uptake are 
immediate consequence of PTEN deletion or due to accumulation of secondary 
mutations in PTEN-/- T cell lymphoma/leukaemia cells. 
 
The main function of PTEN is to act as a lipid phosphatase and its best understood 
function is in the antagonism of PI3K mediated signalling (Leslie & Downes 2004). 
Once PTEN is deleted or downregulated, PI(3,4,5)P3 accumulates in the plasma 
membrane and permits binding of PH domains to the PI(3,4,5)P3. PI(3,4,5)P3 
recruitment of the PH domain of AKT allows the kinase PDK1 to phosphorylate 
AKT on Thr308 site and hence allows for the catalytic activation of AKT. PDK1 also 
contains a PH domain that binds to PI(3,4,5)P3 with high affinity and PDK1 binding 
in the plasma membrane is required for efficient induction of high levels of AKT 
activity, probably by ensuring co-localisation of AKT and PDK1 (L. R. Pearce et al. 
2010).  
 
In many cell systems, AKT plays a key role in maintaining glucose homeostasis and 
cell metabolism (Mahfouz et al. 2014; Hajduch et al. 2001; C. J. Green et al. 2008). 
Indeed, in normal thymocytes development, it is clear that loss of PDK1 and AKT 
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causes defects in glucose transport in T cell progenitors in the thymus precluding 
their development (Hinton et al. 2004; Juntilla et al. 2007). However, it has been 
described that PTEN null progenitors have normal expression of transferrin receptor 
and System L amino acid transporter (CD98) (Finlay et al. 2009). These data question 
whether the increased PI(3,4,5)P3 signalling resulting from loss of PTEN activity is 
sufficient to cause changes in T cell metabolism seen in PTEN-/- T cell 
lymphoma/leukaemia cells.  
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4.2 Results 
4.2.1  PTEN-/- non-transformed thymocytes do not actively proliferate 
The molecular changes that are associated with malignancy appear in PTENfl/fl x 
LckCre+ mice in a timed and synchronous manner (Xue et al. 2008). Thus to analyse 
the PTEN-/- non-transformed thymocytes, we have only used mice younger than 6 
weeks old that did not present any signs of tumour development. These PTEN-/- non-
transformed thymocytes are polyclonal, like WT thymocytes (Fig.4-1). PTEN-/- non-
transformed thymocytes are devoid of secondary mutations, therefore any observed 
changes are due to PTEN loss.  
 
 
Figure 4-1 Schematic illustration of how malignant transformation affects the thymus.  
Initially, PTENfl/fl x LckCre+ mice remain tumour free and PTEN-/- non-transformed 
thymocytes are phenotypically like WT thymocytes.  However, around 8-10 weeks of age, 
PTENfl/fl x LckCre+ mice undergo malignant transformation and develop tumours. These 
PTEN-/- T cell lymphoma/leukaemia cells are mainly monoclonal and have additional 
secondary mutations.  
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PTEN deletion causes accumulation of PI(3,4,5)P3 in the cell membrane and 
subsequent activation of AKT in PTEN-/- non-transformed thymocytes (Finlay et al. 
2009). As AKT can drive proliferation in cells, we assessed the cell cycle status of 
PTEN-/- non-transformed thymocytes. Thus, we examined the percentage of cells in 
each cell cycle phase by staining with the intracellular DNA of viable WT 
thymocytes and PTEN-/- non-transformed thymocytes with Hoechst 33342 and then 
fitted to the Watson-pragmatic model (Watson et al. 1987). The cell cycle analysis in 
Fig. 4-2 showed that the majority of WT thymocytes (approximately 80%) were in 
G1 phase, around 8% were in S phase and 1% were in G2 phase. Similar results were 
achieved for PTEN-/- non-transformed thymocytes, as they had approximately 84% of 
cells in G1 phase, 8% in S phase and 1% in G2 phase. These data indicated that the 
PTEN-/- non-transformed thymocytes did not actively proliferate, which was similar 
to WT thymocytes and in contrast to PTEN-/- T cell lymphoma/leukaemia cells that 
were actively proliferating.  
 
 
Figure 4-2 Analysis of cell cycle of PTEN-/- non-transformed and WT thymocytes.  
Bar graph showing the percentage of viable cells in each stage of cell cycle in WT and PTEN-
/- non-transformed thymocytes. DNA was stained with Hoechst 33342 and non-viable cells 
excluded with DAPI. Cell cycle populations were determined by fitting the data to the 
Watson-pragmatic model. Data are shown as means from 2 biological replicates from 2 
independent experiments. 
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4.2.2 PTEN-/- non-transformed thymocytes remain small in size 
The above data showed that PTEN-/- non-transformed thymocytes remained mostly 
quiescent, like WT thymocytes. The actively proliferating PTEN-/- T cell 
lymphoma/leukaemia cells were big, blast-like cells (Fig. 3-2a). To examine the size 
of PTEN-/- non-transformed thymocytes we analysed the forward scatter and side 
scatter profiles and found that PTEN-/- non-transformed thymocytes were small cells 
and their size was only marginally bigger that WT thymocytes (Fig. 4-3a), however 
they did not blast like PTEN-/- T cell lymphoma/leukaemia cells. Consistent with the 
cells not actively proliferating, the numbers of PTEN-/- non-transformed thymi were 
comparable to WT thymi (Fig. 4-3b). 
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Figure 4-3 A comparison of thymocytes size and cellularity of PTEN-/- non-transformed 
and WT thymi.  
a. Flow cytometric analysis of the size of WT thymocytes and PTEN-/- non-transformed 
thymocytes presented as dot plot graph (left) and histogram of Thy1 positive cells (right) 
showing their size. b. Total numbers of Thy1 positive cells in WT and PTEN-/- non-
transformed thymi. Data are mean of 4 biological replicates from 4 independent experiments. 
P-value was calculated from t-test; ns – not significant.  
 
 
4.2.3 AKT is phosphorylated in PTEN-/- non-transformed thymocytes 
AKT activity can be monitored by assessing its phosphorylation on Thr308 and 
Ser473 by Western blot analysis. Fig. 4-4 shows that WT thymocytes had no 
detectable AKT phosphorylation on Thr308 and Ser473. In contrast, AKT 
phosphorylation was readily detected in PTEN-/- non-transformed thymocytes. As 
comparison, we show that high levels of AKT phosphorylation on Thr308 and Ser473 
were also seen in PTEN-/- T cell lymphoma/leukaemia cells (Fig. 4-4). The total 
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levels of AKT were equal in WT and PTEN-/- non-transformed thymocytes and 
PTEN-/- T cell lymphoma/leukaemia cells. Furthermore, in these experiments we used 
pervanadate, a potent inhibitor of protein-tyrosine phosphatase (Mikalsen & Kaalhus 
1998), that can stimulate PI3K signalling (Atrih et al. 2010) as pharmacological tool 
to achieve the maximal phosphorylation in the cell. The presented data show that 
phosphorylation levels of AKT at Thr308 and Ser473 in PTEN-/- non-transformed 
thymocytes and PTEN-/- T cell lymphoma/leukaemia cells were lower compared to 
the samples treated with pervanadate. The MS-based stoichiometric quantification of 
AKT phosphorylation in human effector CD8+ T cells by Atrih at al., has suggested 
that treatment with pervanadate leads to phosphorylation of 40% of AKT (Thr308) 
site and 11% of AKT (Ser473) site (Atrih et al. 2010). Our data thus showed that 
PTEN deletion did not activate the entire pool of AKT. 
 
 Importantly, we showed that phosphorylation of AKT on Thr308 and Ser473 sites 
was efficiently blocked in PTEN-/- non-transformed and PTEN-/- T cell 
lymphoma/leukaemia cells by the AKTi inhibitor which prevents PI(3,4,5)P3 binding 
to the PH domain of AKT (C. J. Green et al. 2008). These data, thus, support the 
notion that the increased AKT activity caused by PTEN deletion required PI(3,4,5)P3 
binding to the PH domain of AKT.  
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Figure 4-4 The effect of PTEN deletion on AKT phosphorylation in PTEN-/- non-
transformed and PTEN-/- T cell lymphoma/leukaemia cells.  
Total ex vivo isolated WT thymocytes, PTEN-/- non-transformed thymocytes and PTEN-/- T 
cell lymphoma/leukaemia cells were either left untreated or treated with 1µM of AKTi for 1 
hour or pervanadate for 5 minutes. AKTi was used as negative control and pervanadate as 
positive control for AKT phosphorylation. Western blot analysis was performed with 
antibodies against phosphorylated forms of AKT: Thr308 and Ser473, and pan AKT, and 
SMC1 antibodies. SMC1 was used as a loading control. Equal numbers of cells were lysed. 
Numbers represent molecular weights markers and are given in kDa. Data are representative 
of 3 biological replicates from 3 independent experiments.  
 
 
Finlay et al. showed that the activation of AKT results in the phosphorylation of 
Foxo1 and 3a in PTEN-/- non-transformed and PTEN-/- T cell lymphoma/leukaemia 
cells (Finlay et al. 2009). Phosphorylated Foxos are excluded from the nucleus and 
thus cannot induce the expression of target genes i.e. IL-7 receptor alpha (IL-7R) 
(Hedrick et al. 2012; Kerdiles et al. 2009; Brunet et al. 1999). We measured the 
expression of IL-7R to explore if the active AKT seen in PTEN-/- non-transformed 
thymocytes was sufficient to inactivate expression of Foxo regulated genes.  Figure 4-
5 shows that naïve T cells expressed high levels of the IL-7R whereas the expression 
of IL-7R was downregulated in TCRb+ cells isolated from PTENfl/fl x LckCre+ mice. 
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There were also low levels of IL-7R in TCRb+ cells isolated from PTENfl/fl x LckCre+ 
tumour bearing mice. These data confirmed the previous results that PTEN deletion 
was sufficient to inactivate Foxo transcription factors. 
  
 
Figure 4-5 The expression of IL-7R in TCRb+ cells from PTEN null mice.  
Flow cytometric analysis presented as histograms showing expression of IL-7R on ex vivo 
isolated TCRb+ cells from LN from WT mice, PTENfl/fl x LckCre+ mice (green) and PTENfl/fl x 
LckCre+ tumour bearing mice (blue). Data are representative of 3 biological replicates from 3 
independent experiments.  
 
 
Another target of AKT is the protein PRAS40 (Sancak et al. 2007; H. Wang et al. 
2012). The presented data (Fig. 4-6) show that WT thymocytes did not show evidence 
of PRAS40 phosphorylation on AKT substrate sequence, Thr246. However, both 
PTEN-/- non-transformed and PTEN-/-T cell lymphoma/leukaemia cells had high 
levels of Thr246 phosphorylated on PRAS40. The phosphorylation of PRAS40 on 
Thr246 was abolished when cells were treated with the AKT inhibitor, AKTi. The 
maximal level of PRAS40 phosphorylation set by pervanadate treatment in PTEN-/- 
non-transformed and PTEN-/- T cell lymphoma/leukaemia cells was similar to the one 
observed in untreated samples suggesting that maximal PRAS40 phosphorylation was 
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higher in PTEN-/- T cell lymphoma/leukaemia cells compared to PTEN-/- non-
transformed or WT thymocytes (Fig. 4-6). 
 
 
Figure 4-6 Phosphorylation of PRAS40 in WT, PTEN-/- non-transformed thymocytes 
and PTEN-/- T cell lymphoma/leukaemia cells.  
Total ex vivo isolated WT thymocytes, PTEN-/- non-transformed thymocytes and PTEN-/- T 
cell lymphoma/leukaemia cells were either left untreated or treated with 1µM of AKTi for 1 
hour or pervanadate for 5 minutes. AKTi was used as negative control and pervanadate as 
positive control for PRAS40 phosphorylation. Western blot analysis was with antibodies 
against phosphorylated form of PRAS40 (Thr246), pan PRAS40 and SMC1 antibodies. 
SMC1 was used as a loading control. Equal numbers of cells were lysed. Numbers represent 
molecular weights markers and are given in kDa. Data are representative of 3 biological 
replicates from 3 independent experiments.  
 
 
Together, these data indicated that PTEN-/- cells isolated prior and after the malignant 
transformation had phosphorylated AKT as a result of PTEN loss. Furthermore, 
phosphorylated AKT induced activation of its downstream substrates.  
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4.2.4  PTEN-/- non-transformed thymocytes do not show increased rates of 
glucose, glutamine and leucine transport 
We previously showed that PTEN-/- T cell lymphoma/leukaemia cells had increased 
rates of nutrient uptake. In this chapter we also showed that both PTEN-/- T cell 
lymphoma/leukaemia cells and PTEN-/- non-transformed thymocytes had 
phosphorylated AKT. As AKT is known to control growth and nutrient uptake in 
other cell systems (Hajduch et al. 2001; C. J. Green et al. 2008; Mahfouz et al. 2014), 
we determined if PTEN-/- non-transformed thymocytes upregulated nutrient uptake by 
testing the ability of ex vivo isolated WT and PTEN-/- non-transformed thymocytes to 
take up radioactively labelled glucose analogue, 2-DG. As a positive control we used 
IL-2 maintained CTLs. We found that WT thymocytes took lesser amounts of 2-DG 
compared to CTLs that showed 30-fold increase in glucose uptake (Fig. 4-7a). 
Similar to WT thymocytes, PTEN-/- non-transformed thymocytes also had very low 
rates of 2-DG uptake (Fig. 4-7a).  
 
We therefore speculated that PTEN loss may promote the uptake of other nutrient that 
can be used to produce energy and macromolecules, such as glutamine (van der 
Windt & E. L. Pearce 2012). Thus, we measured 3[H]-Glutamine transport in WT and 
PTEN-/- non-transformed thymocytes and compared with IL-2 maintained CTLs. The 
data presented here show that WT thymocytes took 40-fold less glutamine than CTLs 
indicating that they had low levels of glutamine uptake. PTEN-/- non-transformed 
thymocytes showed no increase in glutamine uptake compared to WT thymocytes 
(Fig. 4-7b). It is thus evident, that thymocytes prior to malignant transformation 
cannot upregulate either glucose or glutamine uptake.   
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Figure 4-7 A comparison of glucose, glutamine and leucine uptake by WT and PTEN-/- 
non-transformed thymocytes. 
Ex vivo isolated WT and PTEN-/- non-transformed thymocytes, and IL-2 maintained CTLs 
were assayed for uptake of a. 3[H]-2-Deoxyglucose, b. 3[H]-Glutamine and c. 3[H]-Leucine. 
Units show counts per minute per 1x106 cells. Data are shown as means +/- SD from 3 
biological replicates from 3 independent experiments. P-values were calculated from t-test, ns 
– not significant. d. Flow cytometric analysis presented as histogram showing expression of 
CD98 on surface of Thy1 positive cells from WT and PTEN-/- non-transformed thymocytes. 
Data are representative of at least 3 biological replicates from at least 3 independent 
experiments.  
 
 
In the previous chapter we showed that PTEN-/- T cell lymphoma/leukaemia cells had 
high levels of leucine uptake (Fig. 3-7c). The data presented in Fig. 4-7c show that 
WT thymocytes had low level of leucine uptake compared to CTLs that upregulated 
this process by 33-fold. PTEN-/- non-transformed thymocytes showed a 2-fold 
increase in leucine uptake compared to WT thymocytes but this was a very small 
response compared to CTLs. We also examined expression of the heavy subunit of 
LNAA transporter, CD98. The data indicated that the basal level of CD98 expression 
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observed in WT thymocytes was only marginally increased in PTEN-/- non-
transformed thymocytes compared to the high expression of CD98 seen in the PTEN-
/- T cell lymphoma/leukaemia cells (Fig. 3-7b).  
 
4.2.5  PTEN-/- non-transformed thymocytes take up transferrin at similar rates 
to WT thymocytes  
Lastly, we assessed the expression of the transferrin receptor (CD71) and the uptake 
of transferrin because these processes were upregulated in PTEN-/- T cell 
lymphoma/leukaemia cells. We found that WT thymocytes had low levels of CD71 
expression (Fig. 4-8a) and PTEN-/- non-transformed thymocytes expressed CD71 at 
similar levels compared to WT thymocytes. Moreover, WT thymocytes and PTEN-/- 
non-transformed thymocytes showed minimal level of transferrin uptake compared to 
CTLs (Fig. 4-8b).  
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Figure 4-8 A comparison of the transferrin uptake by WT and PTEN-/- non-transformed 
thymocytes. 
Flow cytometric analysis presented as histograms showing a. expression of CD71 and b. 
transferrin uptake on WT and PTEN-/- non-transformed thymocytes, and IL-2 maintained 
CTLs (red line). Untreated cells were tested to take up transferrin at 37ºC. c. Histograms 
depicting transferrin uptake for untreted cells kept at 37ºC (solid grey) or cells kept at 37ºC 
incubated together with holo-transferrin to block transferrin uptake (green), or kept at 37ºC 
where no labeled transferrin was added (orange) or kept on ice to block the transport (blue). 
Expression of CD71 and transferrin uptake was measured on Thy1 positive cells. Data are 
representative of at least 3 biological replicates from 3 independent experiments.  
 
 
Taken together, all the above data indicated that PTEN-/- non-transformed thymocytes 
were small cells that were predominantly quiescent, not actively proliferating cells 
that did not upregulate nutrient uptake. It is, therefore, apparent that PTEN deletion, 
and hence activation of AKT, did not regulate nutrient uptake and proliferation of 
thymocytes.  
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4.2.6 PTEN-/- T cell lymphoma/leukaemia cells accumulate secondary 
mutations 
As PTEN loss alone could not account for the increase in nutrient uptake and cell 
growth and proliferation that we observed in PTEN-/- T cell lymphoma/leukaemia 
cells, we concluded that other mutations must regulate these processes. c-Myc 
translocations are known secondary mutation in PTEN induced T-ALLs (Guo et al. 
2008) and are not present in non-transformed stage (Bonnet et al. 2011). We therefore 
assessed PTEN-/- non-transformed and PTEN-/- T cell lymphoma/leukaemia cells for 
c-Myc expression. The data in Fig. 4-9 show that while WT and PTEN-/- non-
transformed thymocytes did not express c-Myc, all primary PTEN-/- T cell 
lymphoma/leukaemia cells tested, did express c-Myc. c-Myc overexpression can 
occur as a result of overactivation of Notch1 (Weng et al. 2006). Hagenbeek at al., 
showed that all PTEN-/- T cell lymphoma/leukaemia cells express active Notch1 
(Hagenbeek et al. 2014). In our study, using the same mouse model, we observed that 
active Notch1 was not expressed uniformly in all tested PTEN-/- T cell 
lymphoma/leukaemia cells samples (Fig. 4-9). Of note, the MS data revealed that 
only one tested PTEN-/- T cell lymphoma/leukaemia cells sample showed massive 
upregulation of Notch1 expression (1026 molecules per cell in PTEN-/- T cell 
lymphoma/leukaemia cells compared to approximately 50 molecules per cell in WT). 
These data thus, argue that PTEN-/- T cell lymphoma/leukaemia cells do carry 
secondary mutations i.e. c-Myc and Notch1 and that there is heterogeneity in the 
mutations that drive the same phenotype. However, we would like to further analyse 
PTEN-/- T cell lymphoma/leukaemia cells to establish what is the frequency of 
Notch1 activation. 
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Figure 4-9 Expression of active Notch1 and c-Myc in WT and PTEN-/- non-transformed 
thymocytes and PTEN-/- T cell lymphoma/leukaemia cells.  
Total ex vivo isolated WT and PTEN-/- non-transformed thymocytes, and PTEN-/- T cell 
lymphoma/leukaemia cells were subjected to Western blot analysis for cleaved Notch1 
(Val1744) (NICD), c-Myc and SMC1. SMC1 was used as a loading control. Equal numbers 
of cells were lysed. Numbers represent molecular weights markers and are given in kDa. Data 
are from 6 PTEN-/- T cell lymphoma/leukaemia cells samples (Notch1) and representative of 
10 PTEN-/- T cell lymphoma/leukaemia cells samples (c-Myc).  
 
 
4.2.7 Notch1 induces leucine uptake and mTORc1 activity  
Notch1 expression is strictly regulated during normal T cell development in the 
thymus. It is highly expressed in cells undergoing β selection, a process that requires 
T cells to become metabolically active and upregulate nutrient uptake (Kelly et al. 
2007). Early work from our laboratory revealed that Notch1 signalling is crucial to 
upregulate CD98 expression (Fig. 4-10a) (Kelly et al. 2007). In this context, we 
observed that only PTEN-/- T cell lymphoma/leukaemia cells but not PTEN-/- non-
transformed thymocytes, upregulated expression of CD98 (Fig. 3-7c and 4-7d, 
respectively). To examine if Notch1 can control leucine uptake in T cells, we cultured 
purified CD4/CD8 double negative T cell progenitors isolated from WT thymocytes 
on either OP9 cells or OP9 cells expressing the Notch ligand DL1 (OP9-DL1) and 
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tested their ability to take up radioactively labelled leucine. We found that T cell 
progenitor cells cultured on OP9-DL1, i.e. in the presence of Notch1 ligand, 
increased leucine transport compared to T cell progenitors exposed to OP9 cells 
lacking Noch1 ligands (Fig. 4-10b). Therefore, these data support a model where the 
expression of CD98 and subsequent leucine uptake is dependent on active Notch 
signalling.  
 
 
Figure 4-10 The effects on Notch1 signalling on leucine uptake and mTORc1 activation. 
Purified WT CD4/CD8 DN thymocytes were cultured in the presence (OP9-DL1) or absence 
(OP9) of Notch ligand DL1 on stromal cell monolayers for 3 days. a. Flow cytometric 
analysis presented as histogram of CD98 expression on WT DN thymocytes. b. WT DN 
thymocytes were assayed for uptake of 3[H]-Leucine. Units show counts per minute per 
1x106 cells. Error bars show SD of 1 biological replicate. c. Flow cytometric analysis of 
intracellular pS6 (Ser235/236) performed on WT DN thymocytes. All data are representative 
of 3 biological replicates from 1 experiment.  
 
 
Leucine availability is necessary to induce activation of mTORc1 (BEUGNET et al. 
2003). Because we noted that T cell progenitor cells grown on OP9-DL1 cells could 
increase the uptake of leucine, we speculated that these cells would have active 
mTORc1. Therefore, we analysed the activity of mTORc1 pathway by testing the 
phosphorylation of S6 ribosomal protein, a direct substrate of the mTORc1-regulated 
S6K. Figure 4-10c shows that T cell progenitors cultured in the presence of Notch1 
ligand had a higher phosphorylation of S6 on Ser235/236 than T cell progenitors 
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cultured in the absence of the Notch1 ligand. These data thus imply that Notch 
activity was essential for activation of mTORc1. 
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4.3  Discussion 
Deregulations of PTEN and PI3K/AKT pathway are frequently observed in T-cell 
acute lymphoblastic leukaemia (Gutierrez et al. 2009). PTEN is a potent suppressor 
of PI3K activity and PTEN deletion leads to accumulation of PI(3,4,5)P3 and 
resultant activation of AKT (Fig. 4-1). While the increase in AKT activity was 
thought to drive tumourigenesis by controlling cell metabolism, we have found that 
nutrient uptake and cell growth was not increased in PTEN-/- non-transformed 
thymocytes. Therefore, we concluded that these changes were driven by secondary 
mutations that occur during the malignant transformation (Guo et al. 2008).  
 
Asking whether PTEN-PI3K-AKT pathway is involved in regulation of nutrient 
uptake in PTEN-/- T cell lymphoma/leukaemia cells is an interesting question that 
stems from multiple observations, for example, AKT is the key kinase in regulating 
glucose metabolism in muscle (Mahfouz et al. 2014) or fat cells (C. J. Green et al. 
2008; Hajduch et al. 2001) or in DN3 cells during thymus development (Hinton et al. 
2004; Ciofani & Zúñiga-Pflücker 2005). However, there were also some opposing 
data arguing that in effector T cells active AKT is dispensable for glucose metabolism 
(Macintyre et al. 2011). Further evidence showed that increased expression of CD71 
and CD98 nutrient receptors is a requirement for metabolically active and 
proliferating DN3 cells during normal thymus development (Kelly et al. 2007). In this 
context, PDK1 null T cell progenitors cannot sustain the expression of either CD71 or 
CD98 (Kelly et al. 2007). However, deletion of PDK1 in PTEN null T cell 
progenitors does not lead to a decreased expression of nutrient receptors, rather it 
restores its expression to the level observed in WT thymocytes (Finlay et al. 2009). 
Hence, PTEN deletion drives expression of CD71 and CD98 in T cell progenitors by 
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PDK1 – independent pathways. We observed that PTEN loss was sufficient to 
increase AKT phosphorylation and activity towards substrates including PRAS40 in 
PTEN-/- non-transformed thymocytes and PTEN-/- T cell lymphoma/leukaemia cells. 
However, only PTEN-/- T cell lymphoma/leukaemia cells showed an increase in 
nutrient uptake and PTEN-/- non-transformed thymocytes were phenotypically like 
WT cells in this respect. The data presented in this chapter also demonstrated that 
PTEN-/- non-transformed thymocytes remained small in size and the resulting 
increase in AKT phosphorylation was not able to initiate and/or sustain the increase 
of nutrient uptake that was observed in PTEN-/- T cell lymphoma/leukaemia cells.  
 
Arguably, although PTEN loss was not directly promoting increased metabolism or 
proliferation, it might have been conferring a survival advantage to cells. We 
demonstrated that loss of PTEN resulted in a decrease in the expression of IL-7R as a 
result of AKT-mediated inhibition of Foxo transcription. During thymus 
development, cells undergo two waves of proliferation and one of them is mediated 
by IL-7 signalling. Therefore, early T cell progenitors need to upregulate IL-7R 
expression to respond to IL-7 signalling in order to maintain their survival (Ciofani & 
Zúñiga-Pflücker 2005). With low levels of IL-7R expression, it would therefore be 
expected that PTEN null thymocytes would have decreased survival. However, we 
showed that PTEN-/- non-transformed thymocytes survived normally and thymi of 
PTENfl/fl x LckCre+ mice had similar numbers as their WT counterparts. Indeed, loss of 
PTEN has been shown to rescue T cell numbers in IL-7R knockout mice as 
PTENxIL-7 DKO mice develop normal levels of CD4/CD8 double negative and 
CD4/CD8 double positive thymocytes (Hagenbeek et al. 2004). 
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Increasing the output of the PI3K pathway via PTEN loss was clearly not sufficient to 
increase the nutrient uptake required to increase metabolism. One of the most 
common mutation found in PTEN null T leukaemic cells is the overexpression of c-
Myc (Guo et al. 2008). In this chapter we also showed that c-Myc protein was 
overexpressed in PTEN-/- T cell lymphoma/leukaemia cells but not in PTEN-/- non-
transformed or WT thymocytes. In transformed cells, c-Myc has been shown to 
control metabolism e.g. glycolysis, iron metabolism or cellular proliferation (C. V. 
Dang et al. 2009). What about nutrient uptake? In this respect, c-Myc has been shown 
to regulate glutamine uptake and glutaminolysis (Duran et al. 2012; R. Wang et al. 
2011a), forcing transformed cells to glutamine addition (Wise et al. 2008). It has also 
been shown that c-Myc controls both glucose and glutamine metabolism in T cell 
antigen receptor activated effector CD8+ T cells (R. Wang et al. 2011a). Furthermore, 
PTEN deletion cannot induce the development of T cells lymphoma/leukaemias in 
the absence of c-Myc (J Zhang et al. 2011). Therefore, c-Myc is a potential candidate 
that might regulate metabolism in PTEN-/- T cell lymphoma/leukaemia cells.  
 
One mechanism by which c-Myc can be upregulated is through Notch1 signalling 
(Palomero et al. 2006; Medyouf et al. 2010; Sulis et al. 2008; Weng et al. 2004; 
Herranz et al. 2014). Despite the fact that activating mutations in PEST or HD 
domain of Notch1 are not observed in PTEN induced T-ALL (Hagenbeek et al. 2014; 
Guo et al. 2008), several groups reported that proliferation and viability of PTEN null 
T cell lymphoma/leukaemia cells are sensitive to treatment with Notch1 inhibitors 
(Medyouf et al. 2010; Hagenbeek et al. 2014). In this context, Hagenbeek at al., 
reported that PTEN-/- T cell lymphoma/leukaemia cells express active Notch1 
(Hagenbeek et al. 2014) and suggested that PTEN loss enables for 
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initiation/maintenance of sustained Notch1 signalling via interactions with DL4 
ligand. The data presented in this chapter, however, showed that active Notch1 was 
not uniformly expressed in PTEN-/- T cell lymphoma/leukaemia cells. One possible 
explanation as to why there was this discrepancy was the fact that we used different 
antibody to the one used in the published work. The authors used an antibody that 
detected all forms of Notch1, i.e. full-length peptide and the short extracellular 
juxtamembrane peptide, and a transmembrane sequence, and the intracellular domain 
(NICD). Instead, we used antibody that detected only the active NICD cleaved after 
Val(1744). 
 
Equally, it is possible then that PTEN-/- T cell lymphoma/leukaemia cells accumulate 
different mutations and active Notch1 is present only in a subset of PTEN induced T-
ALLs and when present, can regulate metabolism in these cells. In this context, 
Notch1 regulates glucose and glutamine uptake (Ciofani & Zúñiga-Pflücker 2005), 
personal communication with Dr Mahima Swamy) and expression of nutrient 
receptors, i.e. CD98 (Kelly et al. 2007) in T cell progenitors. We confirmed that 
Notch1 signalling induced expression of CD98 and triggered leucine uptake in T cell 
progenitors. Leucine in turn is an important amino acid that can induce activation of 
mammalian target of rapamycin complex 1 (mTORc1) (Sinclair et al. 2013; 
BEUGNET et al. 2003), a kinase that regulates metabolism also in T cells (Finlay et 
al. 2012). 
 
We, therefore, demonstrated that PTEN deletion and hence AKT activation does not 
regulate nutrient uptake in PTEN-/- T cell lymphoma/leukaemia cells. We propose that 
secondary mutations that occur during the malignant transformations are likely to 
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regulate these processes in PTEN-/- T cell lymphoma/leukaemia cells, such as active 
Notch1 and/or overexpressed c-Myc. Both Notch1 signalling and c-Myc upregulation 
would link to mTORc1 activation and nutrient uptake. Therefore, mTORc1 activation 
might be a critical step in tumour formation.  
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5 Chapter: mTORc1 activity and function in PTEN-/- T cell 
lymphoma/leukaemia cells 
 
5.1  Introduction 
In the previous chapter we demonstrated that PTEN alone was not sufficient to 
initiate/maintain nutrient uptake and proliferation. We proposed then that increased 
nutrient uptake in PTEN-/- T cell lymphoma/leukaemia cells was caused by secondary 
mutations, such as c-Myc and/or Notch1 overactivation. In this context, we showed 
that triggering of Notch1 signalling could induce CD98 expression and subsequently 
leucine uptake and that these events led to activation of mTORc1.  
 
mTORc1 is proposed to regulate cell size, proliferation and tumour growth in PTEN 
null induced solid tumours (Neshat et al. 2001; Podsypanina et al. 2001) and 
leukaemia derived cell lines (Recher et al. 2005; Avellino et al. 2005; Evangelisti et 
al. 2011; Schwarzer et al. 2014). Additionally, the administration of the mTORc1 
inhibitor, rapamycin, to mice with inducible PTEN deletion eliminates actively 
proliferating cells that have the potential to promote tumour formation, called 
leukaemia initiating cells (Yilmaz et al. 2006). Therefore, the first question we asked 
was whether the primary PTEN-/- T cell lymphoma/leukaemia cells have active 
mTORc1.  
 
A common assumption is that mTORc1 activation is caused by PI3K signalling. In 
this respect it should be noted that a lot of published studies about the role of PI3K as 
an mTOR regulator in lymphocytes used inhibitors of PI3K that are now known to 
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have multiple off target effects. For example, it has been described that IL-7 
regulation of metabolism and survival of T-ALL cell lines is mediated via PI3K but 
these data are based on experiments with Ly294002 that will inhibit PI3K, mTOR 
and PIM serine/threonine kinases (Gharbi et al. 2007; Bain et al. 2007). There is also 
evidence in effector CD8+ T cells that it is mTORc1 that regulates T cell metabolism 
(Finlay et al. 2012) and not PI3K/AKT (Macintyre et al. 2011). Loss of mTORc1 
activity, induced by rapamycin treatment leads to the loss of expression of glucose 
transporters and rate-limiting enzymes and decreased glucose uptake and glycolysis. 
Additionally, it was proposed that mTORc1 regulates expression of glucose 
transporters and glycolytic enzymes by controlling expression of Hif1α. Hence, 
functional deletion of Hif1 complexes in CTLs has similar impact on glucose uptake 
and glycolysis as treatment with rapamycin (Finlay et al. 2012). We, thus, tested 
whether mTORc1 can regulate nutrient uptake in PTEN-/- T cell lymphoma/leukaemia 
cells and if PTEN-/- T cell lymphoma/leukaemia cells express Hif1α, and if Hif1α 
expression is regulated by mTORc1. 
 
Finally, we investigated how mTORc1 is activated in PTEN null T cells isolated prior 
and after the malignant transformation. There are thus two main inputs that control 
mTORc1 activation. One comes from the active AKT-TSC2 pathway (Yecies & 
Manning 2011; Menon et al. 2014; Dibble & Cantley 2015). Since we showed that 
AKT is phosphorylated in T cells isolated from PTENfl/fl x LckCre+ mice prior and 
after malignant transformation, we tested if the observed phosphorylation is sufficient 
to phosphorylate TSC2.  Second mechanism depends on amino acids availability, in 
particular leucine (Sinclair et al. 2013; Sancak et al. 2010; Sancak et al. 2008; Bar-
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Peled et al. 2012; Zoncu et al. 2011). Therefore, we assessed if leucine is critical in 
maintenance of mTORc1 in PTEN-/- T cell lymphoma/leukaemia cells.  
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5.2 Results 
5.2.1 mTORc1 is active in PTEN-/- T cell lymphoma/leukaemia cells 
We first sought to establish if PTEN-/- T cell lymphoma/leukaemia cells have active 
mTORc1. In our study we assessed the activity of mTORc1 by measuring the 
phosphorylation of S6K (Thr389) and its substrate S6 (Ser235/236). Figure 5-1a 
shows that there were no detectable levels of phosphorylated S6K in untreated WT 
thymocytes. In contrast, untreated PTEN-/- T cell lymphoma/leukaemia cells showed a 
marked increase in S6K phosphorylation. Treatment with rapamycin leads to rapid 
dephosphorylation of S6K and Fig.5-1a shows that PTEN-/- T cell 
lymphoma/leukaemia cells treated with rapamycin had no detectable phosphorylation 
of S6K (Thr389). In contrast, treatment with phorbol ester, which induces maximal 
levels of S6K phosphorylation in the cell via stimulation of Protein Kinase C (Hinton 
et al. 2006), showed that S6K phosphorylation in PTEN-/- T cell lymphoma/leukaemia 
cells was not maximal and could be further phosphorylated. In addition to primary 
thymocytes isolated from PTENfl/fl x LckCre- mice (WT) and primary T leukaemic 
cells isolated from PTENfl/fl x LckCre+ mice, we also examined the levels of mTORc1 
activity in a murine cell line, F15, derived from PTEN-/- T cell lymphoma/leukaemia 
cells developed in PTENfl/fl x LckCre+ mice. Accordingly, F15 cells had high levels of 
phosphorylated S6K (Thr389). This phosphorylation of S6K (Thr389) was lost when 
cells were treated with the mTORc1 inhibitor, rapamycin. Therefore, PTEN-/- T cell 
leukaemic cultured cells presented similar behaviour to ex vivo isolated primary 
PTEN-/- T cell lymphoma/leukaemia cells and they both had S6K phosphorylated on 
Thr389. This indicates that mTORc1 was active in both cell types. 
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Figure 5-1 Phosphorylation of S6K (Thr389) in WT thymocytes and PTEN-/- T cell 
lymphoma/leukaemia cells.  
a. WT CD4/CD8 DP thymocytes and PTEN-/- T cell lymphoma/leukaemia cells were either 
left untreated or treated with 20 nM rapamycin as negative control or 25 ng/ml phorbol ester 
as positive control for 30 minutes. Western blot analysis with phosphorylated form of S6K 
(Thr389) and panS6 antibodies. Pan S6 was used as a loading control. Equal numbers of cells 
were lysed. Numbers represent molecular weights markers and are given in kDa. Data are 
representative of 3 biological replicates from 3 independent experiments. b. PTEN-/- 
leukaemic cultured cells (F15) were either left untreated or treated with 20 nM rapamycin as 
negative control for 30 minutes. Western blot analysis with phosphorylated form of S6K 
(Thr389) and SMC1 antibodies. SMC1 was used as loading control. Equal numbers of cells 
were lysed. Numbers represent molecular weights markers and are given in kDa. Data are 
representative of 3 independent experiments.  
 
 
To quantify how many cells in a population of PTEN-/- T cell lymphoma/leukaemia 
cells have active mTORc1 we used flow cytometric based assay where measured S6 
phosphorylation on Ser235/236 in ex vivo isolated WT thymocytes and PTEN-/- T cell 
lymphoma/leukaemia cells. WT thymocytes were heterogeneous for pS6, the majority 
of cells were pS6low and only a small percentage of cells, approximately 10%, were 
pS6high (Fig. 5-2b). In contrast, approximately 40-55% of leukaemic cells isolated 
from PTENfl/fl x LckCre+ mice were pS6high (Fig. 5-2a-b). The data in Figure 5-2b 
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show that pS6 staining in WT thymocytes and PTEN-/- T cell lymphoma/leukaemia 
cells was lost when cells were treated with rapamycin. S6 phosphorylation in PTEN-/- 
T cell lymphoma/leukaemia cells was not maximal and could be further 
phosphorylated by treatment with phorbol ester (Fig. 5-2b).  
 
We also evaluated mTORc1 activity in F15 PTEN-/- leukaemic cell line and noted 
that the majority of untreated F15 cells were pS6high and that rapamycin treatment led 
to dephosphorylation of pS6 (Ser235/236) (Fig. 5.2c). These data, thus, imply that 
PTEN-/- T cell lymphoma/leukaemia cells had active mTORc1, where approximately 
half of the population showed high levels of S6 phosphorylation.  
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Figure 5-2 Phosphorylation of S6 (Ser235/236) in WT thymocytes and PTEN-/- T cell 
lymphoma/leukaemia cells.  
Ex vivo isolated WT and PTEN-/- T cell lymphoma/leukaemia cells were either left untreated 
or treated with 20 nM rapamycin as negative control or treated with 25 ng/ml phorbol ester as 
positive control, both for 30 minutes. Then, cells were intracellularly stained for pS6 
(Ser235/236) and surface stained for co-markers CD4 and CD8. Flow cytometric analysis of 
intracellular pS6 (Ser235/236) from WT CD4/CD8 DP thymocytes and PTEN-/- T cell 
lymphoma/leukaemia cells shown as a. hisogram and b. dot plots, the numbers denote 
frequencies of pS6 positive cells. Gates were set up based on rapamycin treated cells and 
transferred into untreated ex vivo cells and phorbol ester treated cells. Data are representative 
of 3 biological replicates from 3 independent experiments. c. Flow cytometric analysis of 
intracellular pS6 (Ser235/236) from PTEN-/- leukaemic cultured cells (F15) presented as 
histogram. Data are representative of 3 independent experiments. 
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5.2.2 mTORc1 inhibition downregulates nutrient uptake in PTEN-/- T cell 
lymphoma/leukaemia cells 
The presented data indicated that mTORc1 was indeed active in PTEN-/- T cell 
lymphoma/leukaemia cells and in PTEN-/- leukaemic murine cell line, F15. In this 
context, it was shown that active mTORc1 can regulate glucose metabolism in 
activated T cells (Finlay et al. 2012). Ex vivo isolated PTEN-/- T cell 
lymphoma/leukaemia cells are not easily maintained in culture. Studies in normal 
effector T cells have shown that long-term (24-48 hours) treatment with rapamycin is 
required to repress glucose transport. Hence, to study the impact of long-term 
inhibition of rapamycin (48 hours), we decided to perform these experiments on the 
PTEN-/- leukaemic cell line - F15. We first examined if glucose uptake is regulated by 
mTORc1. Figure 5-3a shows that untreated F15 cells readily took up the radiolabelled 
glucose analogue, 2-DG. In contrast, rapamycin-treated cells showed a marked 
decrease of glucose uptake (approximately 70%). These data argue that mTORc1 was 
controlling glucose uptake also in PTEN-/- T cell lymphoma/leukaemia cells.  
 
PTEN-/- T cell lymphoma/leukaemia cells increased uptake rates of other nutrients 
such as glutamine, leucine and transferrin.  We, therefore, tested if mTORc1 regulates 
the uptake of these nutrients. First, we measured the capacity of glutamine uptake by 
untreated and rapamycin treated F15 cells. We found that untreated F15 cells had 
high rates of glutamine uptake. In contrast, mTORc1 inhibition led to a decrease in 
glutamine uptake by approximately 50-55% (Fig. 5-3b). We then measured 3[H]-
Leucine uptake by unstimulated and rapamycin treated cells. We found that while 
untreated PTEN-/- leukaemic cells had high levels of leucine uptake, treatment with 
rapamycin resulted in approximately 60% reduction of leucine uptake (Fig. 5-3c). 
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Finally, we examined the expression of transferrin receptor, CD71 and transferrin 
uptake in control and rapamycin treated F15 cells. The data presented in Fig. 5-3d 
show that rapamycin treatment decreased the expression of CD71 compared to 
untreated cells, however the reduction was only partial. Untreated and rapamycin 
treated cells were starved from transferrin for 2 hours after which the uptake of 
fluorescently labelled transferrin was measured. We found that untreated F15 cells 
readily took up transferrin and rapamycin treatment resulted in a decreased transferrin 
uptake. However, rapamycin did not have such a prominent effect as the complete 
block of transferrin uptake either by competition with holo-transferrin or by 
incubation on ice (Fig. 5-3e). These data then, argue that CD71 expression and 
transferrin uptake were controlled by a combination of mTORc1 dependent and 
independent pathways.  
 
To determine if the block in nutrient uptake mediated by rapamycin impacted on the 
ability of the cells to grow and divide, we measured the proliferation rate of untreated 
and rapamycin treated F15 cells. Untreated cells expanded in culture approximately 
5-fold, whereas rapamycin treated F15 cells increased their numbers approximately 
by 2.5 fold over 48 hours (Fig.5-3f). Therefore, treatment with rapamycin led to 2 
times slower proliferation (Fig.5-3g). Additionally, the analysis of the forward and 
side scatter of control and rapamycin treated F15 cells showed that rapamycin treated 
cells were smaller compared to untreated cells (Fig. 5-3h). 
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Figure 5-3 The effects of mTORc1 inhibition on nutrient uptake in PTEN-/- T leukaemic 
cell line.  
PTEN-/- leukaemic cultured cells (F15) were either left untreated or treated with rapamycin 
for 48 hours. The ability of F15 cells to take up a. 3[H]-2Deoxyglucose or b. 3[H]-Glutamine 
or c. 3[H]-Leucine was measured. Units show counts per minute per 1x106 cells. Error bars 
show SD from 1 experiment and are representative of 2 independent experiments. d. Flow 
cytometric analysis presented as histograms showing expression of CD71 and e. transferrin 
uptake. The ability of cells to take up fluorescently labeled transferrin at 37ºC was measured. 
e. (right graph) Histogram depicting transferrin uptake for untreted cells kept at 37ºC (solid 
grey) or treated with rapmycin kept in 37ºC (red) or kept at 37ºC incubated together with 
transferrin competitor (green) or kept on ice (blue) to block transferrin uptake. Data are 
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representative of 2 independent experiments. f. Proliferation curve of cells cultured for two 
days and g. final number of cells per 1 ml after 2 days in the culture. Data shows the mean of 
2 independent experiments. f. Flow cytometric analysis presented as histogram showing the 
size of cells grown for 2 days in rapamycin. Data are representative for 2 independent 
experiments.  
 
 
5.2.3 PTEN-/- T cell Tumours express c-Myc and Hif1α 
So far, we showed that PTEN-/- T cell lymphoma/leukaemia cells could readily take 
up nutrients and that these processes were downregulated when mTORc1 activity was 
inhibited. In activated T cells, c-Myc and Hif1α are important for initiation and 
maintenance of glucose metabolism and glycolysis. In chapter 4 we showed that 
PTEN-/- T cell lymphoma/leukaemia cells expressed c-Myc, whereas WT and PTEN-/- 
non-transformed thymocytes did not (Fig. 4-9). Fig. 5-4b shows that all PTEN-/- 
leukaemic murine cell lines expressed c-Myc.  
 
It is not known if Hif1α is expressed in primary PTEN-/- T cell lymphoma/leukaemia 
cells. Immune activated effector T cells express only the Hif1α isoform, with Hif1α 
message and protein being only present after activation, irrespective of the oxygen 
tension that cells are exposed to (Finlay et al. 2012; Lukashev et al. 2001; Makino et 
al. 2003). Under normoxic conditions, Hif1α is targeted by PHDs and rapidly 
degraded whereas its expression is stabilised under hypoxia (1% O2) (Jianhe Huang et 
al. 2002). We aimed to determine if Hif1α is present in PTEN-/- non-transformed 
thymocytes and in PTEN-/- T cell lymphoma/leukaemia cells under normoxic (we 
have used 21% O2) or hypoxic (we have used 1% O2) conditions or in cells directly 
analysed ex vivo. Figure 5-4a shows that ex vivo isolated WT and PTEN-/- non-
transformed thymocytes did not express Hif1α. Similarly, Hif1α was not expressed in 
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WT and PTEN-/- non-transformed thymocytes cultured in either normoxic or hypoxic 
conditions. In contrast, PTEN-/- T cell lymphoma/leukaemia cells showed expression 
of Hif1α even in ex vivo isolated samples and this expression was further upregulated 
when cells were cultured in hypoxic (1% O2) environment. We also found, that 
PTEN-/- leukaemic murine cell lines expressed Hif1α under hypoxia and in two of the 
cell lines (F04 and F15), Hif1α protein was stabilised and expressed even under 
normoxic conditions (Fig. 5-4b). The proper function of Hif1α requires its binding 
with Hif1β and Hif1β is constitutively expressed in cells (Semenza 2001). We 
examined expression of Hif1β and found that WT and PTEN-/- non-transformed 
thymocytes, and PTEN-/- T cell lymphoma/leukaemia cells expressed Hif1β (Fig. 5-
4c). To summarise we showed that PTEN-/- T cell lymphoma/leukaemia cells 
expressed Hif1α and c-Myc whereas PTEN-/- non-transformed and WT thymocytes 
did not. 
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Figure 5-4 Expression of Hif1α and c-Myc by WT thymocytes and primary PTEN-/- T 
cells and PTEN-/- leukaemic cell lines.  
Ex vivo isolated total WT thymocytes, PTEN-/- non-transformed thymocytes and PTEN-/- T 
cell lymphoma/leukaemia cells were either lysed immediately after isolation (ex vivo) or 
cultured under normoxia (21% O2) or hypoxia (1% O2) for 4 hours. a. and c. Western blot 
analysis with Hif1α, Hif1β, SMC1 and pan AKT antibodies. SMC1 and pan AKT were used 
as loading controls. Equal numbers of cells were lysed. Numbers represent molecular weights 
markers and are given in kDa. Data are representative of 3 biological replicates from 3 
independent experiments. b. PTEN-/- leukaemic cultured cells (F15) were either cultured 
under normoxia (21% O2) or hypoxia 1% O2) for 4 hours. Western blot analysis with Hif1α, 
c-Myc and SMC1 antibodies. SMC1 was used as a loading control. Equal numbers of cells 
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were lysed. Numbers represent molecular weights markers and are given in kDa. Data are 
representative of 3 independent experiments.  
 
 
5.2.4 mTORc1 inhibition leads to a loss of Hif1α expression in PTEN-/- T cell 
lymphoma/leukaemia cells  
In activated T cells mTORc1 controls expression of Hif1α (Finlay et al. 2012). Hif1α 
known target genes include glucose transporters and rate-limiting enzymes. Earlier in 
this chapter, we showed that chronic inhibition of mTORc1 with rapamycin led to 
decrease in glucose, glutamine and leucine uptake (experiments were performed in 
21% O2 environment). Thus we asked if mTORc1 could regulate expression of Hif1α 
in PTEN-/- T cell lymphoma/leukaemia cells. Because Hif1α expression in F04 and 
F15 cells was readily detected under normoxic conditions, we performed the 
following experiments in this condition. We treated PTEN-/- leukaemic F04 and F15 
cells with rapamycin for 24 or 48 hours to understand if/when Hif1α expression was 
blocked when mTORc1 is inhibited. The presented data show that rapamycin 
treatment was effective at blocking mTORc1 activity in F04 and F15 cells, because it 
resulted in dephosphorylation of S6K on Thr389 (Fig. 5-5). Furthermore, Hif1α 
expression was strongly decreased in rapamycin treated cells (Fig. 5-5). Therefore, 
these data indicate that mTORc1 regulated Hif1α expression in PTEN-/- T cell 
lymphoma/leukaemia cells. We also assessed expression of Hif1β, a binding partner 
of Hif1α that is required for Hif1α transcriptional activity, and showed that its 
expression was intact in untreated cells, however rapamycin treatment led to a 
reduction in its expression (Fig. 5-5). In activated T cells, mTORc1 does not regulate 
AKT phosphorylation/activity (Finlay et al. 2012) and we also observed that 
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rapamycin treated F15 cells retained AKT phosphorylation on Thr308, similar to 
untreated cells (Fig. 5-5). The evidence that mTORc1 controlled expression of Hif1α 
meant that there was the potential for Hif1α to be involved in the regulation of 
metabolism in PTEN-/- T cell lymphoma/leukaemia cells.  
 
 
Figure 5-5 The effect of mTORc1 inhibition of Hif1α expression in PTEN-/- leukaemic 
cell lines.  
PTEN-/- leukaemic cells, F04 and F15 cells were either left untreated or treated with 20 nM 
rapamycin for 24 hours or 48 hours under normoxia condition. Western blot analysis was for 
antibodies against Hif1α, Hif1β, pS6K (Thr389), pAKT (Thr308) and SMC1. SMC1 was 
used as a loading control. Equal numbers of cells were lysed. Numbers represent molecular 
weights markers and are given in kDa. Data are representative of 2 independent experiments.  
 
 
5.2.5 PTEN-/- non-transformed thymocytes have very low mTORC1 activity  
We showed that PTEN-/- T cell lymphoma/leukaemia cells had active mTORc1 and 
expressed Hif1α. Do PTEN-/- non-transformed thymocytes have active mTORc1? To 
test this, we first probed PTEN-/- non-transformed thymocytes for the phosphorylated 
form of S6K on Thr389 site. Figure 5-6a shows that there was only a small increase 
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in phosphorylation of S6K (Thr389) compared to PTEN-/- T cell 
lymphoma/leukaemia cells (the same Western blot analysis as in Fig. 5-1a). 
Treatment with rapamycin of PTEN-/- non-transformed thymocytes resulted in loss of 
S6K phosphorylation, whereas the treatment with phorbol ester showed that S6K 
phosphorylation in PTEN-/- non-transformed thymocytes was not maximal and could 
be further phosphorylated.   
 
The data presented above caused us to question whether the lower mTORc1 activity 
in PTEN-/- non-transformed thymocytes compared to PTEN-/- T cell 
lymphoma/leukaemia cells reflected that in the non-transformed thymocytes 
mTORc1 is only active in a small subset of cells. Thus, we used the flow cytometric 
based assay to quantify S6 phosphorylation on Ser235/236 in ex vivo isolated WT and 
PTEN-/- non-transformed thymocytes. WT thymocytes were heterogeneous for pS6, 
the majority of cells were pS6low and only a small percentage of cells (5% to 7%) 
were pS6high (Fig. 5-6b-c), whereas approximately 11% of PTEN-/- non-transformed 
thymocytes were pS6high (Fig. 5-6b-c). The data in Figure 5-6c show that pS6 staining 
in WT thymocytes and PTEN-/- non-transformed thymocytes was lost when cells 
were treated with rapamycin. In contrast, stimulation with phorbol ester induced S6 
phosphorylation in the pS6low population (Fig. 5-6c). These data show that only in a 
very small subset of PTEN-/- non-transformed thymocytes mTORc1-S6K signalling 
was active to mediate phosphorylation of S6. In most thymocytes, PTEN deletion was 
not sufficient to activate mTORc1. 
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Figure 5-6 mTORc1 activity in PTEN-/- non-transformed thymocytes.  
a. WT CD4/CD8 DP thymocytes, PTEN-/- non-transformed thymocytes and PTEN-/- T cell 
lymphoma/leukaemia cells were either left untreated or treated with 20 nM rapamycin as 
negative control or 25 ng/ml phorbol ester as positive control for 30 minutes. Western blot 
analysis with phosphorylated form of S6K (Thr389) and pan S6 antibodies. Pan S6 was used 
as a loading control. The same Western blot analysis as in Fig. 5-1a. Equal numbers of cells 
were lysed. Numbers represent molecular weights markers and are given in kDa. Data are 
representative of 3 biological replicates from 3 independent experiments. b. Ex vivo isolated 
WT thymocytes and PTEN-/- non-transformed thymocytes were either left untreated or treated 
with 20 nM rapamycin as negative control or treated with 25 ng/ml phorbol ester as positive 
control, both for 30 minutes and the stained intracellularly for pS6 (Ser235/236) and surface 
stained for co-receptors CD4 and CD8. Flow cytometric analysis presented as histograms 
showing pS6 (Ser235/236) expression in WT CD4/CD8 DP thymocytes and PTEN-/- non-
transformed DP thymocytes. c. Flow cytometric analysis presented as dot plots of pS6 
(Ser235/236) expression, the numbers denotes frequencies of pS6 positive cells. Gates were 
set up based on rapamycin treated cells and transferred into untreated ex vivo cells and 
phorbol ester treated cells. Data are representative of 3 biological replicates from 3 
independent experiments. 
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5.2.6 TSC2 is phosphorylated in PTEN-/- non-transformed thymocytes and in 
PTEN-/- T cell lymphoma/leukaemia cells. 
If mTORc1 activity may be the driving force in controlling nutrient uptake of PTEN-/- 
T cell lymphoma/leukaemia cells, we wanted to understand how mTORc1 activity is 
controlled in the tumours isolated from PTENfl/fl x LckCre+ mice.  mTORc1 activity is 
controlled via different ways and the best described are growth factors and amino 
acids availability.  
 
AKT can phosphorylate TSC2 on several sites, among them there is Thr1462 
(Manning et al. 2002; Inoki et al. 2002). This phosphorylation is important for 
mTORc1 activation as it inhibits TSC2 complex activity and enables RHEB to induce 
mTORc1 activity (Menon et al. 2014). We, therefore, assessed the phosphorylation 
status of TSC2 (Thr1462) in PTEN-/- non-transformed thymocytes and in PTEN-/- T 
cell lymphoma/leukaemia cells via two independent methods. In the first, we used 
immobilised 14-3-3 proteins to pull down the Thr1462 phosphorylated TSC2 from 
cells, and measured the extend of isolation using a pan TSC2 antibody. The rationale 
for this experiment is that AKT phosphorylation sites on TSC2 create 14-3-3 binding 
sites (Y. Li et al. 2002). We found that a low level of TSC2 was present in the 14-3-3 
‘pull downs’ from untreated WT thymocytes. However, Figure 5-7a shows that more 
TSC2 was isolated by 14-3-3 proteins from untreated PTEN-/- non-transformed 
thymocytes and PTEN-/- T cell lymphoma/leukaemia cells. These data, thus, 
suggested that TSC2 was highly phosphorylated in these samples. In canonical 
signalling, treatment with AKTi should block TSC2 (Thr1462) phosphorylation and 
hence block sequestration by 14-3-3. Interestingly however, we did not notice 
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effective reduction of TSC2 expression in samples treated with AKTi in either PTEN-
/- non-transformed thymocytes or PTEN-/- Tumour cells. 
 
 
Figure 5-7 Phosphorylation of TSC2 (Thr1462) in WT thymocytes, PTEN-/- non-
transformed and PTEN-/- T cell lymphoma/leukaemia cells.  
Total ex vivo isolated WT thymocytes, PTEN-/- non-transformed thymocytes and PTEN-/- T 
cell lymphoma/leukaemia cells were either left untreated or treated with 1µM of AKTi for 1 
hour or with pervanadate for 5 minutes. AKTi was used as negative control and pervanadate 
as positive control for TSC2 phosphorylation. a. Western blot analysis with pan TSC2 
antibody from proteins pulled with 14-3-3 coated beads (upper panel) and from total lysates 
(lower panel). Pan TSC2 (input) was used as a loading control. b. Western blot analysis with 
phosphorylated form of TSC2 (Thr1462), pan TSC2 and SMC1 antibodies. SMC1 was used 
as a loading control. Equal numbers of cells were lysed. Numbers represent molecular 
weights markers and are given in kDa. Data are representative of 2 biological replicates from 
2 independent experiments.  
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In the second approach we probed the lysates with antibodies against phosphorylated 
TSC2 (Thr1462) or pan TSC2. The data presented in Fig. 5-7b shows that WT 
thymocytes had basal level of phosphorylated TSC2 (Thr1462) whereas, the 
phosphorylation was slightly higher in PTEN-/- non-transformed thymocytes and 
PTEN-/- T cell lymphoma/leukaemia cells. However, the PTEN-/- non-transformed 
thymocytes and PTEN-/- T cell lymphoma/leukaemia cells appeared to have higher 
levels of total TSC2 protein. Additionally, the TSC2 phosphorylation in the PTEN 
null cells was partially reduced by AKTi treatment. These data are not clear-cut and it 
is possible, then, that in thymocytes, TSC2 is phosphorylated by kinases other than 
AKT. 
 
5.2.7 Leucine is crucial for maintenance of mTORc1 activity in PTEN-/- T cell 
lymphoma/leukaemia cells.  
The signalling pathways that feed in to the TSC2-RHEB-mTORc1 pathway include 
those derived from the cellular content of amino acids. Leucine, in particular, is the 
major activator of mTORc1 (Schriever et al. 2013; BEUGNET et al. 2003). To test if 
leucine is important for maintenance of mTORc1 activity in PTEN-/- T cell 
lymphoma/leukaemia cells we cultured PTEN-/- leukaemic cell lines – F15 in full 
media or in media deprived of leucine or all amino acids (HBSS, negative control) 
and then tested the phosphorylation of S6 (Ser235/236). The time-course analysis 
showed that as soon as 5 minutes after leucine withdrawal, there was a substantial 
loss of S6 phosphorylation in F15 cells compared to untreated cells (Fig. 5-8). After 
15 minutes of leucine washout almost all mTORc1 activity was gone as judged by the 
S6 dephosphorylation (Ser235/236) (Fig. 5-8). Importantly, dephosphorylation of S6 
(Ser235/236) after leucine withdrawal had similar kinetics to the rate of 
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dephosphorylation in cells switched to media lacking all amino acids  (Fig. 5-8). 
Therefore, leucine was essential for switching on mTORc1 activity in PTEN-/- T cell 
lymphoma/leukaemia cells.  
 
 
Figure 5-8 The effects of leucine withdrawal on S6 phosphorylation (Ser235/236) in 
PTEN-/- leukaemic cell line - F15.  
PTEN-/- leukaemic cultured cells (F15) were either cultured for increased times in full media 
or media lacking leucine (red) or all amino acids (blue, the negative control). Flow cytometric 
analysis presented as histograms for expression of phosphorylated form of S6 on Ser235/236 
as indicator of mTORc1 activity. Data are representative of 3 independent experiments.  
 
 
5.2.8 PTEN-/- CTLs cannot sustain the nutrient uptake when deprived of IL-2 
To further investigate whether PTEN deletion is sufficient to drive mTORc1 activity 
and signalling pathways in T cells, we switched to a different cell model, IL-2 
maintained cytotoxic T cells (CTLs). These are very metabolically active and have a 
high level of nutrient uptake (Cornish 2006). IL-2 is a key cytokine that regulates 
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et al. 2013; Cornish 2006). They also express high levels of c-Myc and Hif1α and 
have high levels of mTORc1 activity (Finlay et al. 2012). Therefore understanding 
how PTEN-/- CTLs will respond to IL-2 deprivation could give us insight into 
whether PTEN deletion can keep these cells metabolically active. Importantly, IL-2 
deprivation significantly reduces nutrient uptakes and mTORc1 activity, and 
expression of c-Myc and Hif1α in CTLs (Cornish 2006; Macintyre et al. 2011; Finlay 
et al. 2012).  
 
To generate cultures of WT and PTEN-/- CTLs, purified CD8+ cells were stimulated 
with CD3 antibody that trigger the T cell antigen receptor complex for 2 days, then 
cultured in IL-2 for a further 4 days. Then, for the final 24 hours in culture, CTLs 
were either maintained in IL-2 or deprived of IL-2. Initially, we tested if IL-2 
deprivation affects AKT phosphorylation. Figure 5-8 shows that WT CTLs 
maintained in IL-2 had AKT phosphorylated on Thr308 and Ser473 and this 
phosphorylation was further increased in PTEN-/- CTLs. Deprivation of IL-2 resulted 
in slight increase of AKT phosphorylation in both WT and PTEN-/- CTLs. Therefore, 
IL-2 loss did not adversely affect AKT phosphorylation (Fig. 5-9).  
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Figure 5-9 WT and PTEN-/- CTLs deprived of IL-2 maintain phosphorylation of AKT.  
IL-2 maintained WT and PTEN-/- CTLs were either left untreated or treated with 1µM of 
AKTi, or deprived of IL-2 for the last 24 hours of culture. AKTi was used as negative control 
for AKT phosphorylation. Western blot analysis with phosphorylated forms of AKT: Thr308 
and Ser473, and SMC1 antibodies. SMC1 was used as a loading control. Equal numbers of 
cells were lysed. Numbers represent molecular weights markers and are given in kDa. Data 
are representative of 3 biological replicates from 3 independent experiments.  
 
 
We then tested the ability of IL-2 maintained and IL-2 deprived CTLs to take up 
nutrients. First, we measured if PTEN-/- CTLs deprived of IL-2 could take up 
radiolabeled 2-DG. Both WT and PTEN-/- CTLs maintained in IL-2 had high rates of 
glucose uptake (Fig. 5-10a). However, deprivation of IL-2 resulted in virtually no 
uptake in WT CTLs and PTEN-/- CTLs (Fig. 5-10a). Similarly, WT and PTEN-/- 
CTLs maintained in IL-2 had high rates of glutamine uptake but both WT and PTEN-
/-
 CTLs starved of IL-2 failed to uptake 3[H]-Glutamine (Fig. 5-10b). Next, we tested 
CD71 expression and subsequent uptake of transferrin and observed that IL-2 
maintained WT and PTEN-/- CTLs had high expression of CD71 as well as high rates 
of transferrin uptake (Fig. 5-10c-d). In contrast, WT and PTEN-/- null CTLs deprived 
of IL-2 showed downregulated expression of CD71 and could not take up transferrin 
(Fig. 5-10c-d). Furthermore, expression of CD98 was measured and Figure 5-10e 
shows that both WT and PTEN-/- CTLs maintained in IL-2 had high expression of 
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CD98. Interestingly, and in contrast to previous observations, we noticed that PTEN-/- 
CTLs deprived of IL-2 expressed similar levels of CD98 compared to WT CTLs 
maintained in IL-2 (Fig. 5-10e), whereas IL-2 deprived WT CTLs downregulated 
CD98 expression. Moreover, IL-2 maintained WT and PTEN-/- CTLs had high rates 
of leucine uptake (Fig. 5-10f). Moreover, deprivation of IL-2 resulted in decrease of 
leucine uptake by WT CTLs. However, IL-2 deprivation did not cause a major 
decrease in 3[H]-Leucine uptake in PTEN-/- CTLs. These cells, thus, had comparable 
ability to take up leucine as WT IL-2 maintained CTLs (Fig. 5-10f). Together, these 
data implied that PTEN deletion was not sufficient to maintain glucose and glutamine 
uptakes in CTLs but it could sustain leucine uptake.  
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Figure 5-10 The effects of IL-2 deprivation on nutrient uptake by WT and PTEN-/- 
CTLs.  
IL-2 maintained WT and PTEN-/- CTLs were either left untreated or deprived of IL-2 for the 
last 24 hours of culture and their ability to take up a. 3[H] –Glucose, b. 3[H]-Glutamine and f. 
3[H]-Leucine was measured. Units show counts per minute per 1x106 cells. Error bars show 
mean SD for 1 biological replicate and the data are representative for 3 independent 
experiments. c. Flow cytometric analysis presented as histograms showing expression of 
CD71 and d. transferrin uptake. Data are representative of 3 biological replicates from 3 
independent experiments.  
 
 
To test if leucine taken up by the PTEN-/- CTLs deprived of IL-2 was sufficient to 
sustain mTORc1 activity, we tested WT and PTEN-/- IL-2 maintained and IL-2 
deprived CTLs for expression of phosphorylated S6K (Thr389) and its substrate S6 
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(Ser235/236). Figure 5-11a-b shows that while there were high levels of mTORc1 
activity in WT and PTEN-/- CTLs maintained in IL-2, there was no detectable activity 
of mTORc1 in WT and PTEN-/- CTLs deprived of IL-2. mTORc1 regulates 
expression of Hif1α; therefore we tested for its expression. WT and PTEN-/- CTLs 
maintained in IL-2 had high levels of Hif1α expression (Fig. 5-11c). The loss of 
mTORc1 activity observed in CTLs deprived of IL-2 led to a loss of Hif1α expression 
in these cells (Fig. 5-11c). We also tested expression of c-Myc and found that IL-2 
maintained WT and PTEN-/- CTLs expressed c-Myc, whereas IL-2 deprived WT and 
PTEN-/- CTLs lost c-Myc expression (Fig. 5-11c).  
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Figure 5-11 The effects of IL-2 deprivation on mTORc1 activity and expression of Hif1α 
and c-Myc in WT and PTEN-/- CTLs.  
a. IL-2 maintained WT and PTEN-/- CTLs were either left untreated or deprived of IL-2 for 
the last 24 hours of culture. Western blot analysis with phosphorylated form of S6K (Thr389) 
and SMC1 antibodies. SMC1 was used as a loading control. b. Flow cytometric analysis 
presented as histogram showing pS6 (Ser235/236) expression. Data are representative of 3 
biological replicates from 3 independent experiments. c. IL-2 maintained WT and PTEN-/- 
CTLs were either left untreated or deprived of IL-2 for the last 24 hours of culture. 
Additionally, for the last 4 hours they were cultured either under normoxia (21% O2) or 
hypoxia (1% O2). Western blot analysis with Hif1α, c-Myc and SMC1 antibodies. Equal 
numbers of cells were lysed. Numbers represent molecular weights markers and are given in 
kDa. Data are representative of 3 biological replicates from 3 independent experiments.  
 
 
Overall, we showed that when challenged PTEN null cytotoxic T cells could not 
maintain the nutrient uptake and molecules that are important for mTORc1 activity. 
This confirmed our previous data showing that PTEN deletion was not sufficient for 
mTORc1 activation in T cells. 
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5.3 Discussion 
In the previous chapters we established that PTEN did not induce the metabolic 
switch in PTEN-/- T cell lymphoma/leukaemia cells. Therefore, we proposed 
mTORc1 as a potential candidate in controlling nutrient uptake in PTEN-/- T cell 
lymphoma/leukaemia cells. We, thus, found that mTORc1 was active in tumour 
samples isolated from primary PTENfl/fl x LckCre+ mice. Moreover, we demonstrated 
that mTORc1 activity was required to sustain nutrient uptake in PTEN-/- T cell 
lymphoma/leukaemia cells and hence required to maintain metabolism in these cells.   
 
Upregulation and maintaining of glucose uptake and glycolysis are important for 
activated T cells and mTORc1, via Hif1α, plays a crucial role in regulation of these 
processes (Finlay et al. 2012). Earlier studies reported expression of Hif1α in cancer 
stem cells from mouse splenic-derived lymphoma and in leukaemic cell lines (Y. 
Wang et al. 2011b; Evangelisti et al. 2011). However, it was not known whether 
PTEN induced T cell lymphomas express Hif1α. We found that primary tumours 
isolated from PTENfl/fl x LckCre+ mice did express Hif1α and that its expression was 
detected even in ex vivo isolated samples. In this respect, studies using the drug 
pimonidazole, which acts as a marker for hypoxic tissues, identified the thymus as a 
hypoxic organ with the mean of partial pressure of oxygen (PO2) less than 10 mmHg 
(Hale et al. 2002). As expression of Hif proteins is known to mediate the adaptation 
to cellular hypoxia, we would expect that Hif1α would be present in all our tested 
tissues, i.e. WT and PTEN-/- non-transformed thymocytes and PTEN-/- T cell 
lymphoma/leukaemia cells. The fact that we found Hif1α only in tumour samples 
suggested that probably Hif1α expression was induced by secondary mutations that 
occur around the malignant transformation.  
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We, therefore, proposed that expression of Hif1α is regulated by mTORc1, as we 
found its activity in tumour samples isolated from primary PTENfl/fl x LckCre+ mice. 
In this respect, effector CD8+ T cells and effector CD4+ Th17 producing cells treated 
with rapamycin loose expression of Hif1α and as a result decrease their metabolism 
(Finlay et al. 2012; Shi et al. 2011). We demonstrated that PTEN-/- T cell 
lymphoma/leukaemia cells could regulate these processes in a similar way because 
rapamycin treated PTEN-/- T cell lymphoma/leukaemia cells decreased glucose 
uptake. Preliminary experiments (data not shown) indicated that PTEN-/- T cell 
lymphoma/leukaemia cells also had decreased rate of lactate production. It might be 
beneficial to also determine the expression of rate limiting enzymes in PTEN-/- T cell 
lymphoma/leukaemia cells treated with rapamycin to gain better understanding of 
mTORc1-Hif1α regulation of glucose metabolism. 
 
Interestingly, we also found that mTORc1 could control uptake of other nutrients in 
PTEN-/- T cell lymphoma/leukaemia cells such as glutamine and leucine, as 
rapamycin treatment led to decrease in uptake of these amino acids. Nicklin at al., 
proposed that there is a continuous requirement for glutamine efflux with 
simultaneous import of leucine to fuel mTORc1 activation (Nicklin et al. 2009), but it 
was not clear if mTORc1 can regulate the expression of transporters for glutamine 
and leucine. Our data suggested that at least in PTEN-/- T cell lymphoma/leukaemia 
cells it is possible. Interestingly, rapamycin treatment of PTEN-/- T cell 
lymphoma/leukaemia cells did not result in cell death. Instead, the cells retained their 
ability to proliferate, albeit at lower rate than the untreated controls. Then, how could 
PTEN-/- T cell lymphoma/leukaemia cells proliferate given that they had reduced 
levels of nutrient uptake? One key point here would be that rapamycin treatment 
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decreased glucose uptake by approximately 70% but it did not reduce it to zero. In 
this context, rapidly proliferating cells, like CTLs, will use glucose to produce 
pyruvate that then is used for production of biosynthetic precursors. It is therefore 
possible that the reduced glucose uptake was sufficient to maintain proliferation of 
rapamycin treated PTEN-/- T cell lymphoma/leukaemia cells. Additionally, low 
mTORc1 activity has been linked to the increased formation of autophagosomes 
(Korolchuk et al. 2011). Autophagy is a catabolic process by which the degradation 
of dysfunctional or unwanted proteins and cellular components occurs and takes place 
in lysosomes (Yang & Klionsky 2010). Importantly, metabolites of autophagy can be 
reused to fuel biosynthesis of new macromolecules and hence promote cell survival 
and maintenance of cellular energy levels (Boya et al. 2013). Therefore, low amino 
acids availability observed in rapamycin treated PTEN-/- T cell lymphoma/leukaemia 
cells could further inhibit mTORc1 activity and thus force cells to perform autophagy 
that provided nutrients to support cell division. 
 
What controls mTORc1 activity in PTEN-/- T cell lymphoma/leukaemia cells? In this 
respect our data showed that PTEN deletion and AKT activation was not sufficient to 
activate mTORc1 in most PTEN-/- non-transformed thymocytes or in CTLs. In the 
thymus, the most probable reason for the minimal mTORc1 activity was that PTEN 
deletion was not sufficient to induce glucose, glutamine and leucine uptake, and the 
supply of these nutrients is essential for mTORc1 activity (Finlay et al. 2012; Nicklin 
et al. 2009; Sinclair et al. 2013; Rolf et al. 2013). As a result, PTEN-/- non-
transformed thymocytes that were not able to upregulate uptake of these nutrients, 
also could not induce/sustain mTORc1 activity. 
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To summarise, we showed that leucine availability is critical for continuous mTORc1 
activity in PTEN-/- T cell lymphoma/leukaemia cells. Active mTORc1 in turn 
regulates glucose uptake and glycolysis, and Hif1α expression (Finlay et al. 2012). In 
the next chapter, we will investigate the role of Hif1α after PTEN deletion in an in 
vivo mouse model of T lymphomagenesis and also whether Hif1α can contribute to 
the control of nutrient uptake and hence metabolism in PTENfl/fl x LckCre+ mice.  
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6  Chapter: The role of Hif1α in tumour development of 
PTENfl/fl x LckCre+ mice  
 
6.1 Introduction 
The importance of Hif1α activity in promoting lymphomagenesis was previously 
addressed. In particular, it was noticed that active Hif1α is needed for the survival of 
leukaemia initiating cells (LIC) and hence tumour initiation and its progression (Y. 
Wang et al. 2011b; Giambra et al. 2015). LIC are haematopoietic cells that are 
capable of promoting the development of lymphoma/leukaemias once transplanted to 
immunodeficient or syngeneic mice (Guo et al. 2008). Genetic ablation of Hif1α in 
leukaemic cells that are transplanted into secondary recipients leads to reduction of 
LIC frequency (Giambra et al. 2015). Similarly, pharmacological inhibition of Hif1α 
in cultured lymphoma cells results in reduction of LIC numbers when they are 
transplanted into secondary recipients (Y. Wang et al. 2011b).  
 
Hif1α has been described to be important in non-transformed cells. Hence early 
studies done in embryonic stem (ES) cells revealed that ablation of Hif1α leads to 
reduction of enzymes involved in glucose metabolism (Ryan et al. 2000; Iyer et al. 
1998). Additionally, studies done in T cells showed that deletion of Hif1α in either 
CD4+ Th17 producing cells or CD8+ CTLs also leads to downregulation of glucose 
transporter and glycolytic enzymes, arguing for the importance of Hif1 complexes in 
maintaining the metabolic switch in these cells (E. V. Dang et al. 2011; Shi et al. 
2011; Finlay et al. 2012). Moreover, Tandon at al., showed that knockdown of Hif1α 
in a PTEN deficient haematopoietic progenitor cell line results in decreased rates of 
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glycolysis and this phenotype can be rescued when these cells are forced to express a 
normoxia-stable Hif1α mutant (Tandon et al. 2011). 
 
Given the fact that PTEN-/- T cell lymphoma/leukaemia cells expressed Hif1α and 
that mTORc1 controlled Hif1α expression and also controlled glucose uptake, we 
hypothesised that Hif1α deletion would prevent sustained expression of genes and 
proteins involved in glucose metabolism and hence prevent tumourigenesis in PTEN-
/- T cell lymphoma/leukaemia cells. Therefore, to understand whether Hif1α plays a 
role in glucose metabolism and whether the loss of Hif1α can prevent formation of 
tumours in PTENfl/fl x LckCre+ mice, we decided to simultaneously delete Hif1α and 
Pten genes in T cell progenitors in PTENfl/fl x Hif1αfl/fl x LckCre+ (DKO) mice.  
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6.2 Results 
6.2.1 Hif1α loss does not impair T cell development 
In order to study the impact of Hif1α loss on tumourigenesis in PTENfl/fl x LckCre+ 
mice, we first examined if deletion of Hif1α in T cell progenitors has any effect on T 
cell development. Therefore, Hif1α-floxed mice (Ryan et al. 2000) were purchased 
from The Jackson Laboratory® and backcrossed with mice expressing Cre 
recombinase under the control of the Lck promoter. Thymi of WT and Hif1αfl/fl x 
LckCre+ mice were similar in size and the total numbers of cells were comparable 
between the two, and were within the normal range. Average numbers of total 
thymocytes were 20.5 x 107 for WT and 17.9 x 107 in Hif1α-/- thymi (Fig. 6-1a). 
Figure 6-1b shows that WT and Hif1α-/- thymi had similar distribution of cells in each 
developmental stage. WT thymocytes typically contained around 85% of CD4/CD8 
DPs and approximately 5% of single positive (SP) CD4+ and 1.5% of SP CD8+ cells. 
Accordingly, Hif1α-/- thymi contained approximately 83% of CD4/CD8 DPs, 7% of 
SP CD4+ cells and 2% of SP CD8+ cells. The frequencies of thymic populations 
were reflected by their total numbers (Fig.6-1f). Staining with CD25 and CD44 
markers that can differentiate between the double negative populations, also showed 
similar percentages of cells in DN1 to DN4 in WT and Hif1α-/- thymocytes (Fig.6-
1c). In addition, the surface expression of TCRb and the percentage of TCRbhigh cells 
were similar in WT and Hif1α-/- thymocytes and on average they were 7.5% and 10%, 
respectively (Fig. 6-1d). Moreover, the total numbers for TCRbhigh cells were also 
comparable between WT and Hif1α-/- thymocytes (Fig.6-1g). The similar ratios and 
numbers of TCRbhigh cells were also reflected in the production of mature SP cells in 
the thymus as indicated by comparable percentages of TCRbhigh CD24low cells in WT 
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and Hif1αfl/fl x LckCre+ mice with 5.5% and 8%, respectively (Fig. 6-1e). These data 
thus indicated that loss of Hif1α did not affect T cell development in the thymus.  
 
Neither thymocytes nor naïve cells express Hif1α protein. However, immune 
activated CD8+ T cells induce expression of Hif1α protein and therefore, we used 
them to show that Hif1α is deleted in T cells. Thus, we stimulated cells isolated from 
spleen with CD3 antibody that trigger the T cell antigen receptor complex for 2 days 
and then cultured in IL-2 for the next 4 days. We left cells either untreated 
(normoxia) or treated with 1% O2 (hypoxia) as the positive control, because hypoxia 
allows for the stabilization of Hif1α protein. Western blot analysis in Fig. 6-1h shows 
that while WT CTLs expressed Hif1α under normoxic and hypoxic conditions, Hif1α-
/- CTLs lost Hif1α expression also under hypoxic condition. These data confirmed 
that T cell could develop in the absence of Hif1α.  
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Figure 6-1 Flow cytometric analysis of T cell development in WT and Hif1αfl/fl x LckCre+ 
mice. 
Ex vivo isolated thymi from WT and Hif1α-/- mice were stained with either Thy1, CD4, CD8, 
CD25 or CD44 or Thy1, CD4, CD8, TCRb and CD24 surface markers and subjected to flow 
cytometry analysis presented as: a. Total thymi numbers calculated for Thy1 positive cells. b. 
Dot blot showing expression of CD4 and CD8 markers on Thy1 positive cells. c. Dot plot 
analysis showing expression of CD44 and CD25 markers on double negative cells. d. 
Histogram showing expression of surface TCRb and the percentage of TCRbhigh cells gated 
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on Thy1 positive cells. e. Dot plot showing expression of CD24 and TCRb surface markers, 
gated on Thy1 population. f. Total numbers of CD4/CD8 DP, SP CD4+, SP CD8+ and 
CD4/CD8 DN cells. g. Total numbers of TCRbhigh cells. All data are representative of 5 
biological replicates from 2 independent experiments; p-values were calculated by t-test, ns – 
not significant. h. Western blot analysis of WT and Hif1α-/- CTLs was with antibodies against 
Hif1α and TBP. TBP was used as a loading control. Equal numbers of cells were lysed. 
Numbers represent molecular weights markers and are given in kDa. Data are representative 
of 3 biological replicates from 3 independent experiments. 
 
 
Peripheral lymphocyte populations in spleen (Fig. 6.2a) and lymph nodes (data not 
shown) of WT and Hif1αfl/fl x LckCre+ mice were also isolated and analysed by flow 
cytometry. Figure 6-2a shows that percentages and ratios of T (TCRb+) cells and B 
(B220+) cells were normal. WT spleens typically contained approximately 20% of 
TCRb+ cells and 70% of B220+ cells and the same were found in Hif1α-/- 
splenocytes.  Additionally, both spleen (Fig.6-2b) and lymph nodes (data not shown) 
showed normal ratios of CD4+ and CD8+ cells within the TCRb population. WT 
spleen contained approximately 75% of CD4+ cells and 25% of CD8+ cells and we 
also observed similar distribution of splenocytes in Hif1αfl/fl x LckCre+ mice (Fig. 6-
2b). These data then suggested that in the absence of Hif1α, the ability of T cells to 
survive in secondary lymphoid organs was not impaired.  
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Figure 6-2 Flow cytometric analysis of splenocytes in WT and Hif1αfl/fl x LckCre+ mice. 
Ex vivo isolated splenocytes from WT and Hif1α-/- mice were stained with TCRb, B220, CD4 
and CD8 surface markers and subjected to flow cytometry analysis presented as: a. Dot blot 
showing expression of TCRb and B220 markers on total splenocytes. b. Dot plot analysis 
showing expression of CD4 and CD8 markers on TCRb+ cells. All data are representative of 
5 biological replicates from 2 independent experiments. 
 
 
6.2.1 Loss of Hif1α leads to prolonged lifespan of PTENfl/fl x Hif1αfl/fl x LckCre+ 
mice compared to PTENfl/fl x LckCre+ mice 
Having established that Hif1α loss did not impair T cell development in the thymus, 
we sought to understand if Hif1α was involved in the development of T cell 
lymphoma/leukaemia that occurs following deletion of PTEN in T cell progenitors in 
the thymus. Therefore, we analysed mice with double deletion of PTEN and Hif1α, 
PTENfl/fl x Hif1αfl/fl x LckCre+ (DKO) mice. We then allowed a cohort of PTENfl/fl x 
LckCre+ and PTENfl/fl x Hif1αfl/fl x LckCre+ mice to age. During this time we closely 
monitored the welfare of these animals, and when any signs of tumours appeared, 
such as hunched posture, rough coat, lack of mobility and/or swollen abdomen/neck, 
mice were culled. PTENfl/fl x LckCre+ had a median survival of 68 days and only a 
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small percentage of these mice (14%) survived beyond 100 days. In contrast, the 
majority of DKO mice (76%) at 100 days appeared healthy, without any symptoms of 
tumour development (Fig. 6-3a). Figure 6-3b compares the survival kinetics of 
PTENfl/fl x LckCre+ mice and PTENfl/fl x Hif1αfl/fl x LckCre+ mice. Control WT mice 
remained healthy during the course of the study and typically had a life span of more 
than 12 months (data not shown). As already mentioned, PTENfl/fl x LckCre+ mice 
developed massive T lymphomas and 90% of these mice died by 13th week of age 
and the remaining 10% by 20th week of age. When PTEN and Hif1α were both 
deleted in T cell progenitors, 39 out of 40 mice developed tumours. However, unlike 
PTENfl/fl x LckCre+ mice, DKO mice died between 10th and 50th week of age with the 
median life span of 128 days. These data, thus, implied that simultaneous loss of 
Hif1α and PTEN led to prolonged survival, because DKO mice lived almost twice as 
long as PTENfl/fl x LckCre+ mice. These data would argue that Hif1α was important in 
tumour development and its presence in PTENfl/fl x LckCre+ mice accelerated this 
process.    
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Figure 6-3 The analysis of survival of PTENfl/fl x LckCre+ and PTENfl/fl x Hif1αfl/fl x 
LckCre+ mice.  
Graphs showing the Kaplan-Meier curves for PTENfl/fl x LckCre+ (green) and PTENfl/fl x 
Hif1αfl/fl x LckCre+ (purple) mice. a. Survival analysis at 100 days, the numbers indicate 
percentages of animals that were tumour free at that time. b. Survival analysis until 350 days. 
*** p<0.0001 was calculated by Log-rank (Mantel-Cox) test and by Gehan-Breslow-
Wilcoxon test. Data are for 40 mice in each genotype.  
 
 
To assess that the tumours from the DKO mice did not express Hif1α and PTEN 
proteins, we tested all PTEN-/- x Hif1α-/- T cell lymphoma for genomic deletion of 
Hif1α and Pten genes. To do this we performed genotyping of the tumours using a 
PCR protocol that utilised three primers (Fig. 6-4a-b). The protocol was designed by 
Elizabeth Emslie. Two primers (LoxP F and LoxP R) amplified the region 
surrounding the proximal loxP site, generating a product of approximately 290bp for 
Hif1α or 230bp for PTEN when the loxP site was absent (WT) or approximately 
350bp and 280bp (Hif1α and PTEN, respectively) when the site was present (FL). 
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When the site recognised by LoxP R primer was removed following loxP excision 
(Del), primers LoxP F and R amplified the region in between them generating a 
product of approximately 450bp and 380bp for Hif1α and PTEN, respectively. If the 
loxP sites were intact, primers LoxP F and R could not amplify the region in between 
them, therefore, generated no product, as they were more than 1kbp apart from each 
other.  
 
The analysis of genomic DNA in Fig. 6-4c showed that in the ‘ear control’ we 
detected two products of PCR amplification: loxP flanked (FL) and WT Pten or 
Hif1α alleles. The analysis of genomic DNA isolated from thymocytes from PTENfl/fl 
x Hif1αfl/fl x LckCre- (WT) mice detected one product of PCR amplification of loxP 
flanked (FL) Pten or Hif1α alleles. In contrast, we found that in the DNA from T cell 
lymphoma cells isolated from PTENfl/fl x Hif1αfl/fl x LckCre+ mice there were no Pten 
and Hif1α alleles, as we detected only deleted (Del) product of PCR amplification for 
these alleles. 
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Figure 6-4 Analysis of genomic deletion of Hif1α and Pten genes in WT thymocytes and 
PTEN-/- x Hif1α-/- T cell lymphoma.  
DNA from ex vivo isolated WT thymocytes and PTEN-/- x Hif1α-/- T cell lymphoma was 
tested for the presence of Hif1α and Pten genes. a. Hif1αfl and b. PTENfl exon structure 
showing exons plus PCR primer binding sites. c. PCR analysis of Hif1αWT, Hif1αFL, Hif1αDel 
(upper gel) and PTENWT, PTENFL, PTENDel (lower panel) genomic DNA. The analysis was 
performed for all tumour samples that developed in PTENfl/fl x Hif1αfl/fl x LckCre+ mice and at 
least 3 tumour samples isolated from PTENfl/fl x LckCre+ mice. 
 
 
6.2.2 PTENfl/fl x Hif1αfl/fl x LckCre+ mice develop lymphoma  
Flow cytometric analysis of forward and side scatter of ex vivo isolated PTEN-/- x 
Hif1α-/- T cell lymphomas showed that tumours comprised cells that were large and 
blast-like in contrast to WT thymocytes (Fig. 6-5a). Additionally, we found that 
thymi isolated from PTENfl/fl x LckCre+ mice were massively enlarged and 
accordingly, the number of cells from PTEN-/- x Hif1α-/- thymi was increased on 
average 2-fold compared to the numbers of WT thymi (Fig. 3-2b). Next, we tested the 
a.
b.
    
WT                                       +                                       
PTEN-/- x Hif1α-/- Tumour              +       +       +                                  
PTEN
  200
  300
  400   Del
  FL
  WT
Hif1α  300
  500   Del
  FL
  WT
ear
c.
exon 1 LoxP exon 2 LoxP exon 3 
LoxP F LoxP R R 
exon 4 LoxP exon 5 LoxP exon 6 
LoxP F LoxP R R 
 
 
167 
 
expression of the surface markers CD4 and CD8 Thy1 positive cells. In this respect, 
PTENfl/fl x LckCre+ tumour bearing mice has been shown to have altered thymic 
populations and typically contain either CD4/CD8 DPs only or a mix of CD4/CD8 
DPs and SP CD4, or a mix of CD4/CD8 DN, CD4/CD8 DPs and SP CD4 cells 
(Hagenbeek & Spits 2007). Flow cytometric analysis of surface markers CD4 and 
CD8 on Thy1 positive cells in PTEN-/- x Hif1α-/- T cell lymphoma showed that these 
were abnormally expressed compared to WT thymi (Fig. 6-5c). While WT 
thymocytes were mostly CD4/CD8 DPs, with SP CD4 cells and SP CD8 cells being 
the next biggest populations, 10 out of 16 tumour samples expressed either only 
CD4/CD8 DPs or CD4/CD8 DPs and SP CD4 cells. Another characteristic of PTEN-/- 
T cell lymphoma/leukaemia cells is that they disseminate into peripheral lymphoid 
organs i.e. spleen and lymph nodes (Hagenbeek & Spits 2007). We found that 
tumour-bearing mice with double deletion of PTEN and Hif1α had enlarged spleen 
(Fig. 6-5d) and LN (data not shown) and increased their spleen numbers by more than 
3-fold comparing to WT spleen (Fig. 6-5d). Flow cytometric analysis of surface 
markers of T cells (TCRb) and B cells (B220) showed that WT spleen typically 
contained approximately 24% of TCRb+ cells and 64% of B220+ cells, in contrast to 
tumours isolated from PTENfl/fl x Hif1αfl/fl x LckCre- mice that had 75% of TCRb+ 
cells and only 6% of B220 cells (Fig. 6-5e). These altered ratios of T and B cells in 
PTEN-/- x Hif1α-/- spleens were reflected in a massive 16-fold increase in numbers of 
TCRb+ cells with concomitant 5-fold decrease of B220+ cells (Fig. 6-5f). 
Collectively, these data showed that tumours that developed in PTENfl/fl x Hif1αfl/fl x 
LckCre+ mice had similar characteristics to PTEN-/- T cell leukaemia/lymphomas.  
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Figure 6-5 The analysis of T cell lymphoma from PTENfl/fl x Hif1αfl/fl x LckCre+ mice.  
Ex vivo isolated cells from WT and tumour-bearing PTENfl/fl x Hif1αfl/fl x LckCre+ mice were 
stained with surface markers: thymus-Thy1, CD4 and CD8; spleen-TCRb, B220, CD4 and 
CD8 and subjected to flow cytometry analysis. a. Dot plots graphs and histogram showing 
the size (FSC) of cells isolated from thymus. b. Total number of Thy1 positive cells isolated 
from thymus; * p<0.05 calculated by t-test, each dot represent independent biological 
replicate. c. The table showing the flow cytometric analysis of CD4 and CD8 expression on 
DKO Tumours. d. Total number of cells isolated from spleen; ** p=0.0015 calculated by t-
test, each dot represent independent biological replicate. e. Dot plots showing expression of 
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TCRb (T cells) and B220 (B cells) in spleen. f. Total number of TCRb+ and B220+ cells 
isolated from spleen; *** p=0.0008 (TCRB+) and ** p=0.0023 (B220+) calculated by t-test, 
each dot represent independent biological replicate. Dot plots and histograms are shown as 
representative of at least 4 biological replicates from at least 4 independent experiments. b. d. 
and f. graphs are shown as mean from 4 WT and 5 DKO biological replicates from 4 
independent experiments.  
 
 
6.2.3 PTEN-/- x Hif1α-/- T cell leukaemia/lymphoma increased glucose and 
glutamine uptake compared to WT thymocytes 
The increase in cell size of PTEN-/- x Hif1α-/- T cell lymphoma/leukaemia cells could 
indicate that these cells were more metabolically active than quiescent thymocytes 
and, in this sense, were similar to PTEN-/- T cell lymphoma/leukaemia cells that 
expressed Hif1α. We therefore first monitored the cellular uptake of 3[H]- 2-DG to 
assess glucose transport in primary ex vivo isolated tumour cells from the PTENfl/fl x 
Hif1αfl/fl x LckCre+ mice. As controls we monitored the glucose transport capacity of 
quiescent WT thymocytes and metabolically active IL-2 maintained CTLs. The data 
in Fig.6-6a shows that ex vivo WT thymocytes had very low, approximately 20-fold 
decreased rates of glucose uptake compared to CTLs. In contrast, T leukemic cells 
from the PTENfl/fl x Hif1αfl/fl x LckCre+ mice had 10-fold higher rates of glucose 
uptake compared to WT thymocytes (Fig. 6-6a). The rates of glucose uptake by the 
PTEN-/- x Hif1α-/- T cell lymphoma were thus 2-fold lower than in CTLs. We were 
not able to directly compare the ability of tumours isolated from PTENfl/fl x LckCre+ 
and PTENfl/fl x Hif1αfl/fl x LckCre+ mice to take up radiolabeled glucose, as the tumour 
development in these mice could not be predicted and synchronised. Therefore, we 
used the uptake of glucose by CTLs as a way to standardise and compare the glucose 
uptake capacity of each tumour indirectly. In this respect, we showed that both PTEN-
/- T cell lymphoma/leukaemia cells and PTEN-/- x Hif1α-/- T cell 
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lymphoma/leukaemia cells were 2 times less efficient than CTLs in glucose uptake. 
We concluded, therefore, that PTEN-/- x Hif1α-/- T cell lymphoma/leukaemia cells had 
similar capacity to take up exogenous glucose compared to PTEN-/- T cell 
lymphoma/leukaemia cells.  
 
An important amino acid for fuelling cell growth is glutamine. We thus examined the 
capacity of WT and PTEN-/- x Hif1α-/- T cell lymphoma/leukaemia cells to transport 
3[H]-Glutamine. We also monitored the ability to take up glutamine by CTLs. Figure 
6-6b shows that WT thymocytes had low rate of glutamine uptake and on average it 
was reduced by 20-fold. However, tumours isolated from PTENfl/fl x Hif1αfl/fl x 
LckCre+ had increased rates of glutamine uptake and were comparable to CTLs. We 
showed that PTEN-/- T cell lymphoma/leukaemia cells were approximately two times 
less efficient in uptake of glutamine than CTLs. Therefore, it is likely that the cells 
derived from tumours developed in PTENfl/fl x Hif1αfl/fl x LckCre+ mice were more 
efficient at taking up glutamine than those derived from PTENfl/fl x LckCre+ mice. 
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Figure 6-6 Comparison of glucose and glutamine uptake by WT thymocytes and PTEN-/- 
x Hif1α-/- T cell lymphoma/leukaemia cells. 
 Ex vivo isolated WT thymocytes and PTEN-/- x Hif1α-/- T cell lymphoma/leukaemia cells 
were assayed for uptake of a. 3[H]-2-Deoxyglucose and b. 3[H]-Glutamine. Units show 
counts per minute per 1x106 cells. Error bars show mean SD of 1 biological replicate. All 
data are representative of 3 biological replicates from 3 independent experiments. 
 
 
6.2.4 PTEN-/- x Hif1α-/- T cell lymphoma/leukaemia cells increased leucine 
uptake compared to WT thymocytes 
Analysis of PTEN-/- T cell lymphoma/leukaemia cells showed that they had increased 
expression of subunit of System L amino acid transporter, CD98 and elevated uptake 
of leucine compared to WT thymocytes. Therefore, we first measured if tumours 
isolated from PTENfl/fl x Hif1αfl/fl x LckCre+ mice expressed CD98 on their surface. 
Flow cytometric analysis showed that WT thymocytes had basal level of CD98 
expression and this level was elevated in PTEN-/- x Hif1α-/- T cell 
lymphoma/leukaemia cells (Fig. 6-7a). These data implied that expression of System 
L amino acids transporters were increased in PTEN-/- x Hif1α-/- T cell 
lymphoma/leukaemia cells. System L amino acid transporters transport leucine inside 
the cell, therefore, we compared 3[H]-Leucine uptake in PTEN-/- x Hif1α-/- T cell 
lymphoma, WT thymocytes and CTLs. Figure 6-7b shows that WT thymocytes were 
6-fold less efficient in uptake of leucine compared to CTLs. In contrast, tumours 
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isolated from PTENfl/fl x Hif1αfl/fl x LckCre+ mice increased leucine uptake by 
approximately 10-fold comparing to WT thymocytes. Therefore, these data indicated 
that primary PTEN-/- x Hif1α-/- T cell lymphoma/leukaemia cells had a higher 
capacity to take up exogenous leucine than CTLs. As we observed that PTEN-/- T cell 
lymphoma/leukaemia cells took up leucine at similar rates to CTLs, we propose that 
tumour samples from PTENfl/fl x LckCre+ and PTENfl/fl x Hif1αfl/fl x LckCre+ mice 
might have comparable abilities for transport of exogenous leucine.  
 
 
Figure 6-7 Comparison of CD98 expression and leucine uptake by WT thymocytes and 
PTEN-/- x Hif1α-/- T cell lymphoma/leukaemia cells. 
a. Flow cytometric analysis presented as histogram showing expression of CD98 marker on 
surface of Thy1 positive cells from WT mice and PTEN-/- x Hif1α-/- T cell lymphoma. Data 
are representative of at least 3 biological replicates from at least 3 independent experiments. 
b. The ability of ex vivo isolated WT thymocytes and PTEN-/- x Hif1α-/- T cell lymphoma to 
take up 3[H]-Leucine was tested. Numbers indicate counts per minute per 1x106 cells. The 
error bars indicate mean SD of 1 biological replicate. The data are representative of 3 
biological replicates from 3 independent experiments.  
 
 
6.2.5 PTEN-/- x Hif1α-/- T cell lymphoma increased transferrin uptake 
compared to WT thymocytes 
We found that PTEN-/- T cell lymphoma/leukaemia cells had increased expression of 
CD71, and, as a consequence, had increased ability to transport transferrin. Therefore, 
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using flow cytometry we measured the expression of CD71 on the cell surface of 
PTEN-/- x Hif1α-/- T cell lymphoma/leukaemia cells. We found that, WT thymocytes 
had very low expression of CD71, however tumours isolated from PTENfl/fl x 
Hif1αfl/fl x LckCre+ mice had much higher expression of CD71 (Fig.6-8a). We then 
tested whether the receptor was functional by measuring the cellular uptake of 
transferrin by PTEN-/- x Hif1α-/- T cell lymphoma/leukaemia cells, WT thymocytes 
and IL-2 maintained CTLs. We used a FACS based assay to monitor cellular uptake 
of APC conjugated transferrin. Cells were starved of transferrin for 2 hours after 
which the uptake of transferrin was performed at 37ºC for 10 minutes. The data in 
Fig. 6-8b show that CTLs showed the highest uptake of transferrin (black line, b.) in 
contrast to WT thymocytes that did not have the ability to take up any transferrin. 
However, primary PTEN-/- x Hif1α-/- T cell lymphoma/leukaemia cells showed a 
marked increase in transferrin uptake that was comparable with the uptake observed 
in CTLs, implying that tumour cells had great capacity for iron uptake. The uptake of 
labeled transferrin by the PTEN-/- x Hif1α-/- T cell lymphoma/leukaemia cells was 
specific as it was blocked by unlabeled transferrin competitor and by incubating the 
cells treated with labeled transferrin on ice (Fig. 6-8c). These data demonstrated that 
CD71 expressed on PTEN-/- x Hif1α-/- leukaemia/lymphoma cells was functional and 
permitted the uptake of transferrin into the cells. Therefore, this data argue that 
PTEN-/- x Hif1α-/- T cell lymphoma/leukaemia cells had a similar ability to take up 
transferrin as PTEN-/- T cell lymphoma/leukaemia cells.  
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Figure 6-8 Comparison of CD71 expression and transferrin uptake by WT thymocytes 
and PTEN-/- x Hif1α-/- T cell lymphoma. 
Flow cytometric analysis presented as histograms showing a. expression of CD71 and b. 
transferrin uptake of WT thymocytes, PTEN-/- x Hif1α-/- T cell lymphoma and CTLs (black 
line in b). c. Untreated cells were assayed for the uptake of transferrin at 37ºC. Flow 
cytometric analysis presented as histograms showing transferrin uptake for untreated cells 
kept in 37ºC (solid grey) or cells kept in 37ºC incubated together with holo-transferrin to 
block transferrin uptake (green), or kept in 37ºC where no labeled transferrin was added 
(orange) or kept on ice to block the transport (blue). Expression of CD71 and transferrin 
uptake was measured on Thy1 positive cells and CTLs. Data are representative of 3 
biological replicates from 3 independent experiments.  
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x LckCre+ or PTENfl/fl x LckCre+ mice to take up nutrients normalized to CTLs 
included in the previous paragraphs implied that PTEN-/- x Hif1α-/- 
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transferrin but were better at taking up glutamine than PTEN-/- leukaemia/lymphoma 
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normalized to WT thymocytes (Fig. 6-9). We observed that while PTEN-/- x Hif1α-/- 
leukaemia/lymphoma cells performed similar at taking up glucose, glutamine and 
transferrin, they were better at taking up leucine compared to PTEN-/- 
leukaemia/lymphoma cells. However, we also observed that there were big 
variabilities within the tested genotype for the uptakes (Fig.6-9). Due to this spread it 
is therefore difficult to judge whether tumours isolated from PTENfl/fl x Hif1αfl/fl x 
LckCre+ mice could perform differently that tumours isolated from PTENfl/fl x LckCre+ 
mice. 
 
 
Figure 6-9 The comparative analysis of the nutrient uptake by PTEN-/- x Hif1α-/- 
leukaemia/lymphoma cells and PTEN-/- leukaemia/lymphoma cells.  
The fold change of the nutrient uptake for PTEN-/- x Hif1α-/- leukaemia/lymphoma and 
PTEN-/- leukaemia/lymphoma cells normalised to WT thymocytes. The analysis was 
performed for 3 biological replicates from 3 independent experiments.  
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6.3 Discussion 
In the previous chapter we established that mTORc1 controlled glucose uptake and 
expression of Hif1α in PTEN-/- T cell lymphoma/leukaemia cells. Therefore it was 
possible that mTORc1 via Hif1α expression regulated glucose uptake in PTEN-/- T 
cell lymphoma/leukaemia cells. Because glucose uptake and glycolysis are crucial for 
cells to initiate/sustain their metabolism, we hypothesised that the loss of Hif1α might 
be sufficient to inhibit the development of T cell lymphoma in PTENfl/fl x Hif1αfl/fl x 
LckCre+ mice.  
 
Initially, we wanted to understand if Hif1α loss could adversely impact on T cell 
development in the thymus and T cell maintenance in secondary lymphoid organs. In 
chapter 5 we suggested that Hif1α expression was induced by secondary mutations. 
Hale at al., showed that expression of Hif1α regulated target genes is maintained at 
baseline level in thymus as a result of physiological adaptation to hypoxia in the 
thymus (Hale et al. 2002). Therefore, we could not exclude the possibility that Hif1α 
expression would be important for survival of thymic progenitors. However, analysis 
of Hif1-/- x LckCre+ mice revealed that ablation of Hif1α had no impact on survival of 
T cells in the thymus or their maintenance in the peripheral organs. The result that 
Hif1α was not needed for thymus development is reinforced by another study that 
investigated the role of Hif1α in the development of CD4+ Th17 producing cells and 
used Hif1αfl/fl x CD4Cre+/- mice (E. V. Dang et al. 2011). The authors showed that 
thymi and peripheral organs had normal ratios of cells following the CD4 Cre 
mediated Hif1α deletion. Hif1α has to partner with Hif1β to induce transcription of 
Hif1α target genes. The loss of Hif1β also had no impact on T cell development in the 
thymus (Finlay et al. 2012).  
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However, Hif1α is undoubtedly important for the tumour development in PTENfl/fl x 
Hif1αfl/fl mice. Given the link that expression of Hif1α in immune activated T cells is 
regulated by mTORc1 (Finlay et al. 2012), it is relevant that a study has been 
published where the regulatory subunit of mTORc1, Raptor, was genetically deleted 
together with PTEN in mouse haematopoietic cells (HSC) (Kalaitzidis et al. 2012). 
As a result, the authors found that this double deletion (DKOHSC) led to prolonged 
survival compared to mice where only PTEN was deleted. Therefore, we speculated 
that our PTENfl/fl x Hif1αfl/fl x LckCre+ mice would either behave exactly like the 
DKOHSC mice or they would become sick faster, like PTENfl/fl x LckCre+ mice or they 
would not develop tumours. The later two options would suggest that there is no 
direct regulation between mTORc1 activation and Hif1α expression in PTENfl/fl x 
LckCre+ mice. Interestingly, the survival analysis of mice with double deletion of 
Raptor and PTEN in HSC showed that these mice had similar survival kinetics to our, 
PTENfl/fl x Hif1αfl/fl x LckCre+ mice. These data argue thus, that deletion of either 
Hif1α or Raptor in PTEN null T cell progenitors/haematopoietic cells leads to similar 
result in the overall survival of the mice. These data are consistent with a model that 
Hif1α mediates the effects of mTORc1 in PTEN-/- T cell lymphoma/leukaemia cells.  
 
How would mTORc1 regulate expression of Hif1α? In peripheral T cells mTORc1 
controls expression of Hif1α protein but not mRNA (Finlay et al. 2012) arguing that 
mTORc1 control translation of Hif1α mRNA (Finlay et al. 2012). In this respect, 
Tandon at al., proposed that S6K is the potential link. In their study, they genetically 
deleted S6K, the downstream target of mTORc1, in mouse haematopoietic cells 
(Tandon et al. 2011). Interestingly, their mice with double deletion of PTEN and S6K 
in HSC had similar survival kinetics as PTENfl/fl x LckCre+ mice (our model) and 
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PTENfl/fl x Raptorfl/fl x Mx1Cre+ mice (Kalaitzidis et al. 2012). Therefore, we propose 
that there is a strong correlation between all three studies and the pathway mTORc1-
S6K-Hif1α is important in lymphomagenesis caused by PTEN deletion. 
 
PTENfl/fl x Hif1αfl/fl x LckCre+ mice still developed T cell lymphoma and these cells 
still had high rates of glucose uptake revealing that there are other transcription 
factors that can control expression of nutrient receptors. One potential option would 
be that PTEN-/- x Hif1α-/- T cell lymphoma/leukaemia cells substituted the loss of 
Hif1α with expression of Hif2α, despite the fact that normal T cells do not express 
this isoform (Patel & Simon 2008). We did attempt to test for the presence of Hif2α 
protein in PTEN-/- x Hif1α-/- T cell lymphoma/leukaemia cells. Unfortunately, the 
Western blot analysis did not give us the unequivocal answer. Therefore, we are 
planning to perform quantitative PCR to establish if PTEN-/- x Hif1α-/- T cell 
lymphoma/leukaemia cells have increased Hif2α mRNA.  
 
Are there any other potential drivers that can control glucose uptake in PTEN-/- x 
Hif1α-/- T cell lymphoma/leukaemia cells? In this context, the comparison of the 
capacity to take up glucose by PTEN-/- x Hif1α-/- T cell lymphoma/leukaemia cells 
and PTEN-/- T cell lymphoma/leukaemia cells showed that these tumours had similar 
levels of glucose uptake. In this context, antigen activation of naïve T cells induces 
expression of c-Myc (Preston et al. 2015) that controls induction of glucose and 
glutamine metabolism (R. Wang et al. 2011a). It is possible therefore, that c-Myc 
expression in DKO mice (data not shown) directly contributed to elevated glucose 
uptake but we have no information about how glycolytic these tumours are. Equally, 
we also found that PTEN-/- x Hif1α-/- T cell lymphoma/leukaemia cells had higher 
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capacity to take up glutamine. Exogenous glutamine and its metabolites are also an 
alternative way of generating energy and supplying substrates for anabolic pathways 
and glutaminolysis was shown to be a potent stimulator of mTORc1 in activated T 
cells (Duran et al. 2012). Thus, mTORc1 activity in PTEN-/- x Hif1α-/- T cell 
lymphoma (preliminary data not shown) can directly regulate their nutrient uptake but 
independently of Hif1α.  
 
To summarise, we found that Hif1α plays an important role in tumourigenesis, as 
Hif1α loss enables for the significant delay in tumourigenesis in PTENfl/fl x Hif1αfl/fl x 
LckCre+ mice. We also proposed that Hif1α expression is regulated by mTORc1 in 
PTEN-/- T cell lymphoma/leukaemia. Despite the role in driving the malignancy, we 
found that Hif1α is not crucial for normal T cell development.  
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7 Final discussion 
In the present thesis we questioned whether PTEN deletion-induced accumulation of 
PI(3,4,5)P3 and activation of AKT could initiate the uptake of nutrients in T cells and 
thus maintain T cell metabolism. An important observation was that PTEN-/- T cell 
lymphoma/leukaemia cells had high levels of glucose, glutamine, leucine and 
transferrin uptake, nutrients that are important for rapidly proliferating cells.  These 
cells also had high levels of the activity of the nutrient sensing serine/threonine kinase 
mTORc1. However, PTEN-/- non-transformed thymocytes did not have constitutively 
high levels of nutrients uptake nor did they have high mTORc1 activity. Therefore, 
the increase in nutrient uptake and mTORc1 activity was associated only with 
transformed phenotype and not with PTEN loss. Moreover, it is known that PTEN-/- T 
cell lymphoma/leukaemia cells carry secondary mutations that accumulate during the 
malignant transformation (Guo et al. 2008). Therefore, we propose that secondary 
mutations are responsible for the increase in nutrient uptake and mTORc1 activity to 
fuel metabolism in PTEN-/- T cell lymphoma/leukaemia cells.  
 
Signals that may sustain nutrient signalling/mTORc1 activity in PTEN-/- T cell 
lymphoma/leukaemias  
Two possible mechanisms by which an increase in nutrient uptake and mTORc1 
activity can be brought about in PTEN-/- T cell lymphoma/leukaemia cells include the 
activation of Notch1 or the expression of c-Myc. Notch1 is a major driver in T-ALL 
(Weng et al. 2004; Sulis et al. 2008) and it is an important regulator of nutrient 
receptors expression in T cell progenitors, e.g. CD98 (Kelly et al. 2007). CD98 is a 
constant subunit of System L amino acid transporters that mediate the uptake of 
LNAA, e.g. leucine into cells (Sinclair et al. 2013). Our data showed that only PTEN-
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/- T cell lymphoma/leukaemia cells, but not PTEN-/- non-transformed thymocytes, 
upregulated expression of CD98 and the uptake of leucine. Amino acids, in particular 
leucine, can act as direct activators of mTORc1 kinase complex (BEUGNET et al. 
2003). We also found that PTEN-/- T cell lymphoma/leukaemia cells, but not PTEN-/- 
non-transformed thymocytes had active mTORc1 and its activity was fully dependent 
on constant leucine supply. Active Notch1 signalling can induce c-Myc expression in 
T-ALL (Weng et al. 2006). We confirmed that c-Myc was overexpressed in all tested 
PTEN-/- T cell lymphoma/leukaemia cells, but not in PTEN-/- non-transformed 
thymocytes, thus Notch1 could be a potential regulator of c-Myc expression in PTEN-
/- T cell lymphoma/leukaemia cells. c-Myc can also regulate glutamine uptake and its 
metabolism in immune activated T cells (R. Wang et al. 2011a). mTORc1 activity is 
also dependent on glutamine availability (Nicklin et al. 2009; Duran et al. 2012), thus, 
c-Myc-induced glutamine uptake could further support mTORc1 activity. 
Additionally, expression of transferrin receptor in B cell lymphoma remains under the 
control of c-Myc (O'Donnell et al. 2006). We observed that only PTEN-/- T cell 
lymphoma/leukaemia cells upregulated transferrin uptake and hence these cells were 
able to actively proliferate. Therefore, we propose a model where PTEN-/- T cell 
lymphoma/leukaemia cells that carry active Notch1 mutations can induce expression 
of CD98, thus, allowing for the transport of leucine inside the cells. Notch1-induced 
c-Myc expression, promotes transferrin uptake as well as glutamine uptake, and 
together with leucine induces and sustains mTORc1 activity.  
 
Is Notch1 signalling sufficient to explain nutrient regulation in our T-ALL model? In 
human T-ALL the common Notch1 mutations are found in PEST/HD domains (Weng 
et al. 2004). However, genetic screening of PTEN-induced murine T-ALL samples 
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found no Notch1 mutations in these domains (Hagenbeek et al. 2014; Guo et al. 
2008). Our data showed that active Notch1 was expressed in 3 out of 9 of the tested T 
cell lymphoma/leukaemia cells produced in PTENfl/fl x LckCre+ mice. This type of 
heterogeneity in terms of the involvement of Notch1 has been described previously 
where PTEN-induced T-ALLs were not uniformly sensitive to Notch inhibition 
(Palomero et al. 2006; Palomero & Ferrando 2008; Hagenbeek et al. 2014; Medyouf 
et al. 2010). However, all the T cell lymphoma/leukaemia cells isolated from the 
PTENfl/fl x LckCre+ mice expressed c-Myc. If active Notch1 signalling was only found 
in a subset of the PTEN-/- T cell lymphoma/leukaemia cells, there must be a second 
Notch1 independent mechanism by which c-Myc message can be induced, e.g. 
chromosomal translocations and c-Myc protein stabilised, e.g. mutations in FBW7 
domain that is responsible for degradation of c-Myc (O'Neil et al. 2007; Welcker, 
Orian, Grim, et al. 2004a). Furthermore, in the apparent absence of Notch1 signalling, 
in half of the T-ALL we studied, the increase in leucine transport that we observed 
must be stimulated through Notch1 independent mechanisms. In this respect, in 
normal immune activated T cells the key leucine transporter is the System L amino 
acid transporter subunit Slc7a5, which pairs with CD98 (Sinclair et al. 2013). One 
possibility is that Slc7a5 also plays an important role in PTEN-/- T cell 
lymphoma/leukaemia cells. The analysis of the proteome of PTEN-/- T cell 
lymphoma/leukaemia cells showed they expressed Slc7a5. In this respect, activation 
of calcineurin, a calcium-regulated phosphatase, positively regulates the expression of 
Slc7a5 in activated T cells (Sinclair et al. 2013). The proteomic analysis of PTEN-/- T 
cell lymphoma/leukaemia cells indicated that the expression of a regulatory subunit 
of calcineurin was increased almost 4-fold in one of the tested PTEN-/- T cell 
lymphoma/leukaemia cells sample compared to WT. Interestingly, this increase in the 
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calcineurin regulatory subunit was found in the sample that did not show 
overexpressed Notch1. Therefore, one speculation is that calcineurin activation might 
constitute a Notch1 independent way to control leucine uptake in PTEN-/- T cell 
lymphoma/leukaemia cells. A key follow-up experiment to test this model would be 
to use the calcineurin inhibitor Cyclosporin A or FK506, to determine if blocking the 
calcium-calcineurin signalling can block leucine transport in the PTEN-/- T cell 
lymphoma/leukaemia cells.   
 
One other signal that controls Slc7a5 expression in T cell antigen receptor activated T 
cells is the activation of the JAK kinases by cytokines such as IL-15 and IL-2 
(Preston et al. 2015). T-ALL can express constitutively active IL-7 receptor that 
signal to activate JAK kinases in a ligand independent fashion (Ribeiro et al. 2013). 
We have no information if the T-ALLs that develop in PTENfl/fl x LckCre+ mice 
accumulate IL-7 receptor mutations. However, we could use JAK inhibitors to test 
the involvement of JAK signalling in the control of leucine uptake in the T-ALL. 
 
In the context of PTEN induced T-ALL, inhibitors of Slc7a5 have been shown to 
efficiently reduce the viability and proliferation of T leukaemic cells (Rosilio et al. 
2014). However, our analysis suggested that PTEN-/- T cell lymphoma/leukaemia 
cells expressed Slc7a5 and Slc7a6 subunits of System L amino acid transporters. As 
the expression of Slc7a6 may cause resistance to therapies that target Slc7a5, it is 
important to understand which subunits of System L amino acid transporters are 
expressed in the malignant cells. Our global analysis of proteins from PTEN-/- T cell 
lymphoma/leukaemia cells by MS did not give an unequivocal answer as to which 
System L amino acid transporter, Slc7a5 or Slc7a6, is preferentially expressed, as we 
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observed substantial variability in their expression within tested samples. Thus, rather 
than performing analysis of total cellular proteins, future studies may be required to 
focus the analysis on membrane extracts. One strategy would be to perform CD98 
‘pull down’ experiments, and then subject the samples for MS analysis to look for 
binding partners of CD98. Once it is established which subunits of System L amino 
acid transporters are expressed in PTEN-/- T cell lymphoma/leukaemia cells, we can 
conditionally delete them together with PTEN in early thymic progenitors. This way, 
we can probe if the expression of Slc7a5 can compensate for the absence of the 
Slc7a6, and vice-versa and how each subunit can contribute to the progression of the 
T-ALL.  
 
mTORc1 – a central player in PTEN-/- T cell lymphoma/leukaemia cells metabolism 
Studies performed in T-ALL cells suggested that mTOR inhibitors are cytotoxic for 
these cells (Evangelisti et al. 2011; Yilmaz et al. 2006). We established that mTORc1 
was active in PTEN-/- T cell lymphoma/leukaemia cells and that this activation was 
not a direct response to increased AKT signalling resulted from the loss of PTEN. 
However, we propose that this mTORc1 activation is central for the regulation of 
metabolism in PTEN-/- T cell lymphoma/leukaemia cells. We found that mTORc1 
activity regulated glucose uptake in PTEN-/- T cell lymphoma/leukaemia cells, a 
process that is the hallmark of the metabolic switch that takes place in rapidly 
proliferating cells (Vander Heiden et al. 2009). We also showed that PTEN-/- T cell 
lymphoma/leukaemia cells and not PTEN-/- non-transformed thymocytes expressed 
Hif1α. Moreover, the expression of Hif1α in PTEN-/- T cell lymphoma/leukaemia 
cells was controlled by mTORc1. One of the functions of Hif1α is to regulate the 
expression of glucose transporters and the rate-limiting enzymes of glycolysis (Finlay 
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et al. 2009). We, thus, thought it was possible that by deleting Hif1α in PTEN-/- T cell 
lymphoma/leukaemia cells we would be able to block glucose metabolism in these 
cells and, thereby, block their malignant transformation. Our data did show that Hif1α 
could regulate the development of T cell lymphoma/leukaemias in PTENfl/fl x LckCre+ 
mice. Hence PTENfl/fl x Hif1αfl/fl x LckCre+ mice were able to survive longer than 
PTENfl/fl x LckCre+ animals. The expression of Hif1α in PTEN-/- T cell 
lymphoma/leukaemia cells was controlled by mTORc1 and the impact of Hif1α on 
tumour development in our mouse model phenocopied what happens when Raptor is 
deleted in PTEN null haematopoietic cells (Kalaitzidis et al. 2012). These data argue 
that Hif1α mediates the effects of mTORc1 in the development of PTEN-/- T cell 
lymphoma/leukaemias. However, the loss of mTORC1 activity (Kalaitzidis et al. 
2012; Tandon et al. 2011) or the loss of Hif1α, only delays tumour progression in 
these mouse models of T-ALL. There is, thus, an important question that we would 
like to address in the future. Why do we observe the lag phase in tumour development 
of PTENfl/fl x Hif1αfl/fl x LckCre+ mice? Most probably the lag phase is a result of 
PTEN-/- x Hif1α-/- T cell lymphoma/leukaemia cells finding alternative mechanisms 
to re-adjust their metabolic control. As PTEN is a powerful tumour suppressor, early 
T cell progenitors with PTEN deletion are destined to acquire tumours. We do know 
that c-Myc is expressed in PTEN-/- x Hif1α-/- T cell lymphoma/leukaemia cells. c-
Myc has been described to induce glucose and glutamine uptake in immune activated 
CD8+ T cells (R. Wang et al. 2011a). In terms of production of biosynthetic 
precursors that then are used for macromolecules, it is possible that c-Myc mediated 
glutamine metabolism can in part compensate for the loss in glucose metabolism 
caused by deletion of Hif1α. One way to test this model is to measure the ability of 
PTEN-/- x Hif1α-/- T cell lymphoma/leukaemia cells to perform glycolysis and 
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glutaminolysis. Alternatively, we can measure the relative contribution of glucose 
and glutamine derivatives by measuring how much radiolabeled carbon from each of 
the molecules feeds into the TCA pathway.  
 
However, it is also possible that Hif1α loss in PTEN-/- T cell lymphoma/leukaemia 
cells leads to the generation of new mutations that contribute to tumour development. 
Therefore, it would be interesting to perform whole genome sequencing of tumours 
collected from PTENfl/fl x Hif1αfl/fl x LckCre+ mice and compare them to tumours 
isolated from PTENfl/fl x LckCre+ mice. A more affordable alternative to the whole 
genome sequencing would be to sequence exons that are known to carry mutations. 
However, there is a potential pitfall of this approach. By screening for already 
existing mutations, there is the possibility that new mutations that occurred as a result 
of Hif1α deletion would be overlooked. Therefore, the whole genome sequencing 
should give as better insight into what signalling pathways are deregulated in PTEN-/- 
x Hif1α-/- T cell lymphoma/leukaemia cells and, hence, contribute to better 
understanding of this complex disease.  
 
Taken together, we have shown that activation of the PTEN-PI3K-AKT pathway 
alone does not lead to a robust activation of mTORc1 and nutrient uptake. We also 
propose that mTORc1 is a central player in metabolism regulation of PTEN-/- T cell 
lymphoma/leukaemia cells via regulation of Hif1α expression. Lastly, we have shown 
that loss of Hif1α prolongs the lifespan of PTENfl/fl x Hif1αfl/fl x LckCre+ mice but due 
to unknown mechanisms these mice still develop tumours.  
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